Username

Password

Forgot Password?

Preview

Sign-in free and Explore the Exciting World of BiomedExperts:

Over 1.500.000 Profiles
More than 1.800 Organizations worldwide
State of the Art Network Visualizations

Manage your own Profile
Locate Experts in your Country/Region
Locate Experts in your 1. and 2. Level Network
Connect to Experts Worldwide

NetworkView

Jos Beijnen

This is a preview profile on BiomedExperts - the first literature-based scientific social network. It brings the right researchers together and allows them to collaborate online. Collexis and Dell provide the BiomedExperts network of +1.5 Million pre-calculated profiles free of charge to researchers worldwide.

Research Profile (preview)

Chemicals & Drugs

Procedures

Concepts & Ideas

Disorders

Living Beings

Mice

Sign-in to see full Profile

Network (preview)

Co-Publications
Name
156
Schellens, Jan
147
Rosing, Hilde
128
Schellens, J H M
118
Huitema, Alwin
102
van Tellingen, Olaf
77
ten Bokkel Huinink, Wim
66
Rodenhuis, Sjoerd
58
Bult, Auke
53
Meenhorst, Pieter
52
Mulder, Jan
49
Sparidans, Rolf
48
Underberg, Willy
39
Nuijen, Bastiaan
39
Hillebrand, Michel
35
Koks, Cornelis

Sign-in to see all Coauthors

Publications

TOP 3
Damen Carola W N; Lagas Jurjen S; Rosing Hilde; Schellens Jan H M; Beijnen Jos H
The bioanalysis of vinorelbine and 4-O-deacetylvinorelbine in human and mouse plasma using high-performance liquid chromatography coupled with heated electrospray ionization tandem mass-spectrometry.
Damen Carola W N; Derissen Ellen J B; Schellens Jan H M; Rosing Hilde; Beijnen Jos H
The bioanalysis of the monoclonal antibody trastuzumab by high-performance liquid chromatography with fluorescence detection after immuno-affinity purification from human serum.
Lankheet A G; Hillebrand M J X; Langenberg M H G; Rosing H; Huitema A D R; Voest E E; Schellens J H M; Beijnen J H
A validated assay for the quantitative analysis of vatalanib in human EDTA plasma by liquid chromatography coupled with electrospray ionization tandem mass spectrometry.

Sign-in to see all Publications

Sign in free and see...

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the visualized research activity
of experts around the globe

Sign-in to see more

Geonetwork of Jos Beijnen (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

Sign-in to see more

All Publications

2009: Damen Carola W N; Lagas Jurjen S; Rosing Hilde; Schellens Jan H M; Beijnen Jos H
The bioanalysis of vinorelbine and 4-O-deacetylvinorelbine in human and mouse plasma using high-performance liquid chromatography coupled with heated electrospray ionization tandem mass-spectrometry.
Biomedical chromatography : BMC 2009;23(12):1316-25.
2009: Damen Carola W N; Derissen Ellen J B; Schellens Jan H M; Rosing Hilde; Beijnen Jos H
The bioanalysis of the monoclonal antibody trastuzumab by high-performance liquid chromatography with fluorescence detection after immuno-affinity purification from human serum.
Journal of pharmaceutical and biomedical analysis 2009;50(5):861-6.
2009: Lankheet A G; Hillebrand M J X; Langenberg M H G; Rosing H; Huitema A D R; Voest E E; Schellens J H M; Beijnen J H
A validated assay for the quantitative analysis of vatalanib in human EDTA plasma by liquid chromatography coupled with electrospray ionization tandem mass spectrometry.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 2009;877(29):3625-30.
2009: Pluim Dick; Beijnen Jos H; Schellens Jan H M; van Tellingen Olaf
Simultaneous determination of AZD1152 (prodrug) and AZD1152-hydroxyquinazoline pyrazol anilide by reversed phase liquid chromatography.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 2009;877(29):3549-55.
2009: Damen Carola W N; Chen Weibin; Chakraborty Asish B; van Oosterhout Mike; Mazzeo Jeffrey R; Gebler John C; Schellens Jan H M; Rosing Hilde; Beijnen Jos H
Electrospray ionization quadrupole ion-mobility time-of-flight mass spectrometry as a tool to distinguish the lot-to-lot heterogeneity in N-glycosylation profile of the therapeutic monoclonal antibody trastuzumab.
Journal of the American Society for Mass Spectrometry 2009;20(11):2021-33.
2009: Jansen Robert S; Rosing Hilde; Schellens Jan H M; Beijnen Jos H
Simultaneous quantification of 2',2'-difluorodeoxycytidine and 2',2'-difluorodeoxyuridine nucleosides and nucleotides in white blood cells using porous graphitic carbon chromatography coupled with tandem mass spectrometry.
Rapid communications in mass spectrometry : RCM 2009;23(19):3040-50.
2009: Jansen Robert S; Rosing Hilde; Schellens Jan H M; Beijnen Jos H
Protein versus DNA as a marker for peripheral blood mononuclear cell counting.
Analytical and bioanalytical chemistry 2009;395(3):863-7.
2009: Quaak S G L; van den Berg J H; Oosterhuis K; Beijnen J H; Haanen J B A G; Nuijen B
DNA tattoo vaccination: effect on plasmid purity and transfection efficiency of different topoisoforms.
Journal of controlled release : official journal of the Controlled Release Society 2009;139(2):153-9.
2009: Damen Carola W N; Speijer Han; Hermens Wim T; Schellens Jan H M; Rosing Hilde; Beijnen Jos H
The bioanalysis of trastuzumab in human serum using precipitate-enhanced ellipsometry.
Analytical biochemistry 2009;393(1):73-9.
2009: Tulner Linda R; van der Jagt-Willlems Hanna C; Beijnen Jos H
Intoxication with trazodone caused by dirty facsimile machine.
Journal of the American Geriatrics Society 2009;57(9):1718-9.
2009: Koolen Stijn L W; Huitema Alwin D R; Jansen Robert S; van Voorthuizen Theo; Beijnen Jos H; Smit Willem M; Schellens Jan H M
Pharmacokinetics of gemcitabine and metabolites in a patient with double-sided nephrectomy: a case report and review of the literature.
The oncologist 2009;14(9):944-8.
2009: ter Heine R; Hillebrand M J X; Rosing H; van Gorp E C M; Mulder J W; Beijnen J H; Huitema A D R
Identification and profiling of circulating metabolites of atazanavir, a HIV protease inhibitor.
Drug metabolism and disposition: the biological fate of chemicals 2009;37(9):1826-40.
2009: van Vliet Mariska; von Rosenstiel Inès A; Schindhelm Roger K; Brandjes Dees P M; Beijnen Jos H; Diamant Michaela
Identifying the metabolic syndrome in obese children and adolescents: do age and definition matter?
Current clinical pharmacology 2009;4(3):233-8.
2009: Tulner Linda R; Kuper Ingeborg M J A; van Campen Jos P C M; Koks Cornelis H W; Mac Gillavry Melvin R; Beijnen Jos H; Brandjes Desiderius P M
Treatment of hypertension in an elderly outpatient population in the Netherlands.
The American journal of geriatric pharmacotherapy 2009;7(4):204-9.
2009: Boss David S; Beijnen Jos H; Schellens Jan H M
Clinical experience with aurora kinase inhibitors: a review.
The oncologist 2009;14(8):780-93.
2009: Teunissen S F; Rosing H; Koornstra R H T; Linn S C; Schellens J H M; Schinkel A H; Beijnen J H
Development and validation of a quantitative assay for the analysis of tamoxifen with its four main metabolites and the flavonoids daidzein, genistein and glycitein in human serum using liquid chromatography coupled with tandem mass spectrometry.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 2009;877(24):2519-29.
2009: Engwegen Judith Y M N; Mehra Niven; Haanen John B A G; Schellens Jan H M; Voest Emile E; Beijnen Jos H
Identification of two new serum protein profiles for renal cell carcinoma.
Oncology reports 2009;22(2):401-8.
2009: Damen Carola W N; de Groot Els R; Heij Marianne; Boss David S; Schellens Jan H M; Rosing Hilde; Beijnen Jos H; Aarden Lucien A
Development and validation of an enzyme-linked immunosorbent assay for the quantification of trastuzumab in human serum and plasma.
Analytical biochemistry 2009;391(2):114-20.
2009: Gast Marie-Christine W; van Dulken Eric J; van Loenen Thea K G; Kingma-Vegter Florine; Westerga Johan; Flohil Claudie C; Knol Jaco C; Jimenez Connie R; van Gils Carla H; Wessels Lodewijk F A; Schellens Jan H N; Beijnen Jos H
Detection of breast cancer by surface-enhanced laser desorption/ionization time-of-flight mass spectrometry tissue and serum protein profiling.
The International journal of biological markers 2009;24(3):130-41.
2009: Hendrikx Jeroen J M A; Beijnen Jos H; Schellens Jan H M
Methylnaltrexone.
The oncologist 2009;14(7):679-82.
2009: Boss David S; Siegel-Lakhai Wandena S; van Egmond-Schoemaker Nadja E; Pluim Dick; Rosing Hilde; Ten Bokkel Huinink Wim W; Beijnen Jos H; Schellens Jan H M
Phase I pharmacokinetic and pharmacodynamic study of Carboplatin and topotecan administered intravenously every 28 days to patients with malignant solid tumors.
Clinical cancer research : an official journal of the American Association for Cancer Research 2009;15(13):4475-83.
2009: Gast Marie-Christine W; Van Gils Carla H; Wessels Lodewijk F A; Harris Nathan; Bonfrer Johannes M G; Rutgers Emiel J Th; Schellens Jan H M; Beijnen Jos H
Serum protein profiling for diagnosis of breast cancer using SELDI-TOF MS.
Oncology reports 2009;22(1):205-13.
2009: Gast Marie-Christine W; Schellens Jan H M; Beijnen Jos H
Clinical proteomics in breast cancer: a review.
Breast cancer research and treatment 2009;116(1):17-29.
2009: Oostendorp Roos L; Huitema Alwin; Rosing Hilde; Jansen Robert S; Ter Heine Rob; Keessen Marianne; Beijnen Jos H; Schellens Jan H M
Coadministration of ritonavir strongly enhances the apparent oral bioavailability of docetaxel in patients with solid tumors.
Clinical cancer research : an official journal of the American Association for Cancer Research 2009;15(12):4228-33.
2009: Damen Carola W N; Rosing Hilde; Schellens Jan H M; Beijnen Jos H
Application of dried blood spots combined with high-performance liquid chromatography coupled with electrospray ionisation tandem mass spectrometry for simultaneous quantification of vincristine and actinomycin-D.
Analytical and bioanalytical chemistry 2009;394(4):1171-82.
2009: Ekhart Corine; Rodenhuis Sjoerd; Schellens Jan H M; Beijnen Jos H; Huitema Alwin D R
Carboplatin dosing in overweight and obese patients with normal renal function, does weight matter?
Cancer chemotherapy and pharmacology 2009;64(1):115-22.
2009: Harmsen S; Meijerman I; Beijnen J H; Schellens J H M
Nuclear receptor mediated induction of cytochrome P450 3A4 by anticancer drugs: a key role for the pregnane X receptor.
Cancer chemotherapy and pharmacology 2009;64(1):35-43.
2009: Tulner Linda R; Frankfort Suzanne V; Wesselius Floor; van Campen Jos P C M; Koks Cornelis H W; Beijnen Jos H
Do geriatric outpatients adhere to medication changes advised after assessment? An exploratory pilot study.
Current clinical pharmacology 2009;4(2):154-8.
2009: van Vliet Mariska; von Rosenstiel Inès A; Schindhelm Roger K; Brandjes Desiderius P M; Beijnen Jos H; Diamant Michaela
The association of elevated alanine aminotransferase and the metabolic syndrome in an overweight and obese pediatric population of multi-ethnic origin.
European journal of pediatrics 2009;168(5):585-91.
2009: Tulner Linda R; Kuper Ingeborg M J A; Frankfort Suzanne V; van Campen Jos P C M; Koks Cornelis H W; Brandjes Desiderius P M; Beijnen Jos H
Discrepancies in reported drug use in geriatric outpatients: relevance to adverse events and drug-drug interactions.
The American journal of geriatric pharmacotherapy 2009;7(2):93-104.
2009: Lagas Jurjen S; van Waterschoot Robert A B; van Tilburg Vicky A C J; Hillebrand Michel J; Lankheet Nienke; Rosing Hilde; Beijnen Jos H; Schinkel Alfred H
Brain accumulation of dasatinib is restricted by P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) and can be enhanced by elacridar treatment.
Clinical cancer research : an official journal of the American Association for Cancer Research 2009;15(7):2344-51.
2009: Jansen Robert S; Rosing Hilde; Schellens Jan H M; Beijnen Jos H
Retention studies of 2'-2'-difluorodeoxycytidine and 2'-2'-difluorodeoxyuridine nucleosides and nucleotides on porous graphitic carbon: development of a liquid chromatography-tandem mass spectrometry method.
Journal of chromatography. A 2009;1216(15):3168-74.
2009: Oostendorp Roos L; van de Steeg Evita; van der Kruijssen Cornelia M M; Beijnen Jos H; Kenworthy Kathryn E; Schinkel Alfred H; Schellens Jan H M
Organic anion-transporting polypeptide 1B1 mediates transport of Gimatecan and BNP1350 and can be inhibited by several classic ATP-binding cassette (ABC) B1 and/or ABCG2 inhibitors.
Drug metabolism and disposition: the biological fate of chemicals 2009;37(4):917-23.
2009: Oostendorp Roos L; Beijnen Jos H; Schellens Jan H M
The biological and clinical role of drug transporters at the intestinal barrier.
Cancer treatment reviews 2009;35(2):137-47.
2009: Keizer Ron J; Zamacona Miren K; Jansen Mendel; Critchley David; Wanders Jantien; Beijnen Jos H; Schellens Jan H M; Huitema Alwin D R
Application of population pharmacokinetic modeling in early clinical development of the anticancer agent E7820.
Investigational new drugs 2009;27(2):140-52.
2009: van den Berg Joost H; Nujien Bastiaan; Beijnen Jos H; Vincent Andrew; van Tinteren Harm; Kluge Jörn; Woerdeman Leonie A E; Hennink Wim E; Storm Gert; Schumacher Ton N; Haanen John B A G
Optimization of intradermal vaccination by DNA tattooing in human skin.
Human gene therapy 2009;20(3):181-9.
2009: Oostendorp R L; Loftiss J; Goel S; Smith D A; Dar M M; Witteveen P O; Cohen R B; Lewis L D; Kurian S; Patnaik A; Rosing H; Beijnen J H; Voest E E; Burris H; J
Bioequivalence study of a new oral topotecan formulation, relative to the current topotecan formulation, in patients with advanced solid tumors.
International journal of clinical pharmacology and therapeutics 2009;47(3):195-206.
2009: Damen Carola W N; Israëls Trijn; Caron Huib N; Schellens Jan H M; Rosing Hilde; Beijnen Jos H
Validated assay for the simultaneous quantification of total vincristine and actinomycin-D concentrations in human EDTA plasma and of vincristine concentrations in human plasma ultrafiltrate by high-performance liquid chromatography coupled with tandem mass spectrometry.
Rapid communications in mass spectrometry : RCM 2009;23(6):763-74.
2009: Tran Ly; Baars Joke W; Maessen Harry J; Hoefnagel Cornelis A; Beijnen Jos H; Huitema Alwin D R
A simple and safe method for 131I radiolabeling of rituximab for myeloablative high-dose radioimmunotherapy.
Cancer biotherapy & radiopharmaceuticals 2009;24(1):103-10.
2009: Zandvliet Anthe S; Schellens Jan H M; Copalu William; Beijnen Jos H; Huitema Alwin D R
Covariate-based dose individualization of the cytotoxic drug indisulam to reduce the risk of severe myelosuppression.
Journal of pharmacokinetics and pharmacodynamics 2009;36(1):39-62.
2009: ter Heine R; Davids M; Rosing H; van Gorp E C M; Mulder J W; van der Heide Y T; Beijnen J H; Huitema A D R
Quantification of HIV protease inhibitors and non-nucleoside reverse transcriptase inhibitors in peripheral blood mononuclear cell lysate using liquid chromatography coupled with tandem mass spectrometry.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 2009;877(5-6):575-80.
2009: Ekhart Corine; Rodenhuis Sjoerd; Beijnen Jos H; Huitema Alwin D R
Pharmacokinetics of cyclophosphamide and thiotepa in a conventional fractionated high-dose regimen compared with a novel simplified unfractionated regimen.
Therapeutic drug monitoring 2009;31(1):95-103.
2009: Quaak S G L; Nuijen B; Haanen J B A G; Beijnen J H
Development and validation of an anion-exchange LC-UV method for the quantification and purity determination of the DNA plasmid pDERMATT.
Journal of pharmaceutical and biomedical analysis 2009;49(2):282-8.
2009: Ter Heine R; Rosing H; van Gorp E C M; Mulder J W; Beijnen J H; Huitema A D R
Quantification of etravirine (TMC125) in plasma, dried blood spots and peripheral blood mononuclear cell lysate by liquid chromatography tandem mass spectrometry.
Journal of pharmaceutical and biomedical analysis 2009;49(2):393-400.
2009: Ekhart Corine; Rodenhuis Sjoerd; Smits Paul H M; Beijnen Jos H; Huitema Alwin D R
An overview of the relations between polymorphisms in drug metabolising enzymes and drug transporters and survival after cancer drug treatment.
Cancer treatment reviews 2009;35(1):18-31.
2009: Beumer Jan Handrick; Lopez-Lazaro L; Schellens Jan H M; Beijnen Jos H; van Tellingen Olaf
Evaluation of human plasma protein binding of trabectedin (Yondelis, ET-743).
Current clinical pharmacology 2009;4(1):38-42.
2009: Sparidans Rolf W; Vlaming Maria L H; Lagas Jurjen S; Schinkel Afred H; Schellens Jan H M; Beijnen Jos H
Liquid chromatography-tandem mass spectrometric assay for sorafenib and sorafenib-glucuronide in mouse plasma and liver homogenate and identification of the glucuronide metabolite.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 2009;877(3):269-76.
2009: Ekhart Corine; Doodeman Valerie D; Rodenhuis Sjoerd; Smits Paul H M; Beijnen Jos H; Huitema Alwin D R
Polymorphisms of drug-metabolizing enzymes (GST, CYP2B6 and CYP3A) affect the pharmacokinetics of thiotepa and tepa.
British journal of clinical pharmacology 2009;67(1):50-60.
2009: Ekhart Corine; Kerst J Martijn; Rodenhuis Sjoerd; Beijnen Jos H; Huitema Alwin D R
Altered cyclophosphamide and thiotepa pharmacokinetics in a patient with moderate renal insufficiency.
Cancer chemotherapy and pharmacology 2009;63(2):375-9.
2009: Damen Carola W N; Schellens Jan H M; Beijnen Jos H
Bioanalytical methods for the quantification of therapeutic monoclonal antibodies and their application in clinical pharmacokinetic studies.
Human antibodies 2009;18(3):47-73.
2009: Ter Heine Rob; Huitema Alwin Dr; Jansen Robert S; Smits Paul Hm; van Gorp Eric Cm; Wagenaar Jiri Fp; Beijnen Jos H; Mulder Jan W
Prolonged exposure to tenofovir monotherapy 1 month after treatment discontinuation because of tenofovir-related renal failure.
Antiviral therapy 2009;14(2):299-301.
2009: Gast Marie-Christine W; van Gils Carla H; Wessels Lodewijk F A; Harris Nathan; Bonfrer Johannes M G; Rutgers Emiel J Th; Schellens Jan H M; Beijnen Jos H
Influence of sample storage duration on serum protein profiles assessed by surface-enhanced laser desorption/ionisation time-of-flight mass spectrometry (SELDI-TOF MS).
Clinical chemistry and laboratory medicine : CCLM / FESCC 2009;47(6):694-705.
2009: van Vliet Mariska; von Rosenstiel Inès A; Schindhelm Roger K; Brandjes Desiderius P M; Beijnen Jos H; Diamant Michaela
Ethnic differences in cardiometabolic risk profile in an overweight/obese paediatric cohort in the Netherlands: a cross-sectional study.
Cardiovascular diabetology 2009;8():2.
2009: van Winden Annemieke Wj; Gast Marie-Christine W; Beijnen Jos H; Rutgers Emiel Jth; Grobbee Diederick E; Peeters Petra Hm; van Gils Carla H
Validation of previously identified serum biomarkers for breast cancer with SELDI-TOF MS: a case control study.
BMC medical genomics 2009;2():4.
2009: Brouwers E E M; Söhne M; Kuipers S; van Gorp E C M; Schellens J H M; Koks C H W; Beijnen J H; Huitema A D R
Ciprofloxacin strongly inhibits clozapine metabolism: two case reports.
Clinical drug investigation 2009;29(1):59-63.
2008: Veltkamp Stephan A; Witteveen Els O; Capriati Angela; Crea Attilio; Animati Fabio; Voogel-Fuchs Marja; van den Heuvel Ingeborg J G M; Beijnen Jos H; Voest Emile E; Schellens Jan H M
Clinical and pharmacologic study of the novel prodrug delimotecan (MEN 4901/T-0128) in patients with solid tumors.
Clinical cancer research : an official journal of the American Association for Cancer Research 2008;14(22):7535-44.
2008: Ekhart Corine; Rodenhuis Sjoerd; Smits Paul H M; Beijnen Jos H; Huitema Alwin D R
Relations between polymorphisms in drug-metabolising enzymes and toxicity of chemotherapy with cyclophosphamide, thiotepa and carboplatin.
Pharmacogenetics and genomics 2008;18(11):1009-15.
2008: Deenen Maarten J; Beijnen Jos H; Schellens Jan H M
Is fluorouracil-induced severe toxicity in DPYD*2A individuals related to sex or to treatment regimen?
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008;26(30):4997-8; author reply 4998-9.
2008: Beijnen J H; van der Schoot S C; Nuijen B; Flesch F M; Gore A; Mirejovsky D; Lenaz L
Complexation study of the anticancer agent EO-9 with 2-hydroxypropyl-beta-cyclodextrin.
Drug development and industrial pharmacy 2008;34(10):1130-9.
2008: Zandvliet Anthe S; Schellens Jan H M; Dittrich Christian; Wanders Jantien; Beijnen Jos H; Huitema Alwin D R
Population pharmacokinetic and pharmacodynamic analysis to support treatment optimization of combination chemotherapy with indisulam and carboplatin.
British journal of clinical pharmacology 2008;66(4):485-97.
2008: Quaak S G L; van den Berg J H; Toebes M; Schumacher T N M; Haanen J B A G; Beijnen J H; Nuijen B
GMP production of pDERMATT for vaccination against melanoma in a phase I clinical trial.
European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft für Pharmazeutische Verfahrenstechnik e.V 2008;70(2):429-38.
2008: Meijerman Irma; Beijnen Jos H; Schellens Jan H M
Combined action and regulation of phase II enzymes and multidrug resistance proteins in multidrug resistance in cancer.
Cancer treatment reviews 2008;34(6):505-20.
2008: Frankfort Suzanne V; van Campen Jos P C M; Tulner Linda R; Beijnen Jos H
Serum amyloid beta peptides in patients with dementia and age-matched non-demented controls as detected by surface-enhanced laser desorption ionisation-time of flight mass spectrometry (SELDI-TOF MS).
Current clinical pharmacology 2008;3(3):144-54.
2008: van den Broek Irene; Sparidans Rolf W; Schellens Jan H M; Beijnen Jos H
Liquid chromatography/tandem mass spectrometric method for the quantification of eight proteolytic fragments of ITIH4 with biomarker potential in human plasma and serum.
Rapid communications in mass spectrometry : RCM 2008;22(18):2915-28.
2008: van den Broek Irene; Sparidans Rolf W; Schellens Jan H M; Beijnen Jos H
Quantitative bioanalysis of peptides by liquid chromatography coupled to (tandem) mass spectrometry.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 2008;872(1-2):1-22.
2008: Sparidans Rolf W; Lagas Jurjen S; Schinkel Afred H; Schellens Jan H M; Beijnen Jos H
Liquid chromatography-tandem mass spectrometric assay for diclofenac and three primary metabolites in mouse plasma.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 2008;872(1-2):77-82.
2008: Veltkamp Stephan A; Pluim Dick; van Eijndhoven Maria A J; Bolijn Maria J; Ong Felix H G; Govindarajan Rajgopal; Unadkat Jashvant D; Beijnen Jos H; Schellens Jan H M
New insights into the pharmacology and cytotoxicity of gemcitabine and 2',2'-difluorodeoxyuridine.
Molecular cancer therapeutics 2008;7(8):2415-25.
2008: Marchetti Serena; de Vries Nienke A; Buckle Tessa; Bolijn Maria J; van Eijndhoven Maria A J; Beijnen Jos H; Mazzanti Roberto; van Tellingen Olaf; Schellens Jan H M
Effect of the ATP-binding cassette drug transporters ABCB1, ABCG2, and ABCC2 on erlotinib hydrochloride (Tarceva) disposition in in vitro and in vivo pharmacokinetic studies employing Bcrp1-/-/Mdr1a/1b-/- (triple-knockout) and wild-type mice.
Molecular cancer therapeutics 2008;7(8):2280-7.
2008: Dorlo Thomas P C; van Thiel Pieter P A M; Huitema Alwin D R; Keizer Ron J; de Vries Henry J C; Beijnen Jos H; de Vries Peter J
Pharmacokinetics of miltefosine in Old World cutaneous leishmaniasis patients.
Antimicrobial agents and chemotherapy 2008;52(8):2855-60.
2008: Veltkamp Stephan A; Pluim Dick; van Tellingen Olaf; Beijnen Jos H; Schellens Jan H M
Extensive metabolism and hepatic accumulation of gemcitabine after multiple oral and intravenous administration in mice.
Drug metabolism and disposition: the biological fate of chemicals 2008;36(8):1606-15.
2008: Brouwers Elke E M; Huitema Alwin D R; Schellens Jan H M; Beijnen Jos H
The effects of sulfur-containing compounds and gemcitabine on the binding of cisplatin to plasma proteins and DNA determined by inductively coupled plasma mass spectrometry and high performance liquid chromatography-inductively coupled plasma mass spectrometry.
Anti-cancer drugs 2008;19(6):621-30.
2008: Timmers Gert Jan; Kessels Lonneke W; Wilhelm Abraham J; Veldkamp Agnes I; Bosch Tessa M; Beijnen Jos H; Huijgens Peter C
Effects of cyclosporine a on single-dose pharmacokinetics of intravenous itraconazole in patients with hematologic malignancies.
Therapeutic drug monitoring 2008;30(3):301-5.
2008: Veltkamp Stephan A; Jansen Robert S; Callies Sophie; Pluim Dick; Visseren-Grul Carla M; Rosing Hilde; Kloeker-Rhoades Susanne; Andre Valerie A M; Beijnen Jos H; Slapak Christopher A; Schellens Jan H M
Oral administration of gemcitabine in patients with refractory tumors: a clinical and pharmacologic study.
Clinical cancer research : an official journal of the American Association for Cancer Research 2008;14(11):3477-86.
2008: Appels N M G M; Bolijn M J; Chan K; Stephens T C; Hoctin-Boes G; Middleton M; Beijnen J H; de Bono J S; Harris A L; Schellens J H M
Phase I pharmacokinetic and pharmacodynamic study of the prenyl transferase inhibitor AZD3409 in patients with advanced cancer.
British journal of cancer 2008;98(12):1951-8.
2008: Damen Carola W N; Rosing Hilde; Tibben Matthijs M; van Maanen Maria J; Lagas Jurjen S; Schinkel Alfred H; Schellens Jan H M; Beijnen Jos H
A sensitive assay for the quantitative analysis of vinorelbine in mouse and human EDTA plasma by high-performance liquid chromatography coupled with electrospray tandem mass spectrometry.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 2008;868(1-2):102-9.
2008: Ekhart Corine; Doodeman Valerie D; Rodenhuis Sjoerd; Smits Paul H M; Beijnen Jos H; Huitema Alwin D R
Influence of polymorphisms of drug metabolizing enzymes (CYP2B6, CYP2C9, CYP2C19, CYP3A4, CYP3A5, GSTA1, GSTP1, ALDH1A1 and ALDH3A1) on the pharmacokinetics of cyclophosphamide and 4-hydroxycyclophosphamide.
Pharmacogenetics and genomics 2008;18(6):515-23.
2008: Harmsen S; Koster A S; Beijnen J H; Schellens J H M; Meijerman I
Comparison of two immortalized human cell lines to study nuclear receptor-mediated CYP3A4 induction.
Drug metabolism and disposition: the biological fate of chemicals 2008;36(6):1166-71.
2008: Zandvliet A S; Siegel-Lakhai W S; Beijnen J H; Copalu W; Etienne-Grimaldi M-C; Milano G; Schellens J H M; Huitema A D R
PK/PD model of indisulam and capecitabine: interaction causes excessive myelosuppression.
Clinical pharmacology and therapeutics 2008;83(6):829-39.
2008: Frankfort Suzanne V; Tulner Linda R; van Campen Jos P C M; Verbeek Marcel M; Jansen René W M M; Beijnen Jos H
Amyloid beta protein and tau in cerebrospinal fluid and plasma as biomarkers for dementia: a review of recent literature.
Current clinical pharmacology 2008;3(2):123-31.
2008: ter Heine R; Rosing H; van Gorp E C M; Mulder J W; van der Steeg W A; Beijnen J H; Huitema A D R
Quantification of protease inhibitors and non-nucleoside reverse transcriptase inhibitors in dried blood spots by liquid chromatography-triple quadrupole mass spectrometry.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 2008;867(2):205-12.
2008: Siegel-Lakhai W S; Zandvliet A S; Huitema A D R; Tibben M M; Milano G; Girre V; Diéras V; King A; Richmond E; Wanders J; Beijnen J H; Schellens J H M
A dose-escalation study of indisulam in combination with capecitabine (Xeloda) in patients with solid tumours.
British journal of cancer 2008;98(8):1320-6.
2008: Dorlo Thomas P C; Hillebrand Michel J X; Rosing Hilde; Eggelte Teunis A; de Vries Peter J; Beijnen Jos H
Development and validation of a quantitative assay for the measurement of miltefosine in human plasma by liquid chromatography-tandem mass spectrometry.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 2008;865(1-2):55-62.
2008: de Bree Eelco; Rosing Hilde; Filis Dimitris; Romanos John; Melisssourgaki Maria; Daskalakis Markos; Pilatou Maria; Sanidas Elias; Taflampas Panagiotis; Kalbakis Konstantinos; Beijnen Jos H; Tsiftsis Dimitris D
Cytoreductive surgery and intraoperative hyperthermic intraperitoneal chemotherapy with paclitaxel: a clinical and pharmacokinetic study.
Annals of surgical oncology 2008;15(4):1183-92.
2008: Veltkamp Stephan A; Beijnen Jos H; Schellens Jan H M
Prolonged versus standard gemcitabine infusion: translation of molecular pharmacology to new treatment strategy.
The oncologist 2008;13(3):261-76.
2008: Brouwers Elke E M; Tibben Matthijs; Rosing H; Schellens Jan H M; Beijnen Jos H
The application of inductively coupled plasma mass spectrometry in clinical pharmacological oncology research.
Mass spectrometry reviews 2008;27(2):67-100.
2008: Lagas Jurjen S; Sparidans Rolf W; van Waterschoot Robert A B; Wagenaar Els; Beijnen Jos H; Schinkel Alfred H
P-glycoprotein limits oral availability, brain penetration, and toxicity of an anionic drug, the antibiotic salinomycin.
Antimicrobial agents and chemotherapy 2008;52(3):1034-9.
2008: van Waterschoot Robert A B; van Herwaarden Antonius E; Lagas Jurjen S; Sparidans Rolf W; Wagenaar Els; van der Kruijssen Cornelia M M; Goldstein Joyce A; Zeldin Darryl C; Beijnen Jos H; Schinkel Alfred H
Midazolam metabolism in cytochrome P450 3A knockout mice can be attributed to up-regulated CYP2C enzymes.
Molecular pharmacology 2008;73(3):1029-36.
2008: Damen Carola W N; Rosing Hilde; Schellens Jan H M; Beijnen Jos H
Quantitative aspects of the analysis of the monoclonal antibody trastuzumab using high-performance liquid chromatography coupled with electrospray mass spectrometry.
Journal of pharmaceutical and biomedical analysis 2008;46(3):449-55.
2008: Boss David S; Olmos Renato Valdes; Sinaasappel Michiel; Beijnen Jos H; Schellens Jan H M
Application of PET/CT in the development of novel anticancer drugs.
The oncologist 2008;13(1):25-38.
2008: Gast Marie-Christine W; van Tinteren Harm; Bontenbal Marijke; van Hoesel René Q G C M; Nooij Marianne A; Rodenhuis Sjoerd; Span Paul N; Tjan-Heijnen Vivianne C G; de Vries Elisabeth G E; Harris Nathan; Twisk Jos W R; Schellens Jan H M; Beijnen Jos H
Haptoglobin phenotype is not a predictor of recurrence free survival in high-risk primary breast cancer patients.
BMC cancer 2008;8():389.
2008: ter Heine Rob; Scherpbier Henriette J; Crommentuyn Kristel M L; Bekker Vincent; Beijnen Jos H; Kuijpers Taco W; Huitema Alwin D R
A pharmacokinetic and pharmacogenetic study of efavirenz in children: dosing guidelines can result in subtherapeutic concentrations.
Antiviral therapy 2008;13(6):779-87.
2008: Brouwers Elke E M; Huitema Alwin D R; Beijnen Jos H; Schellens Jan H M
Long-term platinum retention after treatment with cisplatin and oxaliplatin.
BMC clinical pharmacology 2008;8():7.
2008: Zandvliet Anthe S; Schellens Jan H M; Beijnen Jos H; Huitema Alwin D R
Population pharmacokinetics and pharmacodynamics for treatment optimization in clinical oncology.
Clinical pharmacokinetics 2008;47(8):487-513.
2008: Voskuil Dorien W; Vrieling Alina; Korse Catharina M; Beijnen Jos H; Bonfrer Johannes M G; van Doorn Jaap; Kaas Reinie; Oldenburg Hester S A; Russell Nicola S; Rutgers Emiel J T; Verhoef Senno; van Leeuwen Flora E; van't Veer Laura J; Rookus Matti A
Effects of lycopene on the insulin-like growth factor (IGF) system in premenopausal breast cancer survivors and women at high familial breast cancer risk.
Nutrition and cancer 2008;60(3):342-53.
2008: Tulner Linda R; Frankfort Suzanne V; Gijsen George J P T; van Campen Jos P C M; Koks Cornelis H W; Beijnen Jos H
Drug-drug interactions in a geriatric outpatient cohort: prevalence and relevance.
Drugs & aging 2008;25(4):343-55.
2008: Meuleman Wouter; Engwegen Judith Ymn; Gast Marie-Christine W; Beijnen Jos H; Reinders Marcel Jt; Wessels Lodewyk Fa
Comparison of normalisation methods for surface-enhanced laser desorption and ionisation (SELDI) time-of-flight (TOF) mass spectrometry data.
BMC bioinformatics 2008;9():88.
2008: Gast Marie-Christine W; Engwegen Judith Ymn; Schellens Jan Hm; Beijnen Jos H
Comparing the old and new generation SELDI-TOF MS: implications for serum protein profiling.
BMC medical genomics 2008;1():4.
2008: Vainchtein Liia D; Rosing Hilde; Mirejovsky Dorla; Huynh Van; Lenaz Luigi; Schellens Jan H M; Beijnen Jos H
Enhanced resolution triple-quadrupole mass spectrometry for ultra-sensitive and quantitative analysis of the investigational anticancer agent EO9 (apaziquone) and its metabolite EO5a in human and dog plasma to support (pre)-clinical studies of EOquin given intravesically.
Rapid communications in mass spectrometry : RCM 2008;22(4):462-70.
2007: Marchetti Serena; Oostendorp Roos L; Pluim Dick; van Eijndhoven Monique; van Tellingen Olaf; Schinkel Alfred H; Versace Richard; Beijnen Jos H; Mazzanti Roberto; Schellens Jan H
In vitro transport of gimatecan (7-t-butoxyiminomethylcamptothecin) by breast cancer resistance protein, P-glycoprotein, and multidrug resistance protein 2.
Molecular cancer therapeutics 2007;6(12 Pt 1):3307-13.
2007: van Herwaarden Antonius E; Wagenaar Els; van der Kruijssen Cornelia M M; van Waterschoot Robert A B; Smit Johan W; Song Ji-Ying; van der Valk Martin A; van Tellingen Olaf; van der Hoorn José W A; Rosing Hilde; Beijnen Jos H; Schinkel Alfred H
Knockout of cytochrome P450 3A yields new mouse models for understanding xenobiotic metabolism.
The Journal of clinical investigation 2007;117(11):3583-92.
2007: de Vries Nienke A; Zhao Jin; Kroon Emily; Buckle Tessa; Beijnen Jos H; van Tellingen Olaf
P-glycoprotein and breast cancer resistance protein: two dominant transporters working together in limiting the brain penetration of topotecan.
Clinical cancer research : an official journal of the American Association for Cancer Research 2007;13(21):6440-9.
2007: Joerger Markus; Huitema Alwin D R; Richel Dick J; Dittrich Christian; Pavlidis Nikolas; Briasoulis Evangelos; Vermorken Jan B; Strocchi Elena; Martoni Andrea; Sorio Roberto; Sleeboom Henk P; Izquierdo Miguel A; Jodrell Duncan I; Calvert Hilary; Boddy Alan V; Hollema Harry; Féty Regine; Van der Vijgh Wjf J F; Hempel Georg; Chatelut Etienne; Karlsson Mats; Wilkins Justin; Tranchand Brigitte; Schrijvers Ad H G J; Twelves Christian; Beijnen Jos H; Schellens Jan H M
Population pharmacokinetics and pharmacodynamics of paclitaxel and carboplatin in ovarian cancer patients: a study by the European organization for research and treatment of cancer-pharmacology and molecular mechanisms group and new drug development group.
Clinical cancer research : an official journal of the American Association for Cancer Research 2007;13(21):6410-8.
2007: Joerger M; Huitema A D R; Huizing M T; Willemse P H B; de Graeff A; Rosing H; Schellens J H M; Beijnen J H; Vermorken J B
Safety and pharmacology of paclitaxel in patients with impaired liver function: a population pharmacokinetic-pharmacodynamic study.
British journal of clinical pharmacology 2007;64(5):622-33.
2007: de Vries Nienke A; Ouwehand Mariët; Buckle Tessa; Beijnen Jos H; van Tellingen Olaf
Determination of topotecan in human and mouse plasma and in mouse tissue homogenates by reversed-phase high-performance liquid chromatography.
Biomedical chromatography : BMC 2007;21(11):1191-200.
2007: Veltkamp S A; Rosing H; Huitema A D R; Fetell M R; Nol A; Beijnen J H; Schellens J H M
Novel paclitaxel formulations for oral application: a phase I pharmacokinetic study in patients with solid tumours.
Cancer chemotherapy and pharmacology 2007;60(5):635-42.
2007: Vainchtein Liia D; Rosing Hilde; Maier Armin; Fiebig Heinz-Herbert; Schellens Jan H M; Beijnen Jos H
Quantitative and selective assay of 5-methylindirubine, an inhibitor of cyclin-dependent kinases, in murine plasma using coupled liquid chromatography and electrospray tandem mass spectrometry.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 2007;856(1-2):261-6.
2007: Campone Mario; Rademaker-Lakhai Jeany M; Bennouna Jaafar; Howell Stephen B; Nowotnik David P; Beijnen Jos H; Schellens Jan H M
Phase I and pharmacokinetic trial of AP5346, a DACH-platinum-polymer conjugate, administered weekly for three out of every 4 weeks to advanced solid tumor patients.
Cancer chemotherapy and pharmacology 2007;60(4):523-33.
2007: Marchetti Serena; Mazzanti Roberto; Beijnen Jos H; Schellens Jan H M
Concise review: Clinical relevance of drug drug and herb drug interactions mediated by the ABC transporter ABCB1 (MDR1, P-glycoprotein).
The oncologist 2007;12(8):927-41.
2007: Siegel-Lakhai Wandena S; Beijnen Jos H; Vervenne Walter L; Boot Henk; Keessen Marianne; Versola Melissa; Koch Kevin M; Smith Deborah A; Pandite Lini; Richel Dirk J; Schellens Jan H M
Phase I pharmacokinetic study of the safety and tolerability of lapatinib (GW572016) in combination with oxaliplatin/fluorouracil/leucovorin (FOLFOX4) in patients with solid tumors.
Clinical cancer research : an official journal of the American Association for Cancer Research 2007;13(15 Pt 1):4495-502.
2007: Rademaker-Lakhai Jeany M; Beerepoot Laurens V; Mehra Niven; Radema Sandra A; van Maanen Rianne; Vermaat Joost S; Witteveen Els O; Visseren-Grul Carla M; Musib Luna; Enas Nathan; van Hal Gertjan; Beijnen Jos H; Schellens Jan H M; Voest Emile E
Phase I pharmacokinetic and pharmacodynamic study of the oral protein kinase C beta-inhibitor enzastaurin in combination with gemcitabine and cisplatin in patients with advanced cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2007;13(15 Pt 1):4474-81.
2007: Sparidans Rolf W; Lagas Jurjen S; Schinkel Afred H; Schellens Jan H M; Beijnen Jos H
Liquid chromatography-tandem mass spectrometric assays for salinomycin in mouse plasma, liver, brain and small intestinal contents and in OptiMEM cell culture medium.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 2007;855(2):200-10.
2007: van de Wetering Koen; Zelcer Noam; Kuil Annemieke; Feddema Wouter; Hillebrand Michel; Vlaming Maria L H; Schinkel Alfred H; Beijnen Jos H; Borst Piet
Multidrug resistance proteins 2 and 3 provide alternative routes for hepatic excretion of morphine-glucuronides.
Molecular pharmacology 2007;72(2):387-94.
2007: Brouwers E E M; Huitema A D R; Bakker E N; Douma J W; Schimmel K J M; van Weringh G; de Wolf P J; Schellens J H M; Beijnen J H
Monitoring of platinum surface contamination in seven Dutch hospital pharmacies using inductively coupled plasma mass spectrometry.
International archives of occupational and environmental health 2007;80(8):689-99.
2007: Beumer J H; Garner R C; Cohen M B; Galbraith S; Duncan G F; Griffin T; Beijnen J H; Schellens J H M
Human mass balance study of the novel anticancer agent ixabepilone using accelerator mass spectrometry.
Investigational new drugs 2007;25(4):327-34.
2007: van den Broek Irene; Sparidans Rolf W; Schellens Jan H M; Beijnen Jos H
Enzymatic digestion as a tool for the LC-MS/MS quantification of large peptides in biological matrices: measurement of chymotryptic fragments from the HIV-1 fusion inhibitor enfuvirtide and its metabolite M-20 in human plasma.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 2007;854(1-2):245-59.
2007: Ekhart Corine; Gebretensae Abadi; Rosing Hilde; Rodenhuis Sjoerd; Beijnen Jos H; Huitema Alwin D R
Simultaneous quantification of cyclophosphamide and its active metabolite 4-hydroxycyclophosphamide in human plasma by high-performance liquid chromatography coupled with electrospray ionization tandem mass spectrometry (LC-MS/MS).
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 2007;854(1-2):345-9.
2007: Oostendorp Roos L; Beijnen Jos H; Schellens Jan H M; Tellingen Olaf van
Determination of imatinib mesylate and its main metabolite (CGP74588) in human plasma and murine specimens by ion-pairing reversed-phase high-performance liquid chromatography.
Biomedical chromatography : BMC 2007;21(7):747-54.
2007: Kuppens Isa E L M; Witteveen Els O; Jewell Roxanne C; Radema Sandra A; Paul Elaine M; Mangum Steve G; Beijnen Jos H; Voest Emile E; Schellens Jan H M
A phase I, randomized, open-label, parallel-cohort, dose-finding study of elacridar (GF120918) and oral topotecan in cancer patients.
Clinical cancer research : an official journal of the American Association for Cancer Research 2007;13(11):3276-85.
2007: Harmsen S; Meijerman I; Beijnen J H; Schellens J H M
The role of nuclear receptors in pharmacokinetic drug-drug interactions in oncology.
Cancer treatment reviews 2007;33(4):369-80.
2007: Sparidans Rolf W; Prins Jan M; Schellens Jan H M; Beijnen Jos H
Liquid chromatography-tandem mass spectrometric assay for the nucleoside reverse transcriptase inhibitor emtricitabine in human plasma.
Biomedical chromatography : BMC 2007;21(6):621-7.
2007: Jonker Johan W; Musters Sandra; Vlaming Maria L H; Plösch Torsten; Gooijert Karin E R; Hillebrand Michel J; Rosing Hilde; Beijnen Jos H; Verkade Henkjan J; Schinkel Alfred H
Breast cancer resistance protein (Bcrp1/Abcg2) is expressed in the harderian gland and mediates transport of conjugated protoporphyrin IX.
American journal of physiology. Cell physiology 2007;292(6):C2204-12.
2007: Kuppens I E L M; Witteveen P O; Schot M; Schuessler V M; Daehling A; Beijnen J H; Voest E E; Schellens J H M
Phase I dose-finding and pharmacokinetic trial of orally administered indibulin (D-24851) to patients with solid tumors.
Investigational new drugs 2007;25(3):227-35.
2007: Zandvliet Anthe S; Huitema Alwin D R; Copalu William; Yamada Yasuhide; Tamura Tomohide; Beijnen Jos H; Schellens Jan H M
CYP2C9 and CYP2C19 polymorphic forms are related to increased indisulam exposure and higher risk of severe hematologic toxicity.
Clinical cancer research : an official journal of the American Association for Cancer Research 2007;13(10):2970-6.
2007: Oostendorp Roos L; Marchetti Serena; Beijnen Jos H; Mazzanti R; Schellens Jan H M
The effect of hydroxyurea on P-glycoprotein/BCRP-mediated transport and CYP3A metabolism of imatinib mesylate.
Cancer chemotherapy and pharmacology 2007;59(6):855-60.
2007: Frankfort S V; Appels B A; de Boer A; Tulner L R; van Campen J P C M; Koks C H W; Beijnen J H; Schmand B A
Identification of responders and reactive domains to rivastigmine in Alzheimer's disease.
Pharmacoepidemiology and drug safety 2007;16(5):545-51.
2007: Beumer Jan H; Rademaker-Lakhai Jeany M; Rosing Hilde; Hillebrand Michel J X; Bosch Tessa M; Lopez-Lazaro Luis; Schellens Jan H M; Beijnen Jos H
Metabolism of trabectedin (ET-743, Yondelis) in patients with advanced cancer.
Cancer chemotherapy and pharmacology 2007;59(6):825-37.
2007: van der Schoot S C; Nuijen B; Huitema A D R; Beijnen J H
Assessment of performance of manufacturing procedures in a unit for production of investigational anticancer agents, using a mixed effects analysis.
Pharmaceutical research 2007;24(3):605-12.
2007: Bosch T M; Meijerman I; Beijnen J H; van Thiel S W; Vlasveld L T
Lethal toxicity of uracil/tegafur in the treatment of sigmoid carcinoma.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2007;18(3):607-8.
2007: Engwegen Judith Y M N; Mehra Niven; Haanen John B A G; Bonfrer Johannes M G; Schellens Jan H M; Voest Emile E; Beijnen Jos H
Validation of SELDI-TOF MS serum protein profiles for renal cell carcinoma in new populations.
Laboratory investigation; a journal of technical methods and pathology 2007;87(2):161-72.
2007: van Herwaarden Antonius E; Wagenaar Els; Merino Gracia; Jonker Johan W; Rosing Hilde; Beijnen Jos H; Schinkel Alfred H
Multidrug transporter ABCG2/breast cancer resistance protein secretes riboflavin (vitamin B2) into milk.
Molecular and cellular biology 2007;27(4):1247-53.
2007: van der Schoot S C; Vainchtein L D; Beijnen J H; Gore A; Mirejovsky D; Lenaz L; Nuijen B
EO-9 bladder instillations: formulation selection based on stability characteristics and in vitro simulation studies.
International journal of pharmaceutics 2007;329(1-2):135-41.
2007: Brandon Esther F A; Sparidans Rolf W; van Ooijen Ronald D; Meijerman Irma; Lazaro Luis Lopez; Manzanares Ignacio; Beijnen Jos H; Schellens Jan H M
In vitro characterization of the human biotransformation pathways of aplidine, a novel marine anti-cancer drug.
Investigational new drugs 2007;25(1):9-19.
2007: Beumer Jan-Hendrik; Buckle Tessa; Ouwehand Mariet; Franke Niels E F; Lopez-Lazaro Luis; Schellens Jan H M; Beijnen Jos H; van Tellingen Olaf
Trabectedin (ET-743, Yondelis) is a substrate for P-glycoprotein, but only high expression of P-glycoprotein confers the multidrug resistance phenotype.
Investigational new drugs 2007;25(1):1-7.
2007: Sankatsing Sanjay U C; Cornelissen Marion; Kloosterboer Nico; Crommentuyn Kristel M L; Bosch Tessa M; Mul Frederik P; Jurriaans Suzanne; Huitema Alwin D R; Beijnen Jos H; Lange Joep M A; Prins Jan M; Schuitemaker Hanneke
Antiviral activity of HIV type 1 protease inhibitors nelfinavir and indinavir in vivo is not influenced by P-glycoprotein activity on CD4+ T cells.
AIDS research and human retroviruses 2007;23(1):19-27.
2007: van Leeuwen E; Ter Heine R; van der Veen F; Repping S; Beijnen J H; Prins J M
Penetration of atazanavir in seminal plasma of men infected with human immunodeficiency virus type 1.
Antimicrobial agents and chemotherapy 2007;51(1):335-7.
2007: Breedveld Pauline; Pluim Dick; Cipriani Greta; Dahlhaus Femke; van Eijndhoven Maria A J; de Wolf Cornelia J F; Kuil Annemieke; Beijnen Jos H; Scheffer George L; Jansen Gerrit; Borst Piet; Schellens Jan H M
The effect of low pH on breast cancer resistance protein (ABCG2)-mediated transport of methotrexate, 7-hydroxymethotrexate, methotrexate diglutamate, folic acid, mitoxantrone, topotecan, and resveratrol in in vitro drug transport models.
Molecular pharmacology 2007;71(1):240-9.
2007: Vainchtein Liia D; Rosing Hilde; Mirejovsky Dorla; Lenaz Luigi; Schellens Jan H M; Beijnen Jos H
Stability experiments in human urine with EO9 (apaziquone): a novel anticancer agent for the intravesical treatment of bladder cancer.
Journal of pharmaceutical and biomedical analysis 2007;43(1):285-92.
2007: Veltkamp S A; Alderden-Los C; Sharma A; Rosing H; Beijnen J H; Schellens J H M
A pharmacokinetic and safety study of a novel polymeric paclitaxel formulation for oral application.
Cancer chemotherapy and pharmacology 2007;59(1):43-50.
2007: Joerger Markus; Huitema Alwin D R; Richel Dick J; Dittrich Christian; Pavlidis Nikolas; Briasoulis Evangelos; Vermorken Jan B; Strocchi Elena; Martoni Andrea; Sorio Roberto; Sleeboom Henk P; Izquierdo Miguel A; Jodrell Duncan I; Féty Régine; de Bruijn Ernst; Hempel Georg; Karlsson Mats; Tranchand Brigitte; Schrijvers Ad H G J; Twelves Chris; Beijnen Jos H; Schellens Jan H M;
Population pharmacokinetics and pharmacodynamics of doxorubicin and cyclophosphamide in breast cancer patients: a study by the EORTC-PAMM-NDDG.
Clinical pharmacokinetics 2007;46(12):1051-68.
2007: Jansen Robert S; Rosing Hilde; de Wolf Cocky J F; Beijnen Jos H
Development and validation of an assay for the quantitative determination of cladribine nucleotides in MDCKII cells and culture medium using weak anion-exchange liquid chromatography coupled with tandem mass spectrometry.
Rapid communications in mass spectrometry : RCM 2007;21(24):4049-59.
2007: van der Schoot Sabien C; Nuijen Bastiaan; Flesch Frits M; Gore Ashok; Mirejovsky Dorla; Lenaz Luigi; Beijnen Jos H
Development of a bladder instillation of the indoloquinone anticancer agent EO-9 using tert-butyl alcohol as lyophilization vehicle.
AAPS PharmSciTech 2007;8(3):E61.
2007: ter Heine Rob; Alderden-Los Carolien G; Rosing Hilde; Hillebrand Michel J X; van Gorp Eric C M; Huitema Alwin D R; Beijnen Jos H
Fast and simultaneous determination of darunavir and eleven other antiretroviral drugs for therapeutic drug monitoring: method development and validation for the determination of all currently approved HIV protease inhibitors and non-nucleoside reverse transcriptase inhibitors in human plasma by liquid chromatography coupled with electrospray ionization tandem mass spectrometry.
Rapid communications in mass spectrometry : RCM 2007;21(15):2505-14.
2007: Vainchtein Liia D; Rosing Hilde; Thijssen Bas; Schellens Jan H M; Beijnen Jos H
Validated assay for the simultaneous determination of the anti-cancer agent gemcitabine and its metabolite 2',2'-difluorodeoxyuridine in human plasma by high-performance liquid chromatography with tandem mass spectrometry.
Rapid communications in mass spectrometry : RCM 2007;21(14):2312-22.
2007: Brouwers Elke E M; Tibben Matthijs M; Rosing Hilde; Schellens Jan H M; Beijnen Jos H
Determination of ruthenium originating from the investigational anti-cancer drug NAMI-A in human plasma ultrafiltrate, plasma, and urine by inductively coupled plasma mass spectrometry.
Rapid communications in mass spectrometry : RCM 2007;21(9):1521-30.
2007: Bosch Tessa M; Bakker Remko; Schellens Jan H M; Cats Annemieke; Smits Paul H M; Beijnen Jos H
Rapid detection of the DPYD IVS14+1G>A mutation for screening patients to prevent fluorouracil-related toxicity.
Molecular diagnosis & therapy 2007;11(2):105-8.
2007: Meijerman Irma; Sanderson Linda M; Smits Paul H M; Beijnen Jos H; Schellens Jan H M
Pharmacogenetic screening of the gene deletion and duplications of CYP2D6.
Drug metabolism reviews 2007;39(1):45-60.
2006: Veltkamp S A; Hillebrand M J X; Rosing H; Jansen R S; Wickremsinhe E R; Perkins E J; Schellens J H M; Beijnen J H
Quantitative analysis of gemcitabine triphosphate in human peripheral blood mononuclear cells using weak anion-exchange liquid chromatography coupled with tandem mass spectrometry.
Journal of mass spectrometry : JMS 2006;41(12):1633-42.
2006: Kemper E M; Leenders W; Küsters B; Lyons S; Buckle T; Heerschap A; Boogerd W; Beijnen J H; van Tellingen O
Development of luciferase tagged brain tumour models in mice for chemotherapy intervention studies.
European journal of cancer (Oxford, England : 1990) 2006;42(18):3294-303.
2006: Rook E J; van Zanten A P; Van den Brink W; van Ree J M; Beijnen J H
Mast cell mediator tryptase levels after inhalation or intravenous administration of high doses pharmaceutically prepared heroin.
Drug and alcohol dependence 2006;85(3):185-90.
2006: Ekhart Corine; de Jonge Milly E; Huitema Alwin D R; Schellens Jan H M; Rodenhuis Sjoerd; Beijnen Jos H
Flat dosing of carboplatin is justified in adult patients with normal renal function.
Clinical cancer research : an official journal of the American Association for Cancer Research 2006;12(21):6502-8.
2006: Van der Schoot S C; Nuijen B; Sood P; Thurmond K B; Stewart D R; Rice J R; Beijnen J H
Pharmaceutical development, quality control, stability and compatibility of a parenteral lyophilized formulation of the investigational polymer-conjugated platinum antineoplastic agent AP5346.
Die Pharmazie 2006;61(10):835-44.
2006: Lagas Jurjen S; Vlaming Maria L; van Tellingen Olaf; Wagenaar Els; Jansen Robert S; Rosing Hilde; Beijnen Jos H; Schinkel Alfred H
Multidrug resistance protein 2 is an important determinant of paclitaxel pharmacokinetics.
Clinical cancer research : an official journal of the American Association for Cancer Research 2006;12(20 Pt 1):6125-32.
2006: Bosch Tessa M; Huitema Alwin D R; Doodeman Valerie D; Jansen Robert; Witteveen Els; Smit Wim M; Jansen Rob L; van Herpen Carla M; Soesan Marcel; Beijnen Jos H; Schellens Jan H M
Pharmacogenetic screening of CYP3A and ABCB1 in relation to population pharmacokinetics of docetaxel.
Clinical cancer research : an official journal of the American Association for Cancer Research 2006;12(19):5786-93.
2006: Siegel-Lakhai Wandena S; Crul Mirjam; De Porre Peter; Zhang Steven; Chang Ilsung; Boot Henk; Beijnen Jos H; Schellens Jan H M
Clinical and pharmacologic study of the farnesyltransferase inhibitor tipifarnib in cancer patients with normal or mildly or moderately impaired hepatic function.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2006;24(28):4558-64.
2006: Vainchtein Liia D; Rosing Hilde; Mirejovsky Dorla; Huynh Van; Lenaz Luigi; Hillebrand Michel J X; Schellens Jan H M; Beijnen Jos H
Quantitative analysis of EO9 (apaziquone) and its metabolite EO5a in human plasma by high-performance liquid chromatography under basic conditions coupled to electrospray tandem mass spectrometry.
Journal of mass spectrometry : JMS 2006;41(10):1268-76.
2006: Helgason H H; Kruijtzer C M F; Huitema A D R; Marcus S G; ten Bokkel Huinink W W; Schot M E; Schornagel J H; Beijnen J H; Schellens J H M
Phase II and pharmacological study of oral paclitaxel (Paxoral) plus ciclosporin in anthracycline-pretreated metastatic breast cancer.
British journal of cancer 2006;95(7):794-800.
2006: Puri Rajiv; Palit Victor; Loadman Paul M; Flannigan Michael; Shah Tariq; Choudry Guzanfar A; Basu Saurajyoti; Double John A; Lenaz Gino; Chawla Shanta; Beer Mario; Van Kalken Coen; de Boer Richard; Beijnen Jos H; Twelves Christopher J; Phillips Roger M
Phase I/II pilot study of intravesical apaziquone (EO9) for superficial bladder cancer.
The Journal of urology 2006;176(4 Pt 1):1344-8.
2006: Zandvliet Anthe S; Schellens Jan H M; Copalu William; Beijnen Jos H; Huitema Alwin D R
A semi-physiological population pharmacokinetic model describing the non-linear disposition of indisulam.
Journal of pharmacokinetics and pharmacodynamics 2006;33(5):543-70.
2006: de Bree Eelco; Theodoropoulos Panayiotis A; Rosing Hilde; Michalakis John; Romanos John; Beijnen Jos H; Tsiftsis Dimitris D
Treatment of ovarian cancer using intraperitoneal chemotherapy with taxanes: from laboratory bench to bedside.
Cancer treatment reviews 2006;32(6):471-82.
2006: Kroep J R; Smit E F; Giaccone G; Van der Born K; Beijnen J H; Van Groeningen C J; Van der Vijgh W J F; Postmus P E; Pinedo H M; Peters G J
Pharmacology of the paclitaxel-cisplatin, gemcitabine-cisplatin, and paclitaxel-gemcitabine combinations in patients with advanced non-small cell lung cancer.
Cancer chemotherapy and pharmacology 2006;58(4):509-16.
2006: Brouwers E E M; Tibben M M; Rosing H; Hillebrand M J X; Joerger M; Schellens J H M; Beijnen J H
Sensitive inductively coupled plasma mass spectrometry assay for the determination of platinum originating from cisplatin, carboplatin, and oxaliplatin in human plasma ultrafiltrate.
Journal of mass spectrometry : JMS 2006;41(9):1186-94.
2006: Veltkamp S A; Thijssen B; Garrigue J S; Lambert G; Lallemand F; Binlich F; Huitema A D R; Nuijen B; Nol A; Beijnen J H; Schellens J H M
A novel self-microemulsifying formulation of paclitaxel for oral administration to patients with advanced cancer.
British journal of cancer 2006;95(6):729-34.
2006: Joerger Markus; Huitema A D R; Boogerd W; van der Sande J J; Schellens J H M; Beijnen J H
Interactions of serum albumin, valproic acid and carbamazepine with the pharmacokinetics of phenytoin in cancer patients.
Basic & clinical pharmacology & toxicology 2006;99(2):133-40.
2006: Vink Stefan R; Schellens Jan H M; Beijnen Jos H; Sindermann Herbert; Engel Jürgen; Dubbelman Ria; Moppi Gemi; Hillebrand Michel J X; Bartelink Harry; Verheij Marcel
Phase I and pharmacokinetic study of combined treatment with perifosine and radiation in patients with advanced solid tumours.
Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology 2006;80(2):207-13.
2006: de Vries Nienke A; Beijnen Jos H; Boogerd Willem; van Tellingen Olaf
Blood-brain barrier and chemotherapeutic treatment of brain tumors.
Expert review of neurotherapeutics 2006;6(8):1199-209.
2006: Sparidans Rolf W; Dost Frits; Crommentuyn Kristel M L; Huitema Alwin D R; Schellens Jan H M; Beijnen Jos H
Liquid chromatographic assay for the non-peptidic protease inhibitor tipranavir in plasma.
Biomedical chromatography : BMC 2006;20(8):671-3.
2006: Joerger M; Bosch T M; Doodeman V D; Beijnen J H; Smits P H M; Schellens J H M
Novel deoxycytidine kinase gene polymorphisms: a population screening study in Caucasian healthy volunteers.
European journal of clinical pharmacology 2006;62(8):681-4.
2006: van den Berg J H; Beijnen J H; Balm A J M; Schellens J H M
Future opportunities in preventing cisplatin induced ototoxicity.
Cancer treatment reviews 2006;32(5):390-7.
2006: de Bree E; Rosing H; Michalakis J; Romanos J; Relakis K; Theodoropoulos P A; Beijnen J H; Georgoulias V; Tsiftsis D D
Intraperitoneal chemotherapy with taxanes for ovarian cancer with peritoneal dissemination.
European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology 2006;32(6):666-70.
2006: Frankfort Suzanne V; Tulner Linda R; van Campen Jos P C M; Koks Cornelis H W; Beijnen Jos H
The effect of admission to a geriatric ward on medication use: 2002 versus 1985.
Pharmacoepidemiology and drug safety 2006;15(8):602-6.
2006: Meijerman Irma; Beijnen Jos H; Schellens Jan H M
Herb-drug interactions in oncology: focus on mechanisms of induction.
The oncologist 2006;11(7):742-52.
2006: Rook Elisabeth J; Huitema Alwin D R; van den Brink Wim; Hillebrand Michel J X; van Ree Jan M; Beijnen Jos H
Screening for illicit heroin use in patients in a heroin-assisted treatment program.
Journal of analytical toxicology 2006;30(6):390-4.
2006: Joerger M; Huitema A D R; van den Bongard H J G D; Baas P; Schornagel J H; Schellens J H M; Beijnen J H
Determinants of the elimination of methotrexate and 7-hydroxy-methotrexate following high-dose infusional therapy to cancer patients.
British journal of clinical pharmacology 2006;62(1):71-80.
2006: Vlaming M L H; Mohrmann K; Wagenaar E; de Waart D R; Elferink R P J Oude; Lagas J S; van Tellingen O; Vainchtein L D; Rosing H; Beijnen J H; Schellens J H M; Schinkel A H
Carcinogen and anticancer drug transport by Mrp2 in vivo: studies using Mrp2 (Abcc2) knockout mice.
The Journal of pharmacology and experimental therapeutics 2006;318(1):319-27.
2006: Sparidans Rolf W; Bosch T M; Jörger M; Schellens Jan H M; Beijnen Jos H
Liquid chromatography-tandem mass spectrometric assay for the analysis of uracil, 5,6-dihydrouracil and beta-ureidopropionic acid in urine for the measurement of the activities of the pyrimidine catabolic enzymes.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 2006;839(1-2):45-53.
2006: Frankfort S V; Appels B A; De Boer A; Tulner L R; Van Campen J P C M; Koks C H W; Beijnen J H
Treatment effects of rivastigmine on cognition, performance of daily living activities and behaviour in Alzheimer's disease in an outpatient geriatric setting.
International journal of clinical practice 2006;60(6):646-54.
2006: Boekhout Annelies H; Beijnen Jos H; Schellens Jan H M
Symptoms and treatment in cancer therapy-induced early menopause.
The oncologist 2006;11(6):641-54.
2006: Kuppens Isa E L M; Dansin Eric; Boot Henk; Feger Celine; Assadourian Sylvia; Bonneterre Maria-Edith; Beijnen Jos H; Schellens Jan H M; Bonneterre Jacques
Dose-finding phase I clinical and pharmacokinetic study of orally administered irinotecan in patients with advanced solid tumors.
Clinical cancer research : an official journal of the American Association for Cancer Research 2006;12(12):3774-81.
2006: Crommentuyn Kristel M L; Scherpbier Henriëtte J; Kuijpers Taco W; Mathôt Ron A A; Huitema Alwin D R; Beijnen Jos H
Population pharmacokinetics and pharmacodynamics of nelfinavir and its active metabolite M8 in HIV-1-infected children.
The Pediatric infectious disease journal 2006;25(6):538-43.
2006: van den Broek I; Sparidans R W; Huitema A D R; Schellens J H M; Beijnen J H
Development and validation of a quantitative assay for the measurement of two HIV-fusion inhibitors, enfuvirtide and tifuvirtide, and one metabolite of enfuvirtide (M-20) in human plasma by liquid chromatography-tandem mass spectrometry.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 2006;837(1-2):49-58.
2006: Zandvliet Anthe S; Copalu William; Schellens Jan H M; Beijnen Jos H; Huitema Alwin D R
Saturable binding of indisulam to plasma proteins and distribution to human erythrocytes.
Drug metabolism and disposition: the biological fate of chemicals 2006;34(6):1041-6.
2006: Press Rogier R; Buckle Tessa; Beijnen Jos H; van Tellingen Olaf
The effect of P-glycoprotein and cytochrome P450 3a on the oral bioavailability of vinorelbine in mice.
Cancer chemotherapy and pharmacology 2006;57(6):819-25.
2006: Klous M G; Lee W C; Van den Brink W; Van Ree J M; Beijnen J H
Volatilisation of diacetylmorphine: in vitro simulation of 'chasing the dragon'.
Die Pharmazie 2006;61(5):438-45.
2006: de Jonge M E; Huitema A D R; Beijnen J H; Rodenhuis S
High exposures to bioactivated cyclophosphamide are related to the occurrence of veno-occlusive disease of the liver following high-dose chemotherapy.
British journal of cancer 2006;94(9):1226-30.
2006: Engwegen Judith Y M N; Gast Marie-Christine W; Schellens Jan H M; Beijnen Jos H
Clinical proteomics: searching for better tumour markers with SELDI-TOF mass spectrometry.
Trends in pharmacological sciences 2006;27(5):251-9.
2006: Bosch Tessa M; Deenen Maarten; Pruntel Roelof; Smits Paul H M; Schellens Jan H M; Beijnen Jos H; Meijerman Irma
Screening for polymorphisms in the PXR gene in a Dutch population.
European journal of clinical pharmacology 2006;62(5):395-9.
2006: Appels Natalie M G M; Rosing Hilde; Stephens Trevor C; Hughes Andrew; Schellens Jan H M; Beijnen Jos H
Absolute quantification of farnesylated Ras levels in complex samples using liquid chromatography fractionation combined with tryptic digestion and electrospray tandem mass spectrometry.
Analytical biochemistry 2006;352(1):33-40.
2006: Appels Natalie M G M; Rosing Hilde; Stephens Trevor C; Schellens Jan H M; Beijnen Jos H
Quantification of farnesylmethylcysteine in lysates of peripheral blood mononuclear cells using liquid chromatography coupled with electrospray tandem mass spectrometry: pharmacodynamic assay for farnesyl transferase inhibitors.
Analytical chemistry 2006;78(8):2617-22.
2006: Joerger Markus; Huitema Alwin D R; van den Bongard Desiree H J G; Schellens Jan H M; Beijnen Jos H
Quantitative effect of gender, age, liver function, and body size on the population pharmacokinetics of Paclitaxel in patients with solid tumors.
Clinical cancer research : an official journal of the American Association for Cancer Research 2006;12(7 Pt 1):2150-7.
2006: Engwegen Judith Y M N; Helgason Helgi H; Cats Annemieke; Harris Nathan; Bonfrer Johannes M G; Schellens Jan H M; Beijnen Jos H
Identification of serum proteins discriminating colorectal cancer patients and healthy controls using surface-enhanced laser desorption ionisation-time of flight mass spectrometry.
World journal of gastroenterology : WJG 2006;12(10):1536-44.
2006: Leth F Van; Kappelhoff B S; Johnson D; Losso M H; Boron-Kaczmarska A; Saag M S; Livrozet J-M; Hall D B; Leith J; Huitema A D R; Wit F W; Beijnen J H; Lange J M A;
Pharmacokinetic parameters of nevirapine and efavirenz in relation to antiretroviral efficacy.
AIDS research and human retroviruses 2006;22(3):232-9.
2006: Rademaker-Lakhai Jeany M; Crul Mirjam; Zuur Lot; Baas Paul; Beijnen Jos H; Simis Yvonne J W; van Zandwijk Nico; Schellens Jan H M
Relationship between cisplatin administration and the development of ototoxicity.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2006;24(6):918-24.
2006: Appels Natalie M G M; Tung Kien-On; Rosing Hilde; Schellens Jan H M; Beijnen Jos H
A rapid and simple HPLC-UV method for the determination of inhibition characteristics of farnesyl transferase inhibitors.
Biomedical chromatography : BMC 2006;20(2):161-5.
2006: Brandon Esther F A; Bosch Tessa M; Deenen Maarten J; Levink Rianne; van der Wal Everdina; van Meerveld Joyce B M; Bijl Monique; Beijnen Jos H; Schellens Jan H M; Meijerman Irma
Validation of in vitro cell models used in drug metabolism and transport studies; genotyping of cytochrome P450, phase II enzymes and drug transporter polymorphisms in the human hepatoma (HepG2), ovarian carcinoma (IGROV-1) and colon carcinoma (CaCo-2, LS180) cell lines.
Toxicology and applied pharmacology 2006;211(1):1-10.
2006: Rook Elisabeth J; Huitema Alwin D R; van den Brink Wim; van Ree Jan M; Beijnen Jos H
Pharmacokinetics and pharmacokinetic variability of heroin and its metabolites: review of the literature.
Current clinical pharmacology 2006;1(1):109-18.
2006: Klous Marjolein G; Lee WeiChing; Hillebrand Michel J X; van den Brink Wim; van Ree Jan M; Beijnen Jos H
Analysis of diacetylmorphine, caffeine, and degradation products after volatilization of pharmaceutical heroin for inhalation.
Journal of analytical toxicology 2006;30(1):6-13.
2006: Den Brok M W J; Nuijen B; García J L; Miranda E; Calvo P; Manada C; Beijnen J H
Compatibility and stability of the novel anticancer agent ES-285 x HCl formulated with 2-hydroxypropyl-beta-cyclodextrin in infusion devices.
Die Pharmazie 2006;61(1):21-4.
2006: Rook Elisabeth J; van Ree Jan M; van den Brink Wim; Hillebrand Michel J X; Huitema Alwin D R; Hendriks Vincent M; Beijnen Jos H
Pharmacokinetics and pharmacodynamics of high doses of pharmaceutically prepared heroin, by intravenous or by inhalation route in opioid-dependent patients.
Basic & clinical pharmacology & toxicology 2006;98(1):86-96.
2006: Brandon Esther F A; Sparidans Rolf W; Guijt Kees-Jan; Löwenthal Sjoerd; Meijerman Irma; Beijnen Jos H; Schellens Jan H M
In vitro characterization of the human biotransformation and CYP reaction phenotype of ET-743 (Yondelis, Trabectidin), a novel marine anti-cancer drug.
Investigational new drugs 2006;24(1):3-14.
2006: Breedveld Pauline; Beijnen Jos H; Schellens Jan H M
Use of P-glycoprotein and BCRP inhibitors to improve oral bioavailability and CNS penetration of anticancer drugs.
Trends in pharmacological sciences 2006;27(1):17-24.
2006: Vainchtein Liia D; Thijssen Bas; Stokvis Ellen; Rosing Hilde; Schellens Jan H M; Beijnen Jos H
A simple and sensitive assay for the quantitative analysis of paclitaxel and metabolites in human plasma using liquid chromatography/tandem mass spectrometry.
Biomedical chromatography : BMC 2006;20(1):139-48.
2006: Sparidans Rolf W; Dost Frits; Crommentuyn Kristel M L; Huitema Alwin D R; Schellens Jan H M; Beijnen Jos H
Liquid chromatographic assay for the protease inhibitor atazanavir in plasma.
Biomedical chromatography : BMC 2006;20(1):72-6.
2006: Frankfort Suzanne V; Tulner Linda R; van Campen Jos P C M; Koks Cornelis H W; Beijnen Jos H
Evaluation of pharmacotherapy in geriatric patients after performing complete geriatric assessment at a diagnostic day clinic.
Clinical drug investigation 2006;26(3):169-74.
2006: Frankfort Suzanne V; Ouwehand Mariët; van Maanen Maria J; Rosing Hilde; Tulner Linda R; Beijnen Jos H
A simple and sensitive assay for the quantitative analysis of rivastigmine and its metabolite NAP 226-90 in human EDTA plasma using coupled liquid chromatography and tandem mass spectrometry.
Rapid communications in mass spectrometry : RCM 2006;20(22):3330-6.
2006: Frankfort Suzanne V; Doodeman Valerie D; Bakker Remco; Tulner Linda R; van Campen Jos P C M; Smits Paul H M; Beijnen Jos H
ABCB1 genotypes and haplotypes in patients with dementia and age-matched non-demented control patients.
Molecular neurodegeneration 2006;1():13.
2006: Bosch T M; Doodeman V D; Smits P H M; Meijerman I; Schellens J H M; Beijnen J H
Pharmacogenetic screening for polymorphisms in drug-metabolizing enzymes and drug transporters in a Dutch population.
Molecular diagnosis & therapy 2006;10(3):175-85.
2006: Rook Elisabeth J; Huitema Alwin D R; van den Brink Wim; van Ree Jan M; Beijnen Jos H
Population pharmacokinetics of heroin and its major metabolites.
Clinical pharmacokinetics 2006;45(4):401-17.
2006: Bosch Tessa M; Meijerman Irma; Beijnen Jos H; Schellens Jan H M
Genetic polymorphisms of drug-metabolising enzymes and drug transporters in the chemotherapeutic treatment of cancer.
Clinical pharmacokinetics 2006;45(3):253-85.
2006: Beumer Jan H; Beijnen Jos H; Schellens Jan H M
Mass balance studies, with a focus on anticancer drugs.
Clinical pharmacokinetics 2006;45(1):33-58.
2005: Frankfort Suzanne V; Appels Bregje A; de Boer Anthonius; Tulner Linda R; van Campen Jos P C M; Koks Cornelis H W; Beijnen Jos H
Discontinuation of rivastigmine in routine clinical practice.
International journal of geriatric psychiatry 2005;20(12):1167-71.
2005: de Jonge Milly E; Huitema Alwin D R; van Dam Selma M; Rodenhuis Sjoerd; Beijnen Jos H
Population pharmacokinetics of cyclophosphamide and its metabolites 4-hydroxycyclophosphamide, 2-dechloroethylcyclophosphamide, and phosphoramide mustard in a high-dose combination with Thiotepa and Carboplatin.
Therapeutic drug monitoring 2005;27(6):756-65.
2005: Klous Marjolein G; Van den Brink Wim; Van Ree Jan M; Beijnen Jos H
Development of pharmaceutical heroin preparations for medical co-prescription to opioid dependent patients.
Drug and alcohol dependence 2005;80(3):283-95.
2005: Siegel-Lakhai W S; Crul M; Zhang S; Sparidans R W; Pluim D; Howes A; Solanki B; Beijnen J H; Schellens J H M
Phase I and pharmacological study of the farnesyltransferase inhibitor tipifarnib (Zarnestra, R115777) in combination with gemcitabine and cisplatin in patients with advanced solid tumours.
British journal of cancer 2005;93(11):1222-9.
2005: Stokvis Ellen; Rosing Hilde; Beijnen Jos H
Liquid chromatography-mass spectrometry for the quantitative bioanalysis of anticancer drugs.
Mass spectrometry reviews 2005;24(6):887-917.
2005: Crommentuyn K M L; Kappelhoff B S; Mulder J W; Mairuhu A T A; van Gorp E C M; Meenhorst P L; Huitema A D R; Beijnen J H
Population pharmacokinetics of lopinavir in combination with ritonavir in HIV-1-infected patients.
British journal of clinical pharmacology 2005;60(4):378-89.
2005: Rademaker-Lakhai Jeany M; Crul Mirjam; Pluim Dick; Sparidans Rolf W; Baas Paul; Beijnen Jos H; van Zandwijk Nico; Schellens Jan H M
Phase I clinical and pharmacologic study of a 2-weekly administration of cisplatin and gemcitabine in patients with advanced non-small cell lung cancer.
Anti-cancer drugs 2005;16(9):1029-36.
2005: Brandon Esther F A; Meijerman Irma; Klijn Joyce S; den Arend Dineke; Sparidans Rolf W; Lázaro Louis López; Beijnen Jos H; Schellens Jan H M
In-vitro cytotoxicity of ET-743 (Trabectedin, Yondelis), a marine anti-cancer drug, in the Hep G2 cell line: influence of cytochrome P450 and phase II inhibition, and cytochrome P450 induction.
Anti-cancer drugs 2005;16(9):935-43.
2005: Beumer J H; Rademaker-Lakhai J M; Rosing H; Lopez-Lazaro L; Beijnen J H; Schellens J H M
Trabectedin (Yondelis, formerly ET-743), a mass balance study in patients with advanced cancer.
Investigational new drugs 2005;23(5):429-36.
2005: Klous Marjolein G; Bronner Gaby M; Nuijen Bastiaan; van Ree Jan M; Beijnen Jos H
Pharmaceutical heroin for inhalation: thermal analysis and recovery experiments after volatilisation.
Journal of pharmaceutical and biomedical analysis 2005;39(5):944-50.
2005: de Jonge Milly E; Huitema Alwin D R; Holtkamp Marjo J; van Dam Selma M; Beijnen Jos H; Rodenhuis Sjoerd
Aprepitant inhibits cyclophosphamide bioactivation and thiotepa metabolism.
Cancer chemotherapy and pharmacology 2005;56(4):370-8.
2005: Den Brok Monique W J; Nuijen Bastiaan; Kettenes-Van Den Bosch J Jantina; Van Steenbergen M J; Buluran Josie N; Harvey Michael D; Grieshaber Charles K; Beijnen Jos H
Pharmaceutical development of a parenteral lyophilised dosage form for the novel anticancer agent C1311.
PDA journal of pharmaceutical science and technology / PDA 2005;59(5):285-97.
2005: Kappelhoff Bregt S; Huitema Alwin D R; van Leth Frank; Robinson Patrick A; MacGregor Thomas R; Lange Joep M A; Beijnen Jos H;
Pharmacokinetics of nevirapine: once-daily versus twice-daily dosing in the 2NN study.
HIV clinical trials 2005;6(5):254-61.
2005: Siegel-Lakhai Wandena S; Beijnen Jos H; Schellens Jan H M
Current knowledge and future directions of the selective epidermal growth factor receptor inhibitors erlotinib (Tarceva) and gefitinib (Iressa).
The oncologist 2005;10(8):579-89.
2005: Appels Natalie M G M; Beijnen Jos H; Schellens Jan H M
Development of farnesyl transferase inhibitors: a review.
The oncologist 2005;10(8):565-78.
2005: Klous Marjolein G; Rook Elisabeth J; Hillebrand Michel J X; van den Brink Wim; van Ree Jan M; Beijnen Jos H
Deuterodiacetylmorphine as a marker for use of illicit heroin by addicts in a heroin-assisted treatment program.
Journal of analytical toxicology 2005;29(6):564-9.
2005: Kappelhoff Bregt S; Huitema Alwin D R; Sankatsing Sanjay U C; Meenhorst Pieter L; Van Gorp Eric C M; Mulder Jan W; Prins Jan M; Beijnen Jos H
Population pharmacokinetics of indinavir alone and in combination with ritonavir in HIV-1-infected patients.
British journal of clinical pharmacology 2005;60(3):276-86.
2005: Rook Elisabeth J; Hillebrand Michel J X; Rosing Hilde; van Ree Jan M; Beijnen Jos H
The quantitative analysis of heroin, methadone and their metabolites and the simultaneous detection of cocaine, acetylcodeine and their metabolites in human plasma by high-performance liquid chromatography coupled with tandem mass spectrometry.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 2005;824(1-2):213-21.
2005: den Brok Monique W J; Nuijen Bastiaan; Hillebrand Michel J X; Grieshaber Charles K; Harvey Michael D; Beijnen Jos H
Development and validation of an LC-UV method for the quantification and purity determination of the novel anticancer agent C1311 and its pharmaceutical dosage form.
Journal of pharmaceutical and biomedical analysis 2005;39(1-2):46-53.
2005: Bardelmeijer Heleen A; Roelofs Arjan B G H; Hillebrand Michel J X; Beijnen Jos H; Schellens Jan H M; van Tellingen Olaf
Metabolism of docetaxel in mice.
Cancer chemotherapy and pharmacology 2005;56(3):299-306.
2005: Huisman Maarten T; Chhatta Aniska A; van Tellingen Olaf; Beijnen Jos H; Schinkel Alfred H
MRP2 (ABCC2) transports taxanes and confers paclitaxel resistance and both processes are stimulated by probenecid.
International journal of cancer. Journal international du cancer 2005;116(5):824-9.
2005: den Brok Monique W J; Nuijen Bastiaan; Challa Eric E; Lutz Christian; Opitz Hans Georg; Beijnen Jos H
Compatibility and stability of Imexon in infusion devices and its in vitro biocompatibility.
Anti-cancer drugs 2005;16(7):727-32.
2005: Beumer Jan-Hendrik; Hillebrand Michel J X; Pluim Dick; Rosing Hilde; Foley Karen; Yule S Murray; Schellens Jan H M; Beijnen Jos H
Human metabolism of [(14)C]indisulam following i.v. infusion in cancer patients.
Investigational new drugs 2005;23(4):317-30.
2005: Brouwers E E M; Tibben M M; Joerger M; van Tellingen O; Rosing H; Schellens J H M; Beijnen J H
Determination of oxaliplatin in human plasma and plasma ultrafiltrate by graphite-furnace atomic-absorption spectrometry.
Analytical and bioanalytical chemistry 2005;382(7):1484-90.
2005: Den Brok Monique W J; Nuijen Bastiaan; Meijer Dieuwke M; Millán Elena; Manada Consuelo; Beijnen Jos H
Pharmaceutical development of a parenteral lyophilised formulation of the investigational anticancer agent ES-285.HCl.
PDA journal of pharmaceutical science and technology / PDA 2005;59(4):246-57.
2005: den Brok Monique W J; Nuijen Bastiaan; Hillebrand Michel J X; Lutz Christian; Opitz Hans-Georg; Beijnen Jos H
LC-UV method development and validation for the investigational anticancer agent imexon and identification of its degradation products.
Journal of pharmaceutical and biomedical analysis 2005;38(4):686-94.
2005: Kappelhoff Bregt S; Huitema Alwin D R; Mairuhu Albert T A; Schellens Jan H M; Beijnen Jos H
No pharmacokinetic drug-drug interaction between nevirapine and paclitaxel.
Anti-cancer drugs 2005;16(6):627-30.
2005: van Herwaarden Antonius E; Smit Johan W; Sparidans Rolf W; Wagenaar Els; van der Kruijssen Cornelia M M; Schellens Jan H M; Beijnen Jos H; Schinkel Alfred H
Midazolam and cyclosporin a metabolism in transgenic mice with liver-specific expression of human CYP3A4.
Drug metabolism and disposition: the biological fate of chemicals 2005;33(7):892-5.
2005: Crommentuyn K M L; Huitema A D R; Beijnen J H
Bioanalysis of HIV protease inhibitors in samples from sanctuary sites.
Journal of pharmaceutical and biomedical analysis 2005;38(1):139-47.
2005: de Jonge Milly E; Huitema Alwin D R; Rodenhuis Sjoerd; Beijnen Jos H
Sparse sampling design for therapeutic drug monitoring of sequentially administered cyclophosphamide, thiotepa, and carboplatin (CTC).
Therapeutic drug monitoring 2005;27(3):393-402.
2005: Crommentuyn Kristel M; Huitema Alwin D; Brinkman Kees; van der Ende Marchina E; de Wolf Frank; Beijnen Jos H;
Therapeutic drug monitoring of nevirapine reduces pharmacokinetic variability but does not affect toxicity or virologic success in the ATHENA study.
Journal of acquired immune deficiency syndromes (1999) 2005;39(2):249-50.
2005: Brandon Esther F A; van Ooijen Ronald D; Sparidans Rolf W; Lázaro Luis López; Heck Albert J R; Beijnen Jos H; Schellens Jan H M
Structure elucidation of aplidine metabolites formed in vitro by human liver microsomes using triple quadrupole mass spectrometry.
Journal of mass spectrometry : JMS 2005;40(6):821-31.
2005: van Kesteren Charlotte; Zandvliet Anthe S; Karlsson Mats O; Mathôt Ron A A; Punt Cornelis J A; Armand Jean-Pierre; Raymond Eric; Huitema Alwin D R; Dittrich Christian; Dumez Herlinde; Roché Henri H; Droz Jean-Pierre; Ravic Miroslav; Yule S Murray; Wanders Jantien; Beijnen Jos H; Fumoleau Pierre; Schellens Jan H M
Semi-physiological model describing the hematological toxicity of the anti-cancer agent indisulam.
Investigational new drugs 2005;23(3):225-34.
2005: Kuppens I E L M; van Maanen M J; Rosing H; Schellens J H M; Beijnen J H
Quantitative analysis of docetaxel in human plasma using liquid chromatography coupled with tandem mass spectrometry.
Biomedical chromatography : BMC 2005;19(5):355-61.
2005: Zelcer Noam; van de Wetering Koen; Hillebrand Michel; Sarton Elise; Kuil Annemieke; Wielinga Peter R; Tephly Thomas; Dahan Albert; Beijnen Jos H; Borst Piet
Mice lacking multidrug resistance protein 3 show altered morphine pharmacokinetics and morphine-6-glucuronide antinociception.
Proceedings of the National Academy of Sciences of the United States of America 2005;102(20):7274-9.
2005: Klous Marjolein G; Huitema Alwin D R; Rook Elisabeth J; Hillebrand Michel J X; Hendriks Vincent M; Van den Brink Wim; Beijnen Jos H; Van Ree Jan M
Pharmacokinetic comparison of two methods of heroin smoking: 'chasing the dragon' versus the use of a heating device.
European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology 2005;15(3):263-9.
2005: den Brok Monique W J; Nuijen Bastiaan; Lutz Christiane; Opitz Hans-Georg; Beijnen Jos H
Pharmaceutical development of a lyophilised dosage form for the investigational anticancer agent Imexon using dimethyl sulfoxide as solubilising and stabilising agent.
Journal of pharmaceutical sciences 2005;94(5):1101-14.
2005: Beumer J H; Schellens J H M; Beijnen J H
Hepatotoxicity and metabolism of trabectedin: a literature review.
Pharmacological research : the official journal of the Italian Pharmacological Society 2005;51(5):391-8.
2005: Joerger M; Huitema A D R; Meenhorst P L; Schellens J H M; Beijnen J H
Pharmacokinetics of low-dose doxorubicin and metabolites in patients with AIDS-related Kaposi sarcoma.
Cancer chemotherapy and pharmacology 2005;55(5):488-96.
2005: de Jonge Milly E; Huitema Alwin D R; van Dam Selma M; Beijnen Jos H; Rodenhuis Sjoerd
Significant induction of cyclophosphamide and thiotepa metabolism by phenytoin.
Cancer chemotherapy and pharmacology 2005;55(5):507-10.
2005: de Maat Monique M R; Beijnen Jos H; Schellens Jan H M; Mulder Jan W
Chronic hepatotoxicity after long-term antiretroviral treatment including nevirapine.
The Journal of infection 2005;50(3):262-4.
2005: den Brok Monique W J; Nuijen Bastiaan; Harms Remko; Buluran Josie N; Harvey Michael D; Grieshaber Charles K; Beijnen Jos H
Compatibility and stability of the novel anti-cancer agent C1311 in infusion devices and its in vitro biocompatibility.
Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners 2005;11(1):13-9.
2005: Rademaker-Lakhai Jeany M; Horenblas Simon; Meinhardt Willem; Stokvis Ellen; de Reijke Theo M; Jimeno José M; Lopez-Lazaro Luis; Lopez Martin José A; Beijnen Jos H; Schellens Jan H M
Phase I clinical and pharmacokinetic study of kahalalide F in patients with advanced androgen refractory prostate cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2005;11(5):1854-62.
2005: de Jonge Milly E; Huitema Alwin Dr; Schellens Jan Hm; Rodenhuis Sjoerd; Beijnen Jos H
Population pharmacokinetics of orally administered paclitaxel formulated in Cremophor EL.
British journal of clinical pharmacology 2005;59(3):325-34.
2005: Bos A M E; De Vos F Y F L; de Vries E G E; Beijnen J H; Rosing H; Mourits M J E; van der Zee A G J; Gietema J A; Willemse P H B
A phase I study of intraperitoneal topotecan in combination with intravenous carboplatin and paclitaxel in advanced ovarian cancer.
European journal of cancer (Oxford, England : 1990) 2005;41(4):539-48.
2005: de Jonge Milly E; Huitema Alwin D R; van Dam Selma M; Rodenhuis Sjoerd; Beijnen Jos H
Effects of co-medicated drugs on cyclophosphamide bioactivation in human liver microsomes.
Anti-cancer drugs 2005;16(3):331-6.
2005: Schoemaker Nadja E; Kuppens I E L M; Huinink Wim W Ten Bokkel; Lefebvre Patricia; Beijnen Jos H; Assadourian Sylvie; Sanderink Ger-Jan; Schellens Jan H M
Phase I study of an oral formulation of irinotecan administered daily for 14 days every 3 weeks in patients with advanced solid tumours.
Cancer chemotherapy and pharmacology 2005;55(3):263-70.
2005: Kappelhoff Bregt S; Huitema Alwin D R; Crommentuyn Kristel M L; Mulder Jan W; Meenhorst Pieter L; van Gorp Eric C M; Mairuhu Albert T A; Beijnen Jos H
Development and validation of a population pharmacokinetic model for ritonavir used as a booster or as an antiviral agent in HIV-1-infected patients.
British journal of clinical pharmacology 2005;59(2):174-82.
2005: van Tellingen Olaf; Bardelmeijer Heleen A; Buckle Tessa; Ouwehand Mariet; Beijnen Jos H; Schellens Jan H M
Cannulation of the jugular vein in mice.
Laboratory animals 2005;39(1):130.
2005: de Jonge Milly E; Huitema Alwin D R; Tukker Annemarie C; van Dam Selma M; Rodenhuis Sjoerd; Beijnen Jos H
Accuracy, feasibility, and clinical impact of prospective Bayesian pharmacokinetically guided dosing of cyclophosphamide, thiotepa, and carboplatin in high-dose chemotherapy.
Clinical cancer research : an official journal of the American Association for Cancer Research 2005;11(1):273-83.
2005: Zandvliet Anthe S; Huitema Alwin D R; de Jonge Milly E; den Hoed Rob; Sparidans Rolf W; Hendriks Vincent M; van den Brink Wim; van Ree Jan M; Beijnen Jos H
Population pharmacokinetics of caffeine and its metabolites theobromine, paraxanthine and theophylline after inhalation in combination with diacetylmorphine.
Basic & clinical pharmacology & toxicology 2005;96(1):71-9.
2005: Kuppens I E L M; Bosch T M; van Maanen M J; Rosing H; Fitzpatrick A; Beijnen J H; Schellens J H M
Oral bioavailability of docetaxel in combination with OC144-093 (ONT-093).
Cancer chemotherapy and pharmacology 2005;55(1):72-8.
2005: Silvertand L H H; Vazvaei F; Weigl P; Rosing H; Hillebrand M J X; van Maanen M J; Beijnen J H
Simultaneous quantification of fludarabine and cyclophosphamide in human plasma by high-performance liquid chromatography coupled with electrospray ionization tandem mass spectrometry.
Rapid communications in mass spectrometry : RCM 2005;19(24):3673-80.
2005: de Jonge Milly E; Huitema Alwin D R; Rodenhuis Sjoerd; Beijnen Jos H
Clinical pharmacokinetics of cyclophosphamide.
Clinical pharmacokinetics 2005;44(11):1135-64.
2005: Kuppens Isa E L M; Breedveld P; Beijnen J H; Schellens J H M
Modulation of oral drug bioavailability: from preclinical mechanism to therapeutic application.
Cancer investigation 2005;23(5):443-64.
2005: Kappelhoff Bregt S; van Leth Frank; Robinson Patrick A; MacGregor Thomas R; Baraldi Ezio; Montella Francesco; Uip David E; Thompson Melanie A; Russell Darren B; Lange Joep M A; Beijnen Jos H; Huitema Alwin D R;
Are adverse events of nevirapine and efavirenz related to plasma concentrations?
Antiviral therapy 2005;10(4):489-98.
2005: Kappelhoff Bregt S; Huitema Alwin D R; Yalvaç Zeynep; Prins Jan M; Mulder Jan W; Meenhorst Pieter L; Beijnen Jos H
Population pharmacokinetics of efavirenz in an unselected cohort of HIV-1-infected individuals.
Clinical pharmacokinetics 2005;44(8):849-61.
2005: Appels Natalie M G M; van Maanen Maria J; Rosing Hilde; Schellens Jan H M; Beijnen Jos H
Quantitative analysis of the farnesyl transferase inhibitor lonafarnib (Sarasartrade mark, SCH66336) in human plasma using high-performance liquid chromatography coupled with tandem mass spectrometry.
Rapid communications in mass spectrometry : RCM 2005;19(15):2187-92.
2005: Bosch Tessa M; Kjellberg Linda M; Bouwers Anja; Koeleman Bobby P C; Schellens Jan H M; Beijnen Jos H; Smits Paul H M; Meijerman Irma
Detection of single nucleotide polymorphisms in the ABCG2 gene in a Dutch population.
American journal of pharmacogenomics : genomics-related research in drug development and clinical practice 2005;5(2):123-31.
2005: Kappelhoff Bregt S; Huitema Alwin D R; Beijnen Jos H
Should non-nucleoside reverse transcriptase inhibitors be combined?
Drugs in R&D 2005;6(2):61-9.
2005: Kappelhoff Bregt S; van Leth Frank; MacGregor Thomas R; Lange Joep; Beijnen Jos H; Huitema Alwin D R;
Nevirapine and efavirenz pharmacokinetics and covariate analysis in the 2NN study.
Antiviral therapy 2005;10(1):145-55.
2005: de Jonge Milly E; Huitema Alwin D R; Schellens Jan H M; Rodenhuis Sjoerd; Beijnen Jos H
Individualised cancer chemotherapy: strategies and performance of prospective studies on therapeutic drug monitoring with dose adaptation: a review.
Clinical pharmacokinetics 2005;44(2):147-73.
2005: Stokvis Ellen; Rosing Hilde; Beijnen Jos H
Stable isotopically labeled internal standards in quantitative bioanalysis using liquid chromatography/mass spectrometry: necessity or not?
Rapid communications in mass spectrometry : RCM 2005;19(3):401-7.
2004: Stokvis E; Ouwehand M; Nan L G A H; Kemper E M; van Tellingen O; Rosing H; Beijnen J H
A simple and sensitive assay for the quantitative analysis of paclitaxel in human and mouse plasma and brain tumor tissue using coupled liquid chromatography and tandem mass spectrometry.
Journal of mass spectrometry : JMS 2004;39(12):1506-12.
2004: Frankfort Suzanne V; Tulner Linda R; Knol Wilma; van Campen Jos P C M; Schellens Jan H N; Beijnen Jos H
Prescription error resulting in valproic acid intoxication.
Journal of the American Geriatrics Society 2004;52(12):2142-3.
2004: Klous Marjolein G; Nuijen Bastiaan; van den Brink Wim; Van Ree Jan M; Beijnen Jos H
Pharmaceutical development of an intravenous dosage form of diacetylmorphine hydrochloride.
PDA journal of pharmaceutical science and technology / PDA 2004;58(6):287-95.
2004: Klous Marjolein G; Nuijen Bastiaan; Van den Brink Wim; Van Ree Jan M; Beijnen Jos H
Process characterisation, optimisation and validation of production of diacetylmorphine/caffeine sachets: a design of experiments approach.
International journal of pharmaceutics 2004;285(1-2):65-75.
2004: Crommentuyn Kristel M L; Mulder Jan W; Mairuhu Albert T A; van Gorp Eric C M; Meenhorst Pieter L; Huitema Alwin D R; Beijnen Jos H
The plasma and intracellular steady-state pharmacokinetics of lopinavir/ritonavir in HIV-1-infected patients.
Antiviral therapy 2004;9(5):779-85.
2004: Stokvis Ellen; Rosing Hilde; Causon Roger C; Schellens Jan H M; Beijnen Jos H
Quantitative analysis of the P-glycoprotein inhibitor Elacridar (GF120918) in human and dog plasma using liquid chromatography with tandem mass spectrometric detection.
Journal of mass spectrometry : JMS 2004;39(10):1122-30.
2004: Schoemaker N E; Kuppens I E L M; Moiseyenko V; Glimelius B; Kjaer M; Starkhammer H; Richel D J; Smaaland R; Bertelsen K; Poulsen J P; Voznyi E; Norum J; Fennelly D; Tveit K M; Garin A; Gruia G; Mourier A; Sibaud D; Lefebvre P; Beijnen J H; Schellens J H M; ten Bokkel Huinink W W
A randomised phase II multicentre trial of irinotecan (CPT-11) using four different schedules in patients with metastatic colorectal cancer.
British journal of cancer 2004;91(8):1434-41.
2004: Klous M G; Nuijen B; van den Brink W; van Ree J M; Beijnen J H
Development and manufacture of diacetylmorphine/caffeine sachets for inhalation via 'chasing the dragon' by heroin addicts.
Drug development and industrial pharmacy 2004;30(7):775-84.
2004: Breedveld Pauline; Zelcer Noam; Pluim Dick; Sönmezer Ozgür; Tibben Matthijs M; Beijnen Jos H; Schinkel Alfred H; van Tellingen Olaf; Borst Piet; Schellens Jan H M
Mechanism of the pharmacokinetic interaction between methotrexate and benzimidazoles: potential role for breast cancer resistance protein in clinical drug-drug interactions.
Cancer research 2004;64(16):5804-11.
2004: Beijnen Jos H; Schellens Jan H M
Drug interactions in oncology.
The lancet oncology 2004;5(8):489-96.
2004: de Maat Monique M R; Nellen Jeannine F J B; Huitema Alwin D R; Wit Ferdinand W M N; Mulder Jan W; Prins Jan M; Beijnen Jos H
Race is not associated with nevirapine pharmacokinetics.
Therapeutic drug monitoring 2004;26(4):456-8.
2004: Kemper E Marleen; Boogerd Willem; Thuis Ingrid; Beijnen Jos H; van Tellingen Olaf
Modulation of the blood-brain barrier in oncology: therapeutic opportunities for the treatment of brain tumours?
Cancer treatment reviews 2004;30(5):415-23.
2004: Brandon Esther F A; Sparidans Rolf W; Meijerman Irma; Manzanares Ignasio; Beijnen Jos H; Schellens Jan H M
In vitro characterization of the biotransformation of thiocoraline, a novel marine anti-cancer drug.
Investigational new drugs 2004;22(3):241-51.
2004: Bardelmeijer Heleen A; Ouwehand Mariët; Beijnen Jos H; Schellens Jan H M; van Tellingen Olaf
Efficacy of novel P-glycoprotein inhibitors to increase the oral uptake of paclitaxel in mice.
Investigational new drugs 2004;22(3):219-29.
2004: Stokvis Ellen; Rosing Hilde; López-Lázaro Luis; Schellens Jan H M; Beijnen Jos H
A more sensitive MS detector does not obviously lead to a more sensitive assay: experiences with ES-285.
Biomedical chromatography : BMC 2004;18(6):403-7.
2004: Stokvis E; Rosing H; López-Lázaro L; Schellens J H M; Beijnen J H
Switching from an analogous to a stable isotopically labeled internal standard for the LC-MS/MS quantitation of the novel anticancer drug Kahalalide F significantly improves assay performance.
Biomedical chromatography : BMC 2004;18(6):400-2.
2004: den Brok Monique W J; van der Schoot Sabien C; Nuijen Bastiaan; Hillebrand Michel J X; Beijnen Jos H
2-Hydroxypropyl-beta-cyclodextrin extracts 2-phenylphenol from silicone tubing.
International journal of pharmaceutics 2004;278(2):303-9.
2004: Pluim Dick; van Waardenburg Robert C A M; Beijnen Jos H; Schellens Jan H M
Cytotoxicity of the organic ruthenium anticancer drug Nami-A is correlated with DNA binding in four different human tumor cell lines.
Cancer chemotherapy and pharmacology 2004;54(1):71-8.
2004: Peters Godefridus J; Noordhuis Paul; Van Groeningen Cornelis J; Giaccone Giuseppe; Holwerda Ulbe; Voorn Daphne; Schrijvers Ad; Schornagel Jan H; Beijnen Jos H; Fumoleau Pierre; Schellens Jan H M
The effect of food on the pharmacokinetics of S-1 after single oral administration to patients with solid tumors.
Clinical cancer research : an official journal of the American Association for Cancer Research 2004;10(12 Pt 1):4072-6.
2004: Rademaker-Lakhai Jeany M; van den Bongard Desiree; Pluim Dick; Beijnen Jos H; Schellens Jan H M
A Phase I and pharmacological study with imidazolium-trans-DMSO-imidazole-tetrachlororuthenate, a novel ruthenium anticancer agent.
Clinical cancer research : an official journal of the American Association for Cancer Research 2004;10(11):3717-27.
2004: Kerbusch T; Groenewegen G; Mathôt R A A; Herben V M M; ten Bokkel Huinink W W; Swart M; Ambaum B; Rosing H; Jansen S; Voest E E; Beijnen J H; Schellens J H M
Phase I and pharmacokinetic study of the combination of topotecan and ifosfamide administered intravenously every 3 weeks.
British journal of cancer 2004;90(12):2268-77.
2004: Rademaker-Lakhai Jeany M; Terret Catherine; Howell Stephen B; Baud Christiane M; De Boer Richard F; Pluim Dick; Beijnen Jos H; Schellens Jan H M; Droz Jean-Pierre
A Phase I and pharmacological study of the platinum polymer AP5280 given as an intravenous infusion once every 3 weeks in patients with solid tumors.
Clinical cancer research : an official journal of the American Association for Cancer Research 2004;10(10):3386-95.
2004: Kemper E M; Verheij M; Boogerd W; Beijnen J H; van Tellingen O
Improved penetration of docetaxel into the brain by co-administration of inhibitors of P-glycoprotein.
European journal of cancer (Oxford, England : 1990) 2004;40(8):1269-74.
2004: Crommentuyn K M L; Rosing H; Hillebrand M J X; Huitema A D R; Beijnen J H
Simultaneous quantification of the new HIV protease inhibitors atazanavir and tipranavir in human plasma by high-performance liquid chromatography coupled with electrospray ionization tandem mass spectrometry.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 2004;804(2):359-67.
2004: de Jonge Milly E; Huitema Alwin D R; Rodenhuis Sjoerd; Beijnen Jos H
Integrated Population Pharmacokinetic Model of both cyclophosphamide and thiotepa suggesting a mutual drug-drug interaction.
Journal of pharmacokinetics and pharmacodynamics 2004;31(2):135-56.
2004: Stokvis E; Rosing H; López-Lázaro L; Beijnen J H
Simple and sensitive liquid chromatographic quantitative analysis of the novel marine anticancer drug Yondelis (ET-743, trabectedin) in human plasma using column switching and tandem mass spectrometric detection.
Journal of mass spectrometry : JMS 2004;39(4):431-6.
2004: Crommentuyn Kristel M L; Mulder Jan W; Sparidans Rolf W; Huitema Alwin D R; Schellens Jan H M; Beijnen Jos H
Drug-drug interaction between itraconazole and the antiretroviral drug lopinavir/ritonavir in an HIV-1-infected patient with disseminated histoplasmosis.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2004;38(8):e73-5.
2004: de Jonge Milly E; van den Bongard H J G Desirée; Huitema Alwin D R; Mathôt Ron A A; Rosing Hilde; Baas Paul; van Zandwijk Nico; Beijnen Jos H; Schellens Jan H M
Bayesian pharmacokinetically guided dosing of paclitaxel in patients with non-small cell lung cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2004;10(7):2237-44.
2004: Sankatsing Sanjay U C; Beijnen Jos H; Schinkel Alfred H; Lange Joep M A; Prins Jan M
P glycoprotein in human immunodeficiency virus type 1 infection and therapy.
Antimicrobial agents and chemotherapy 2004;48(4):1073-81.
2004: van den Bongard H J G Desirée; Sparidans Rolf W; Critchley David J P; Beijnen Jos H; Schellens Jan H M
Pharmacokinetic drug-drug interaction of the novel anticancer agent E7070 and acenocoumarol.
Investigational new drugs 2004;22(2):151-8.
2004: Stokvis E; Rosing H; Crul M; Rieser M J; Heck A J R; Schellens J H M; Beijnen J H
Quantitative analysis of the novel anticancer drug ABT-518, a matrix metalloproteinase inhibitor, plus the screening of six metabolites in human plasma using high-performance liquid chromatography coupled with electrospray tandem mass spectrometry.
Journal of mass spectrometry : JMS 2004;39(3):277-88.
2004: de Jonge Milly E; van Dam Selma M; Hillebrand Michel J X; Rosing Hilde; Huitema Alwin D R; Rodenhuis Sjoerd; Beijnen Jos H
Simultaneous quantification of cyclophosphamide, 4-hydroxycyclophosphamide, N,N',N"-triethylenethiophosphoramide (thiotepa) and N,N',N"-triethylenephosphoramide (tepa) in human plasma by high-performance liquid chromatography coupled with electrospray ionization tandem mass spectrometry.
Journal of mass spectrometry : JMS 2004;39(3):262-71.
2004: Kuppens Isa E L M; Boot Henk; Beijnen Jos H; Schellens Jan H M; Labadie Jerry
Capecitabine induces severe angina-like chest pain.
Annals of internal medicine 2004;140(6):494-5.
2004: Kemper E Marleen; Cleypool Cindy; Boogerd Willem; Beijnen Jos H; van Tellingen Olaf
The influence of the P-glycoprotein inhibitor zosuquidar trihydrochloride (LY335979) on the brain penetration of paclitaxel in mice.
Cancer chemotherapy and pharmacology 2004;53(2):173-8.
2004: Sparidans Rolf W; Schellens Jan H M; López-Lázaro Luis; Jimeno José M; Beijnen Jos H
Liquid chromatographic assay for the cyclic depsipeptide aplidine, a new marine antitumor drug, in whole blood using derivatization with trans-4'-hydrazino-2-stilbazole.
Biomedical chromatography : BMC 2004;18(1):16-20.
2004: van den Bongard H J G Desirée; Kemper E Marleen; van Tellingen Olaf; Rosing Hilde; Mathôt Ron A A; Schellens Jan H M; Beijnen Jos H
Development and validation of a method to determine the unbound paclitaxel fraction in human plasma.
Analytical biochemistry 2004;324(1):11-5.
2004: Beumer Jan Hendrik; Rosing Hilde; Hillebrand Michel J X; Nan-Offeringa Lianda G A H; Foley Karen; Yule S Murray; Heck Albert J R; Schellens Jan H M; Beijnen Jos H
Quantitative determination of the novel anticancer drug E7070 (indisulam) and its metabolite (1,4-benzenedisulphonamide) in human plasma, urine and faeces by high-performance liquid chromatography coupled with electrospray ionization tandem mass spectrometry.
Rapid communications in mass spectrometry : RCM 2004;18(23):2839-48.
2004: Kappelhoff Bregt S; Crommentuyn Kristel M L; de Maat Monique M R; Mulder Jan W; Huitema Alwin D R; Beijnen Jos H
Practical guidelines to interpret plasma concentrations of antiretroviral drugs.
Clinical pharmacokinetics 2004;43(13):845-53.
2004: Sankatsing Sanjay U C; Hoggard Patrick G; Huitema Alwin D R; Sparidans Rolf W; Kewn Stephen; Crommentuyn Kristel M L; Lange Joep M A; Beijnen Jos H; Back David J; Prins Jan M
Effect of mycophenolate mofetil on the pharmacokinetics of antiretroviral drugs and on intracellular nucleoside triphosphate pools.
Clinical pharmacokinetics 2004;43(12):823-32.
2004: Stokvis Ellen; Nan-Offeringa Lianda G A H; Ouwehand Mariët; Tibben Matthijs M; Rosing Hilde; Schnaars Yvonne; Grigat Martina; Romeis Peter; Schellens Jan H M; Beijnen Jos H
Quantitative analysis of D-24851, a novel anticancer agent, in human plasma and urine by liquid chromatography coupled with tandem mass spectrometry.
Rapid communications in mass spectrometry : RCM 2004;18(13):1465-71.
2004: van Ruth Serge; Mathôt Ron A A; Sparidans Rolf W; Beijnen Jos H; Verwaal Vic J; Zoetmulder Frans A N
Population pharmacokinetics and pharmacodynamics of mitomycin during intraoperative hyperthermic intraperitoneal chemotherapy.
Clinical pharmacokinetics 2004;43(2):131-43.
2003: den Brok Monique W J; Nuijen Bastiaan; Miranda Elena; Floriano Pablo; Munt Simon; Manzanares Ignacio; Beijnen Jos H
Development and validation of a liquid chromatography-ultraviolet absorbance detection assay using derivatisation for the novel marine anticancer agent ES-285 x HCl [(2S,3R)-2-amino-3-octadecanol hydrochloride] and its pharmaceutical dosage form.
Journal of chromatography. A 2003;1020(2):251-8.
2003: Missotten Guy S; Beijnen Jos H; Keunen Jan E; Bonfrer Johannes M
Proteomics in uveal melanoma.
Melanoma research 2003;13(6):627-9.
2003: Huitema Alwin D R; Kuiper Rob A J; Meenhorst Pieter L; Mulder Jan W; Beijnen Jos H
Photophobia in a patient with high indinavir plasma concentrations.
Therapeutic drug monitoring 2003;25(6):735-7.
2003: Kemper E M; Ouwehand M; Beijnen J H; van Tellingen O
Bioanalysis of zosuquidar trihydrochloride (LY335979) in small volumes of human and murine plasma by ion-pairing reversed-phase high-performance liquid chromatography.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 2003;798(1):63-8.
2003: van Tellingen O; Buckle T; Jonker J W; van der Valk M A; Beijnen J H
P-glycoprotein and Mrp1 collectively protect the bone marrow from vincristine-induced toxicity in vivo.
British journal of cancer 2003;89(9):1776-82.
2003: Bouma M; Nuijen B; Harms R; Rice J R; Nowotnik D P; Stewart D R; Jansen B A J; van Zutphen S; Reedijk J; van Steenbergen M J; Talsma H; Bult A; Beijnen J H
Pharmaceutical development of a parenteral lyophilized formulation of the investigational polymer-conjugated platinum anticancer agent AP 5280.
Drug development and industrial pharmacy 2003;29(9):981-95.
2003: Sparidans Rolf W; Silvertand Linda; Dost Frits; Rothbarth Joost; Mulder Gerard J; Schellens Jan H M; Beijnen Jos H
Simple high-performance liquid chromatographic assay for melphalan in perfusate, rat liver and tumour tissue.
Biomedical chromatography : BMC 2003;17(7):458-64.
2003: van Herwaarden Antonius E; Jonker Johan W; Wagenaar Els; Brinkhuis Remco F; Schellens Jan H M; Beijnen Jos H; Schinkel Alfred H
The breast cancer resistance protein (Bcrp1/Abcg2) restricts exposure to the dietary carcinogen 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine.
Cancer research 2003;63(19):6447-52.
2003: de Maat Monique M; ter Heine Rob; van Gorp Eric C M; Mulder Jan W; Mairuhu Albert T A; Beijnen Jos H
Case series of acute hepatitis in a non-selected group of HIV-infected patients on nevirapine-containing antiretroviral treatment.
AIDS (London, England) 2003;17(15):2209-14.
2003: Crul Mirjam; Schoemaker Nadja E; Pluim Dick; Maliepaard Marc; Underberg René W M; Schot Margaret; Sparidans Rolf W; Baas Paul; Beijnen Jos H; Van Zandwijk Nico; Schellens Jan H M
Randomized phase I clinical and pharmacologic study of weekly versus twice-weekly dose-intensive cisplatin and gemcitabine in patients with advanced non-small cell lung cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2003;9(10 Pt 1):3526-33.
2003: Twelves C; Hoekman K; Bowman A; Vermorken J B; Anthoney A; Smyth J; van Kesteren C; Beijnen J H; Uiters J; Wanders J; Gomez J; Guzmán C; Jimeno J; Hanauske A
Phase I and pharmacokinetic study of Yondelis (Ecteinascidin-743; ET-743) administered as an infusion over 1 h or 3 h every 21 days in patients with solid tumours.
European journal of cancer (Oxford, England : 1990) 2003;39(13):1842-51.
2003: de Maat Monique M R; ter Heine Rob; Mulder Jan W; Meenhorst Pieter L; Mairuhu Albert T A; van Gorp Eric C M; Huitema Alwin D R; Beijnen Jos H
Incidence and risk factors for nevirapine-associated rash.
European journal of clinical pharmacology 2003;59(5-6):457-62.
2003: van Kesteren Ch; de Vooght M M M; López-Lázaro L; Mathôt R A A; Schellens J H M; Jimeno J M; Beijnen J H
Yondelis (trabectedin, ET-743): the development of an anticancer agent of marine origin.
Anti-cancer drugs 2003;14(7):487-502.
2003: Bardelmeijer H A; Buckle T; Ouwehand M; Beijnen J H; Schellens J H M; van Tellingen O
Cannulation of the jugular vein in mice: a method for serial withdrawal of blood samples.
Laboratory animals 2003;37(3):181-7.
2003: Kappelhoff Bregt S; Rosing Hilde; Huitema Alwin D R; Beijnen Jos H
Simple and rapid method for the simultaneous determination of the non-nucleoside reverse transcriptase inhibitors efavirenz and nevirapine in human plasma using liquid chromatography.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 2003;792(2):353-62.
2003: Kemper E Marleen; van Zandbergen A Erik; Cleypool Cindy; Mos Henk A; Boogerd Willem; Beijnen Jos H; van Tellingen Olaf
Increased penetration of paclitaxel into the brain by inhibition of P-Glycoprotein.
Clinical cancer research : an official journal of the American Association for Cancer Research 2003;9(7):2849-55.
2003: Bongard H J G D van den; Pluim D; Waardenburg R C A M van; Ravic M; Beijnen J H; Schellens J H M
In vitro pharmacokinetic study of the novel anticancer agent E7070: red blood cell and plasma protein binding in human blood.
Anti-cancer drugs 2003;14(6):405-10.
2003: Callies Sophie; de Alwis Dinesh P; Harris Adrian; Vasey Paul; Beijnen Jos H; Schellens Jan H; Burgess Michael; Aarons Leon
A population pharmacokinetic model for paclitaxel in the presence of a novel P-gp modulator, Zosuquidar Trihydrochloride (LY335979).
British journal of clinical pharmacology 2003;56(1):46-56.
2003: Sparidans Rolf W; Crommentuyn Kristel M L; Schellens Jan H M; Beijnen Jos H
Liquid chromatographic assay for the antiviral nucleotide analogue tenofovir in plasma using derivatization with chloroacetaldehyde.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 2003;791(1-2):227-33.
2003: Brandon Esther F A; Raap Christiaan D; Meijerman Irma; Beijnen Jos H; Schellens Jan H M
An update on in vitro test methods in human hepatic drug biotransformation research: pros and cons.
Toxicology and applied pharmacology 2003;189(3):233-46.
2003: de Maat Monique M R; Huitema Alwin D R; Mulder Jan W; Meenhorst Pieter L; van Gorp Eric C M; Mairuhu Albert T A; Beijnen Jos H
Subtherapeutic antiretroviral plasma concentrations in routine clinical outpatient HIV care.
Therapeutic drug monitoring 2003;25(3):367-73.
2003: de Jonge Milly E; Mathôt Ron A A; van Dam Selma M; Rodenhuis Sjoerd; Beijnen Jos H
Sorption of thiotepa to polyurethane catheter causes falsely elevated plasma levels.
Therapeutic drug monitoring 2003;25(3):261-3.
2003: van Kesteren Ch; Mathôt R A A; Beijnen J H; Schellens J H M
Pharmacokinetic-pharmacodynamic guided trial design in oncology.
Investigational new drugs 2003;21(2):225-41.
2003: Bouma Marjan; Nuijen Bastiaan; Stewart Donald R; Shannon Kevin F; St John John V; Rice John R; Harms Remko; Jansen Bart A J; van Zutphen Steven; Reedijk Jan; Bult Auke; Beijnen Jos H
Pharmaceutical quality control of the investigational polymer-conjugated platinum anticancer agent AP 5280.
PDA journal of pharmaceutical science and technology / PDA 2003;57(3):198-207.
2003: Stokvis E; Nan-Offeringa L; Rosing H; López-Lázaro L; Aceña J L; Miranda E; Lyubimov A; Levine B S; D'Aleo C; Schellens J H M; Beijnen J H
Quantitative analysis of ES-285, an investigational marine anticancer drug, in human, mouse, rat, and dog plasma using coupled liquid chromatography and tandem mass spectrometry.
Journal of mass spectrometry : JMS 2003;38(5):548-54.
2003: Wielinga Peter R; van der Heijden Ingrid; Reid Glen; Beijnen Jos H; Wijnholds Jan; Borst Piet
Characterization of the MRP4- and MRP5-mediated transport of cyclic nucleotides from intact cells.
The Journal of biological chemistry 2003;278(20):17664-71.
2003: Koks Cees H W; Huitema Alwin D R; Kroon Eugene D M B; Chuenyam Theshinee; Sparidans Rolf W; Lange Joep M A; Beijnen Jos H
Population pharmacokinetics of itraconazole in Thai HIV-1-infected persons.
Therapeutic drug monitoring 2003;25(2):229-33.
2003: Bardelmeijer Heleen A; Oomen Ingrid A M; Hillebrand Michel J X; Beijnen Jos H; Schellens Jan H M; van Tellingen Olaf
Metabolism of paclitaxel in mice.
Anti-cancer drugs 2003;14(3):203-9.
2003: Bouma Marjan; Nuijen Bastiaan; Jansen Martine T; Sava Gianni; Picotti Fabrizio; Flaibani Antonella; Bult Auke; Beijnen Jos H
Development of a LC method for pharmaceutical quality control of the antimetastatic ruthenium complex NAMI-A.
Journal of pharmaceutical and biomedical analysis 2003;31(2):215-28.
2003: Crommentuyn K M L; Rosing H; Nan-Offeringa L G A H; Hillebrand M J X; Huitema A D R; Beijnen J H
Rapid quantification of HIV protease inhibitors in human plasma by high-performance liquid chromatography coupled with electrospray ionization tandem mass spectrometry.
Journal of mass spectrometry : JMS 2003;38(2):157-66.
2003: de Bree Eelco; Rosing Hilde; Beijnen Jos H; Romanos John; Michalakis John; Georgoulias Vasilis; Tsiftsis Dimitris D
Pharmacokinetic study of docetaxel in intraoperative hyperthermic i.p. chemotherapy for ovarian cancer.
Anti-cancer drugs 2003;14(2):103-10.
2003: Kruijtzer C M F; Boot H; Beijnen J H; Lochs H L; Parnis F X; Planting A S T; Pelgrims J M G; Williams R; Mathôt R A A; Rosing H; Schot M E; Van Tinteren H; Schellens J H M
Weekly oral paclitaxel as first-line treatment in patients with advanced gastric cancer.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2003;14(2):197-204.
2003: Schoemaker Nadja E; Rosing Hilde; Jansen Sindy; Schellens Jan H M; Beijnen Jos H
High-performance liquid chromatographic analysis of the anticancer drug irinotecan (CPT-11) and its active metabolite SN-38 in human plasma.
Therapeutic drug monitoring 2003;25(1):120-4.
2003: Huisman Maarten T; Smit Johan W; Wiltshire Hugh R; Beijnen Jos H; Schinkel Alfred H
Assessing safety and efficacy of directed P-glycoprotein inhibition to improve the pharmacokinetic properties of saquinavir coadministered with ritonavir.
The Journal of pharmacology and experimental therapeutics 2003;304(2):596-602.
2003: Crul Mirjam; van Waardenburg Robert C A M; Bocxe Suzanne; van Eijndhoven Maria A J; Pluim Dick; Beijnen Jos H; Schellens Jan H M
DNA repair mechanisms involved in gemcitabine cytotoxicity and in the interaction between gemcitabine and cisplatin.
Biochemical pharmacology 2003;65(2):275-82.
2003: de Maat Monique M R; Huitema Alwin D R; Mulder Jan W; Meenhorst Pieter L; van Gorp Eric C M; Mairuhu Albert T A; Beijnen Jos H
Drug Interaction of Fluvoxamine and Fluoxetine with Nevirapine in HIV-1-Infected Individuals.
Clinical drug investigation 2003;23(10):629-37.
2003: de Vries-Sluijs Theodora E M S; Dieleman Jeanne P; Arts Dennis; Huitema Alwin D R; Beijnen Jos H; Schutten Martin; van der Ende Marchina E
Low nevirapine plasma concentrations predict virological failure in an unselected HIV-1-infected population.
Clinical pharmacokinetics 2003;42(6):599-605.
2003: de Maat Monique M R; Ekhart G Corine; Huitema Alwin D R; Koks Cornelis H W; Mulder Jan W; Beijnen Jos H
Drug interactions between antiretroviral drugs and comedicated agents.
Clinical pharmacokinetics 2003;42(3):223-82.
2002: Crul M; van Waardenburg R C A M; Beijnen J H; Schellens J H M
DNA-based drug interactions of cisplatin.
Cancer treatment reviews 2002;28(6):291-303.
2002: Kruijtzer C M F; Schellens J H M; Mezger J; Scheulen M E; Keilholz U; Beijnen J H; Rosing H; Mathôt R A A; Marcus S; van Tinteren H; Baas P
Phase II and pharmacologic study of weekly oral paclitaxel plus cyclosporine in patients with advanced non-small-cell lung cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2002;20(23):4508-16.
2002: Schoemaker Nadja E; Mathôt Ron A A; Schöffski Patrick; Rosing Hilde; Schellens Jan H M; Beijnen Jos H
Development of an optimal pharmacokinetic sampling schedule for rubitecan administered orally in a daily times five schedule.
Cancer chemotherapy and pharmacology 2002;50(6):514-7.
2002: Crul Mirjam; Beerepoot Laurens V; Stokvis Ellen; Vermaat Johannes S P; Rosing Hilde; Beijnen Jos H; Voest Emile E; Schellens Jan H M
Clinical pharmacokinetics, pharmacodynamics and metabolism of the novel matrix metalloproteinase inhibitor ABT-518.
Cancer chemotherapy and pharmacology 2002;50(6):473-8.
2002: Wielinga P R; Reid G; Challa E E; van der Heijden I; van Deemter L; de Haas M; Mol C; Kuil A J; Groeneveld E; Schuetz J D; Brouwer C; De Abreu R A; Wijnholds J; Beijnen J H; Borst P
Thiopurine metabolism and identification of the thiopurine metabolites transported by MRP4 and MRP5 overexpressed in human embryonic kidney cells.
Molecular pharmacology 2002;62(6):1321-31.
2002: van Kesteren Charlotte; Mathôt R A A; Raymond E; Armand J P; Fumoleau P; Punt C; Ravic M; Wanders J; Beijnen J H; Schellens J H M;
Development and validation of limited sampling strategies for prediction of the systemic exposure to the novel anticancer agent E7070 (N-(3-chloro-7-indolyl)-1,4-benzenedisulphonamide).
British journal of clinical pharmacology 2002;54(5):463-71.
2002: Huisman Maarten T; Smit Johan W; Crommentuyn Kristel M L; Zelcer Noam; Wiltshire Hugh R; Beijnen Jos H; Schinkel Alfred H
Multidrug resistance protein 2 (MRP2) transports HIV protease inhibitors, and transport can be enhanced by other drugs.
AIDS (London, England) 2002;16(17):2295-301.
2002: Van Kesteren Charlotte; Beijnen Jos H; Schellens Jan H M
E7070: a novel synthetic sulfonamide targeting the cell cycle progression for the treatment of cancer.
Anti-cancer drugs 2002;13(10):989-97.
2002: Jonker Johan W; Buitelaar Marije; Wagenaar Els; Van Der Valk Martin A; Scheffer George L; Scheper Rik J; Plosch Torsten; Kuipers Folkert; Elferink Ronald P J Oude; Rosing Hilde; Beijnen Jos H; Schinkel Alfred H
The breast cancer resistance protein protects against a major chlorophyll-derived dietary phototoxin and protoporphyria.
Proceedings of the National Academy of Sciences of the United States of America 2002;99(24):15649-54.
2002: Bouma M; Nuijen B; Sava G; Perbellini A; Flaibani A; van Steenbergen M J; Talsma H; Kettenes-van den Bosch J J; Bult A; Beijnen J H
Pharmaceutical development of a parenteral lyophilized formulation of the antimetastatic ruthenium complex NAMI-A.
International journal of pharmaceutics 2002;248(1-2):247-59.
2002: Bouma Marjan; Nuijen Bastiaan; Jansen Martine T; Sava Gianni; Flaibani Antonella; Bult Auke; Beijnen Jos H
A kinetic study of the chemical stability of the antimetastatic ruthenium complex NAMI-A.
International journal of pharmaceutics 2002;248(1-2):239-46.
2002: Bardelmeijer Heleen A; Ouwehand Mariët; Buckle Tessa; Huisman Maarten T; Schellens Jan H M; Beijnen Jos H; van Tellingen Olaf
Low systemic exposure of oral docetaxel in mice resulting from extensive first-pass metabolism is boosted by ritonavir.
Cancer research 2002;62(21):6158-64.
2002: Boelaert Johan R; Dom Geneviève M; Huitema Alwin D; Beijnen Jos H; Lange Joep M
The boosting of didanosine by allopurinol permits a halving of the didanosine dosage.
AIDS (London, England) 2002;16(16):2221-3.
2002: Bouma Marjan; Nuijen Bastiaan; Jansen Martine T; Sava Gianni; Bult Auke; Beijnen Jos H
Photostability profiles of the experimental antimetastatic ruthenium complex NAMI-A.
Journal of pharmaceutical and biomedical analysis 2002;30(4):1287-96.
2002: de Jonge M E; Mathôt R A A; Dalesio O; Huitema A D R; Rodenhuis S; Beijnen J H
Relationship between irreversible alopecia and exposure to cyclophosphamide, thiotepa and carboplatin (CTC) in high-dose chemotherapy.
Bone marrow transplantation 2002;30(9):593-7.
2002: Sparidans Rolf W; Crul Mirjam; Schellens Jan H M; Beijnen Jos H
Isocratic ion-exchange chromatographic assay for the nucleotide gemcitabine triphosphate in human white blood cells.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 2002;780(2):423-30.
2002: Rothbarth Joost; Sparidans Rolf W; Beijnen Jos H; Schultze-Kool Leo J; Putter Hein; van de Velde Cornelis J H; Mulder Gerard J
Reduced liver uptake of arterially infused melphalan during retrograde rat liver perfusion with unaffected liver tumor uptake.
The Journal of pharmacology and experimental therapeutics 2002;303(2):736-40.
2002: Bouma M; Nuijen B; Stewart D R; Rice J R; Jansen B A J; Reedijk J; Bult A; Beijnen J H
Stability and compatibility of the investigational polymer-conjugated platinum anticancer agent AP 5280 in infusion systems and its hemolytic potential.
Anti-cancer drugs 2002;13(9):915-24.
2002: de Maat Monique M R; Huitema Alwin D R; Mulder Jan W; Meenhorst Pieter L; van Gorp Eric C M; Beijnen Jos H
Population pharmacokinetics of nevirapine in an unselected cohort of HIV-1-infected individuals.
British journal of clinical pharmacology 2002;54(4):378-85.
2002: Van Kesteren Ch; Mathôt R A A; Raymond E; Armand J P; Dittrich Ch; Dumez H; Roché H; Droz J P; Punt C; Ravic M; Wanders J; Beijnen J H; Fumoleau P; Schellens J H M;
Population pharmacokinetics of the novel anticancer agent E7070 during four phase I studies: model building and validation.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2002;20(19):4065-73.
2002: van sen Bongard H J G Desirée; Pluim Dick; Rosing Hilde; Nan-Offeringa Lianda; Schot Margaret; Ravic Miroslav; Schellens Jan H M; Beijnen Jos H
An excretion balance and pharmacokinetic study of the novel anticancer agent E7070 in cancer patients.
Anti-cancer drugs 2002;13(8):807-14.
2002: Stokvis E; Rosing H; López-Lázaro L; Rodriguez I; Jimeno J M; Supko J G; Schellens J H M; Beijnen J H
Quantitative analysis of the novel depsipeptide anticancer drug Kahalalide F in human plasma by high-performance liquid chromatography under basic conditions coupled to electrospray ionization tandem mass spectrometry.
Journal of mass spectrometry : JMS 2002;37(9):992-1000.
2002: Schoemaker N E; van Kesteren C; Rosing H; Jansen S; Swart M; Lieverst J; Fraier D; Breda M; Pellizzoni C; Spinelli R; Grazia Porro M; Beijnen J H; Schellens J H M; ten Bokkel Huinink W W
A phase I and pharmacokinetic study of MAG-CPT, a water-soluble polymer conjugate of camptothecin.
British journal of cancer 2002;87(6):608-14.
2002: De Maat Monique M R; Mathôt Ron A A; Veldkamp Agnes I; Huitma Aldwin D R; Mulder Jan W; Meenhorst Pieter L; Van Gorp Eric C M; Carlier Hilde; Beijnen Jos H
Hepatotoxicity following nevirapine-containing regimens in HIV-1-infected individuals.
Pharmacological research : the official journal of the Italian Pharmacological Society 2002;46(3):295-300.
2002: De Jonge Milly E; Mathôt Ron A A; Van Dam Selma M; Beijnen Jos H; Rodenhuis Sjoerd
Extremely high exposures in an obese patient receiving high-dose cyclophosphamide, thiotepa and carboplatin.
Cancer chemotherapy and pharmacology 2002;50(3):251-5.
2002: Koks C H W; Meenhorst P L; Bult A; Beijnen J H
Itraconazole solution: summary of pharmacokinetic features and review of activity in the treatment of fluconazole-resistant oral candidosis in HIV-infected persons.
Pharmacological research : the official journal of the Italian Pharmacological Society 2002;46(2):195-201.
2002: Raymond E; ten Bokkel Huinink W W; Taïeb J; Beijnen J H; Faivre S; Wanders J; Ravic M; Fumoleau P; Armand J P; Schellens J H M;
Phase I and pharmacokinetic study of E7070, a novel chloroindolyl sulfonamide cell-cycle inhibitor, administered as a one-hour infusion every three weeks in patients with advanced cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2002;20(16):3508-21.
2002: van Heeswijk Rolf P G; Scherpbier Henriëtte J; de Koning Linda A; Heymans Hugo S A; Lange Joep M A; Beijnen Jos H; Hoetelmans Richard M W
The pharmacokinetics of nelfinavir in HIV-1-infected children.
Therapeutic drug monitoring 2002;24(4):487-91.
2002: Crul M; Rosing H; de Klerk G J; Dubbelman R; Traiser M; Reichert S; Knebel N G; Schellens J H M; Beijnen J H; ten Bokkel Huinink W W
Phase I and pharmacological study of daily oral administration of perifosine (D-21266) in patients with advanced solid tumours.
European journal of cancer (Oxford, England : 1990) 2002;38(12):1615-21.
2002: Schoemaker Nadja E; Rosing Hilde; Jansen Sindy; Schöffski Patrick; Rizzo Jinee; Schellens Jan H M; Beijnen Jos H
Determination of 9-nitrocamptothecin and its metabolite 9-aminocamptothecin in human plasma using high-performance liquid chromatography with ultraviolet and fluorescence detection.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 2002;775(2):231-7.
2002: Koks C H W; Crommentuyn K M L; Mathôt R A A; Mulder J W; Meenhorst P L; Beijnen J H
Prognostic factors for the clinical effectiveness of fluconazole in the treatment of oral candidiasis in HIV-1-infected individuals.
Pharmacological research : the official journal of the Italian Pharmacological Society 2002;46(1):89-94.
2002: Herben Virginie M M; Schoemaker nadja E; Rosing Hilde; van Zomeren Desiree M; ten Bokkel Huinink Wim W; Dubbelman Ria; Hearn Solange; Schellens Jan H M; Beijnen Jos H
Urinary and fecal excretion of topotecan in patients with malignant solid tumours.
Cancer chemotherapy and pharmacology 2002;50(1):59-64.
2002: van den Bongard H J G D; Mathôt R A A; van Tellingen O; Schellens J H M; Beijnen J H
A population analysis of the pharmacokinetics of Cremophor EL using nonlinear mixed-effect modelling.
Cancer chemotherapy and pharmacology 2002;50(1):16-24.
2002: Tibben M M; Rademaker-Lakhai J M; Rice J R; Stewart D R; Schellens J H M; Beijnen J H
Determination of total platinum in plasma and plasma ultrafiltrate, from subjects dosed with the platinum-containing N-(2-hydroxypropyl)methacrylamide copolymer AP5280, by use of graphite-furnace Zeeman atomic-absorption spectrometry.
Analytical and bioanalytical chemistry 2002;373(4-5):233-6.
2002: Kruijtzer C M F; Beijnen J H; Rosing H; ten Bokkel Huinink W W; Schot M; Jewell R C; Paul E M; Schellens J H M
Increased oral bioavailability of topotecan in combination with the breast cancer resistance protein and P-glycoprotein inhibitor GF120918.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2002;20(13):2943-50.
2002: Hofstra L S; Bos A M E; de Vries E G E; van der Zee A G J; Willemsen A T M; Rosing H; Beijnen J H; Mulder N H; Aalders J G; Willemse P H B
Kinetic modeling and efficacy of intraperitoneal paclitaxel combined with intravenous cyclophosphamide and carboplatin as first-line treatment in ovarian cancer.
Gynecologic oncology 2002;85(3):517-23.
2002: Crul M; de Klerk G J; Swart M; van't Veer L J; de Jong D; Boerrigter L; Palmer P A; Bol C J; Tan H; de Gast G C; Beijnen J H; Schellens J H M
Phase I clinical and pharmacologic study of chronic oral administration of the farnesyl protein transferase inhibitor R115777 in advanced cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2002;20(11):2726-35.
2002: Malingré Mirte M; Hendrix Emile A; Schellens Jan H M; Koks Cees H W; Tibben Matthijs M; Challa Eric E; Beijnen Jos H
Acute poisoning after oral intake of a toluene-containing paint thinner.
European journal of pediatrics 2002;161(6):354-5.
2002: Kerbusch Thomas; Mathôt Ron A A; Otten Hans M M B; Meesters Eelco W; van Kan Hendrikus J M; Schellens Jan H M; Beijnen Jos H
Bayesian pharmacokinetics of lithium after an acute self-intoxication and subsequent haemodialysis: a case report.
Pharmacology & toxicology 2002;90(5):243-5.
2002: Mould Diane R; Holford Nicholas H G; Schellens Jan H M; Beijnen Jos H; Hutson Paul R; Rosing Hilde; ten Bokkel Huinink Willem W; Rowinsky Eric K; Schiller Joan H; Russo Mark; Ross Graham
Population pharmacokinetic and adverse event analysis of topotecan in patients with solid tumors.
Clinical pharmacology and therapeutics 2002;71(5):334-48.
2002: van Kesteren Charlotte; Twelves Chris; Bowman Angela; Hoekman Klaas; López-Lázaro Luis; Jimeno José; Guzman Cecilia; Mathôt Ron A A; Simpson Andrew; Vermorken Jan B; Smyth John; Schellens Jan H M; Hillebrand Michel J X; Rosing Hilde; Beijnen Jos H
Clinical pharmacology of the novel marine-derived anticancer agent Ecteinascidin 743 administered as a 1- and 3-h infusion in a phase I study.
Anti-cancer drugs 2002;13(4):381-93.
2002: Cardiello Peter G; van Heeswijk Rolf P; Hassink Elly A; Srasuebkul Preeyaporn; Mahanontharit Apicha; Samor Tarika M; Worarien Wassana; Beijnen Jos H; Hoetelmans Richard M; Ruxrungtham Kiat; Cooper David A; Lange Joep M; Phanuphak Praphan
Simplifying protease inhibitor therapy with once-daily dosing of saquinavir soft-gelatin capsules/ritonavir (1600/100 mg): HIVNAT 001.3 study.
Journal of acquired immune deficiency syndromes (1999) 2002;29(5):464-70.
2002: Crul Mirjam; Mathôt Ron A; Giaccone Giuseppe; Punt Cornelis A; Rosing Hilde; Hillebrand Michel X; Ando Yoshitaka; Nishi Nobosuke; Tanaka Hideji; Schellens Jan M; Beijnen Jos H
Population pharmacokinetics of the novel anticancer agent KRN7000.
Cancer chemotherapy and pharmacology 2002;49(4):287-93.
2002: Huitema A D R; Spaander M; Mathjt R A A; Tibben M M; Holtkamp M J; Beijnen J H; Rodenhuis S
Relationship between exposure and toxicity in high-dose chemotherapy with cyclophosphamide, thiotepa and carboplatin.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2002;13(3):374-84.
2002: Meerum Terwogt Jetske M; Groenewegen Gerard; Pluim Dick; Maliepaard Marc; Tibben Matthijs M; Huisman Albert; ten Bokkel Huinink Wim W; Schot Margaret; Welbank Helen; Voest Emile E; Beijnen Jos H; Schellens Jan M
Phase I and pharmacokinetic study of SPI-77, a liposomal encapsulated dosage form of cisplatin.
Cancer chemotherapy and pharmacology 2002;49(3):201-10.
2002: de Maat Monique M R; Frankfort Suzanne V; Mathôt Ron A A; Mulder Jan W; Meenhorst Pieter L; van Gorp Eric C M; Koks Cornelis H W; Hoetelmans Richard M W; de Boer Anthonius; Beijnen Jos H
Discrepancies between medical and pharmacy records for patients on anti-HIV drugs.
The Annals of pharmacotherapy 2002;36(3):410-5.
2002: Koks Cees H W; Sparidans Rolf W; Lucassen Georgette; Crommentuyn Kristel M L; Beijnen Jos H
Selective high-performance liquid chromatographic assay for itraconazole and hydroxyitraconazole in plasma from human immunodeficiency virus-infected patients.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 2002;767(1):103-10.
2002: Bardelmeijer Heleen A; Ouwehand Mariët; Malingré Mirte M; Schellens Jan H M; Beijnen Jos H; van Tellingen Olaf
Entrapment by Cremophor EL decreases the absorption of paclitaxel from the gut.
Cancer chemotherapy and pharmacology 2002;49(2):119-25.
2002: van Heeswijk Rolf P G; Cohen Stuart James W T; Burger David M; Beijnen Jos H; Borleffs Jan C C; Hoetelmans Richard M W;
Long-term suppression of viral replication despite low plasma saquinavir concentrations in the CHEESE Study.
British journal of clinical pharmacology 2002;53(2):211-2.
2002: Crul M; de Klerk G J; Swart M; Weiner L; Palmer P A; Bol C J; Beijnen J H; Schellens J H M
Evaluation of the bioequivalence of tablets and capsules containing the novel anticancer agent R115777 (Zarnestra) in patients with advanced solid tumors.
European journal of drug metabolism and pharmacokinetics 2002;27(1):61-5.
2002: Schoemaker Nadja E; Herben Virginie M M; de Jong Laurina A; van Waardenburg Robert C A M; Pluim Dick; ten Bokkel Huinink Wim W; Beijnen Jos H; Schellens Jan H M
Topoisomerase I levels in white blood cells of patients with ovarian cancer treated with paclitaxel-cisplatin-topotecan in a phase I study.
Anti-cancer drugs 2002;13(1):87-91.
2002: Villalona-Calero Miguel A; Eckhardt S Gail; Weiss Geoffrey; Hidalgo Manuel; Beijnen Jos H; van Kesteren Charlotte; Rosing Hilde; Campbell Elizabeth; Kraynak Maura; Lopez-Lazaro Luis; Guzman Cecilia; Von Hoff Daniel D; Jimeno Jose; Rowinsky Eric K
A phase I and pharmacokinetic study of ecteinascidin-743 on a daily x 5 schedule in patients with solid malignancies.
Clinical cancer research : an official journal of the American Association for Cancer Research 2002;8(1):75-85.
2002: Kruijtzer C M F; Beijnen J H; Schellens J H M
Improvement of oral drug treatment by temporary inhibition of drug transporters and/or cytochrome P450 in the gastrointestinal tract and liver: an overview.
The oncologist 2002;7(6):516-30.
2001: van Heeswijk R P; Veldkamp A; Mulder J W; Meenhorst P L; Lange J M; Beijnen J H; Hoetelmans R M
Combination of protease inhibitors for the treatment of HIV-1-infected patients: a review of pharmacokinetics and clinical experience.
Antiviral therapy 2001;6(4):201-29.
2001: Huitema A D; Mathôt R A; Tibben M M; Rodenhuis S; Beijnen J H
Validation of a therapeutic drug monitoring strategy for thiotepa in a high-dose chemotherapy regimen.
Therapeutic drug monitoring 2001;23(6):650-7.
2001: Veldkamp A I; van Heeswijk R P; Mulder J W; Meenhorst P L; Hoetelmans R M; Lange J M; Beijnen J H
Limited sampling strategies for the estimation of the systemic exposure to the HIV-1 nonnucleoside reverse transcriptase inhibitor nevirapine.
Therapeutic drug monitoring 2001;23(6):606-11.
2001: van Kesteren C; Mathjt R A; López-Lázaro L; Cvitkovic E; Taamma A; Jimeno J M; Guzman C; Schellens J H; Misset J L; Brain E; Hillebrand M J; Rosing H; Beijnen J H
A comparison of limited sampling strategies for prediction of Ecteinascidin 743 clearance when administered as a 24-h infusion.
Cancer chemotherapy and pharmacology 2001;48(6):459-66.
2001: Zelcer N; Saeki T; Reid G; Beijnen J H; Borst P
Characterization of drug transport by the human multidrug resistance protein 3 (ABCC3).
The Journal of biological chemistry 2001;276(49):46400-7.
2001: Hofstra L S; Bos A M; de Vries E G; van der Zee A G; Beijnen J H; Rosing H; Mulder N H; Aalders J G; Willemse P H
A phase I and pharmacokinetic study of intraperitoneal topotecan.
British journal of cancer 2001;85(11):1627-33.
2001: Malingré M M; Schellens J H; Van Tellingen O; Ouwehand M; Bardelmeijer H A; Rosing H; Koopman F J; Schot M E; Ten Bokkel Huinink W W; Beijnen J H
The co-solvent Cremophor EL limits absorption of orally administered paclitaxel in cancer patients.
British journal of cancer 2001;85(10):1472-7.
2001: Bardelmeijer H A; Ouwehand M; Beijnen J H; Schellens J H; van Tellingen O
Determination of cyclosporin A in human and mouse plasma by reversed-phase high-performance liquid chromatography.
Journal of chromatography. B, Biomedical sciences and applications 2001;763(1-2):201-6.
2001: Schoemaker N E; Frigerio E; Fraier D; Schellens J H; Rosing H; Jansen S; Beijnen J H
High-performance liquid chromatographic analysis for the determination of a novel polymer-bound camptothecin derivative (MAG-camptothecin) and free camptothecin in human plasma.
Journal of chromatography. B, Biomedical sciences and applications 2001;763(1-2):173-83.
2001: Nuijen B; Bouma M; Talsma H; Manada C; Jimeno J M; Lopez-Lazaro L; Bult A; Beijnen J H
Development of a lyophilized parenteral pharmaceutical formulation of the investigational polypeptide marine anticancer agent kahalalide F.
Drug development and industrial pharmacy 2001;27(8):767-80.
2001: Kerbusch T; Mathjt R A; Keizer H J; Ouwerkerk J; Rodenhuis S; Schellens J H; Beijnen J H
Population pharmacokinetics and exploratory pharmacodynamics of ifosfamide and metabolites after a 72-h continuous infusion in patients with soft tissue sarcoma.
European journal of clinical pharmacology 2001;57(6-7):467-77.
2001: Sparidans R W; Rosing H; Hillebrand M J; López-Lázaro L; Jimeno J M; Manzanares I; van Kesteren C; Cvitkovic E; van Oosterom A T; Schellens J H; Beijnen J H
Search for metabolites of ecteinascidin 743, a novel, marine-derived, anti-cancer agent, in man.
Anti-cancer drugs 2001;12(8):653-66.
2001: Kerbusch T; Jansen R L; Mathôt R A; Huitema A D; Jansen M; van Rijswijk R E; Beijnen J H
Modulation of the cytochrome P450-mediated metabolism of ifosfamide by ketoconazole and rifampin.
Clinical pharmacology and therapeutics 2001;70(2):132-41.
2001: Kemper E M; Jansen B; Brouwer K R; Schellens J H; Beijnen J H; van Tellingen O
Bioanalysis and preliminary pharmacokinetics of the acridonecarboxamide derivative GF120918 in plasma of mice and humans by ion-pairing reversed-phase high-performance liquid chromatography with fluorescence detection.
Journal of chromatography. B, Biomedical sciences and applications 2001;759(1):135-43.
2001: Malingré M M; Ten Bokkel Huinink W W; Duchin K; Schellens J H; Beijnen J H
Pharmacokinetics of oral cyclosporin A when co-administered to enhance the oral absorption of paclitaxel.
Anti-cancer drugs 2001;12(7):591-3.
2001: Sparidans R W; Stokvis E; Jimeno J M; López-Lázaro L; Schellens J H; Beijnen J H
Chemical and enzymatic stability of a cyclic depsipeptide, the novel, marine-derived, anti-cancer agent kahalalide F.
Anti-cancer drugs 2001;12(7):575-82.
2001: Koks C H; Crommentuyn K M; Hoetelmans R M; Mathôt R A; Beijnen J H
Can fluconazole concentrations in saliva be used for therapeutic drug monitoring?
Therapeutic drug monitoring 2001;23(4):449-53.
2001: Van den Brande J; Nannan Panday V R; Hoekman K; Rosing H; Huijskes R V; Verheijen R H; Beijnen J H; Vermorken J B
Pharmacologic study of paclitaxel administered with or without the cytoprotective agent amifostine, and given as a single agent or in combination with epirubicin and cisplatin in patients with advanced solid tumors.
American journal of clinical oncology 2001;24(4):401-3.
2001: Veldkamp A I; van Heeswijk R P; Mulder J W; Meenhorst P L; Schreij G; van der Geest S; Lange J M; Beijnen J H; Hoetelmans R M
Steady-state pharmacokinetics of twice-daily dosing of saquinavir plus ritonavir in HIV-1-infected individuals.
Journal of acquired immune deficiency syndromes (1999) 2001;27(4):344-9.
2001: Malingré M M; Ten Bokkel Huinink W W; Mackay M; Schellens J H; Beijnen J H
Pharmacokinetics of oral cyclosporin A when co-administered to enhance the absorption of orally administered docetaxel.
European journal of clinical pharmacology 2001;57(4):305-7.
2001: Schrama J G; Baars J W; Holtkamp M J; Schornagel J H; Beijnen J H; Rodenhuis S
Phase II study of a multi-course high-dose chemotherapy regimen incorporating cyclophosphamide, thiotepa, and carboplatin in stage IV breast cancer.
Bone marrow transplantation 2001;28(2):173-80.
2001: Nuijen B; Bouma M; Manada C; Jimeno J M; Bult A; Beijnen J H
In vitro hemolysis and buffer capacity studies with the novel marine anticancer agent kahalalide F and its reconstitution vehicle cremophor EL/ethanol.
PDA journal of pharmaceutical science and technology / PDA 2001;55(4):223-9.
2001: Kerbusch T; vanPutten J W; Groen H J; Huitema A D; Mathjt R A; Beijnen J H
Population pharmacokinetics of ifosfamide and its 2- and 3-dechloroethylated and 4-hydroxylated metabolites in resistant small-cell lung cancer patients.
Cancer chemotherapy and pharmacology 2001;48(1):53-61.
2001: van Maanen M J; Huitema A D; Rodenhuis S; Beijnen J H
Urinary excretion of thioTEPA and its metabolites in patients treated with high-dose cyclophosphamide, thioTEPA and carboplatin.
Anti-cancer drugs 2001;12(6):519-24.
2001: Kerbusch T; Mathôt R A; Keizer H J; Kaijser G P; Schellens J H; Beijnen J H
Influence of dose and infusion duration on pharmacokinetics of ifosfamide and metabolites.
Drug metabolism and disposition: the biological fate of chemicals 2001;29(7):967-75.
2001: Veldkamp A I; Harris M; Montaner J S; Moyle G; Gazzard B; Youle M; Johnson M; Kwakkelstein M O; Carlier H; van Leeuwen R; Beijnen J H; Lange J M; Reiss P; Hoetelmans R M
The steady-state pharmacokinetics of efavirenz and nevirapine when used in combination in human immunodeficiency virus type 1-infected persons.
The Journal of infectious diseases 2001;184(1):37-42.
2001: Huitema A D; Mathôt R A; Tibben M M; Rodenhuis S; Beijnen J H
A mechanism-based pharmacokinetic model for the cytochrome P450 drug-drug interaction between cyclophosphamide and thioTEPA and the autoinduction of cyclophosphamide.
Journal of pharmacokinetics and pharmacodynamics 2001;28(3):211-30.
2001: van den Bongard H J; Mathjt R A; Boogerd W; Schornagel J H; Soesan M; Schellens J H; Beijnen J H
Successful rescue with leucovorin and thymidine in a patient with high-dose methotrexate induced acute renal failure.
Cancer chemotherapy and pharmacology 2001;47(6):537-40.
2001: Koks C H; Crommentuyn K M; Hoetelmans R M; Burger D M; Koopmans P P; Mathôt R A; Mulder J W; Meenhorst P L; Beijnen J H
The effect of fluconazole on ritonavir and saquinavir pharmacokinetics in HIV-1-infected individuals.
British journal of clinical pharmacology 2001;51(6):631-5.
2001: Huitema A D; Reinders C; Tibben M M; Rodenhuis S; Beijnen J H
Sensitive gas chromatographic determination of the cyclophosphamide metabolite 2-dechloroethylcyclophosphamide in human plasma.
Journal of chromatography. B, Biomedical sciences and applications 2001;757(2):349-57.
2001: Veldkamp A I; Weverling G J; Lange J M; Montaner J S; Reiss P; Cooper D A; Vella S; Hall D; Beijnen J H; Hoetelmans R M
High exposure to nevirapine in plasma is associated with an improved virological response in HIV-1-infected individuals.
AIDS (London, England) 2001;15(9):1089-95.
2001: Malingré M M; Beijnen J H; Schellens J H
Oral delivery of taxanes.
Investigational new drugs 2001;19(2):155-62.
2001: Nuijen B; Bouma M; Schellens J H; Beijnen J H
Progress in the development of alternative pharmaceutical formulations of taxanes.
Investigational new drugs 2001;19(2):143-53.
2001: Witkamp A J; de Bree E; Kaag M M; Boot H; Beijnen J H; van Slooten G W; van Coevorden F; Zoetmulder F A
Extensive cytoreductive surgery followed by intra-operative hyperthermic intraperitoneal chemotherapy with mitomycin-C in patients with peritoneal carcinomatosis of colorectal origin.
European journal of cancer (Oxford, England : 1990) 2001;37(8):979-84.
2001: Kerbusch T; Herben V M; Jeuken M J; Ouwerkerk J; Keizer H J; Beijnen J H
Distribution of ifosfamide and metabolites between plasma and erythrocytes.
Biopharmaceutics & drug disposition 2001;22(3):99-108.
2001: Malingré M M; Beijnen J H; Rosing H; Koopman F J; van Tellingen O; Duchin K; Ten Bokkel Huinink W W; Swart M; Lieverst J; Schellens J H
A phase I and pharmacokinetic study of bi-daily dosing of oral paclitaxel in combination with cyclosporin A.
Cancer chemotherapy and pharmacology 2001;47(4):347-54.
2001: Malingré M M; Beijnen J H; Rosing H; Koopman F J; van Tellingen O; Duchin K; ten Bokkel Huinink W W; Swart M; Lieverst J; Schellens J H
The effect of different doses of cyclosporin A on the systemic exposure of orally administered paclitaxel.
Anti-cancer drugs 2001;12(4):351-8.
2001: Meerum Terwogt J M; ten Bokkel Huinink W W; Schellens J H; Schot M; Mandjes I A; Zurlo M G; Rocchetti M; Rosing H; Koopman F J; Beijnen J H
Phase I clinical and pharmacokinetic study of PNU166945, a novel water-soluble polymer-conjugated prodrug of paclitaxel.
Anti-cancer drugs 2001;12(4):315-23.
2001: Waterval J C; Bloks J C; Sparidans R W; Beijnen J H; Rodriguez-Campos I M; Bult A; Lingeman H; Underberg W J
Degradation kinetics of aplidine, a new marine antitumoural cyclic peptide, in aqueous solution.
Journal of chromatography. B, Biomedical sciences and applications 2001;754(1):161-8.
2001: Maliepaard M; van Gastelen M A; Tohgo A; Hausheer F H; van Waardenburg R C; de Jong L A; Pluim D; Beijnen J H; Schellens J H
Circumvention of breast cancer resistance protein (BCRP)-mediated resistance to camptothecins in vitro using non-substrate drugs or the BCRP inhibitor GF120918.
Clinical cancer research : an official journal of the American Association for Cancer Research 2001;7(4):935-41.
2001: Huisman M T; Smit J W; Wiltshire H R; Hoetelmans R M; Beijnen J H; Schinkel A H
P-glycoprotein limits oral availability, brain, and fetal penetration of saquinavir even with high doses of ritonavir.
Molecular pharmacology 2001;59(4):806-13.
2001: Crul M; de Klerk G J; Beijnen J H; Schellens J H
Ras biochemistry and farnesyl transferase inhibitors: a literature survey.
Anti-cancer drugs 2001;12(3):163-84.
2001: Crul M; van den Bongard H J; Tibben M M; van Tellingen O; Sava G; Schellens J H; Beijnen J H
Validated method for the determination of the novel organo-ruthenium anticancer drug NAMI-A in human biological fluids by Zeeman atomic absorption spectrometry.
Fresenius' journal of analytical chemistry 2001;369(5):442-5.
2001: de Maat M M; Hoetelmans R M; Math t R A; van Gorp E C; Meenhorst P L; Mulder J W; Beijnen J H
Drug interaction between St John's wort and nevirapine.
AIDS (London, England) 2001;15(3):420-1.
2001: Malingré M M; Richel D J; Beijnen J H; Rosing H; Koopman F J; Ten Bokkel Huinink W W; Schot M E; Schellens J H
Coadministration of cyclosporine strongly enhances the oral bioavailability of docetaxel.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2001;19(4):1160-6.
2001: Kerbusch T; de Kraker J; Keizer H J; van Putten J W; Groen H J; Jansen R L; Schellens J H; Beijnen J H
Clinical pharmacokinetics and pharmacodynamics of ifosfamide and its metabolites.
Clinical pharmacokinetics 2001;40(1):41-62.
2001: Sparidans R W; Hoetelmans R M; Beijnen J H
Liquid chromatographic assay for simultaneous determination of abacavir and mycophenolic acid in human plasma using dual spectrophotometric detection.
Journal of chromatography. B, Biomedical sciences and applications 2001;750(1):155-61.
2001: Huitema A D; Mathôt R A; Tibben M M; Schellens J H; Rodenhuis S; Beijnen J H
Population pharmacokinetics of thioTEPA and its active metabolite TEPA in patients undergoing high-dose chemotherapy.
British journal of clinical pharmacology 2001;51(1):61-70.
2001: Malingré M M; Beijnen J H; Rosing H; Koopman F J; Jewell R C; Paul E M; Ten Bokkel Huinink W W; Schellens J H
Co-administration of GF120918 significantly increases the systemic exposure to oral paclitaxel in cancer patients.
British journal of cancer 2001;84(1):42-7.
2001: Nuijen B; Bouma M; Manada C; Jimeno J M; Lazaro L L; Bult A; Beijnen J H
Compatibility and stability of the investigational polypeptide marine anticancer agent kahalalide F in infusion devices.
Investigational new drugs 2001;19(4):273-81.
2000: van Kesteren C; Cvitkovic E; Taamma A; López-Lázaro L; Jimeno J M; Guzman C; Math t R A; Schellens J H; Misset J L; Brain E; Hillebrand M J; Rosing H; Beijnen J H
Pharmacokinetics and pharmacodynamics of the novel marine-derived anticancer agent ecteinascidin 743 in a phase I dose-finding study.
Clinical cancer research : an official journal of the American Association for Cancer Research 2000;6(12):4725-32.
2000: Schellens J H; Malingré M M; Kruijtzer C M; Bardelmeijer H A; van Tellingen O; Schinkel A H; Beijnen J H
Modulation of oral bioavailability of anticancer drugs: from mouse to man.
European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences 2000;12(2):103-10.
2000: Malingré M M; Schellens J H; van Tellingen O; Rosing H; Koopman F J; Duchin K; Huinink W W; Swart M; Beijnen J H
Metabolism and excretion of paclitaxel after oral administration in combination with cyclosporin A and after i.v. administration.
Anti-cancer drugs 2000;11(10):813-20.
2000: Nuijen B; Bouma M; Manada C; Jimeno J M; Schellens J H; Bult A; Beijnen J H
Pharmaceutical development of anticancer agents derived from marine sources.
Anti-cancer drugs 2000;11(10):793-811.
2000: van den Bongard H J; Mathôt R A; Beijnen J H; Schellens J H
Pharmacokinetically guided administration of chemotherapeutic agents.
Clinical pharmacokinetics 2000;39(5):345-67.
2000: Bardelmeijer H A; Beijnen J H; Brouwer K R; Rosing H; Nooijen W J; Schellens J H; van Tellingen O
Increased oral bioavailability of paclitaxel by GF120918 in mice through selective modulation of P-glycoprotein.
Clinical cancer research : an official journal of the American Association for Cancer Research 2000;6(11):4416-21.
2000: van der Vange N; van Goethem A R; Zoetmulder F A; Kaag M M; van de Vaart P J; ten Bokkel Huinink W W; Beijnen J H
Extensive cytoreductive surgery combined with intra-operative intraperitoneal perfusion with cisplatin under hyperthermic conditions (OVHIPEC) in patients with recurrent ovarian cancer: a feasibility pilot.
European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology 2000;26(7):663-8.
2000: Meerum Terwogt J; van Tellingen O; Nannan Panday V R; Huizing M T; Schellens J H; ten Bokkel Huinink W W; Boschma M U; Giaccone G; Veenhof C H; Beijnen J H
Cremophor EL pharmacokinetics in a phase I study of paclitaxel (Taxol) and carboplatin in non-small cell lung cancer patients.
Anti-cancer drugs 2000;11(9):687-94.
2000: Jonker J W; Smit J W; Brinkhuis R F; Maliepaard M; Beijnen J H; Schellens J H; Schinkel A H
Role of breast cancer resistance protein in the bioavailability and fetal penetration of topotecan.
Journal of the National Cancer Institute 2000;92(20):1651-6.
2000: Kerbusch T; Jeuken M J; Derraz J; van Putten J W; Huitema A D; Beijnen J H
Determination of ifosfamide, 2- and 3-dechloroethyifosfamide using gas chromatography with nitrogen-phosphorus or mass spectrometry detection.
Therapeutic drug monitoring 2000;22(5):613-20.
2000: van Heeswijk R P; Veldkamp A I; Mulder J W; Meenhorst P L; Wit F W; Reiss P; Lange J M; Kwakkelstein M O; Beijnen J H; Hoetelmans R M
Nevirapine plus didanosine: once or twice daily combination?
Journal of acquired immune deficiency syndromes (1999) 2000;25(1):93-5.
2000: Huitema A D; Tibben M M; Kerbusch T; Kettenes-van den Bosch J J; Rodenhuis S; Beijnen J H
Simple and selective determination of the cyclophosphamide metabolite phosphoramide mustard in human plasma using high-performance liquid chromatography.
Journal of chromatography. B, Biomedical sciences and applications 2000;745(2):345-55.
2000: Huitema A D; Smits K D; Mathôt R A; Schellens J H; Rodenhuis S; Beijnen J H
The clinical pharmacology of alkylating agents in high-dose chemotherapy.
Anti-cancer drugs 2000;11(7):515-33.
2000: Bardelmeijer H A; van Tellingen O; Schellens J H; Beijnen J H
The oral route for the administration of cytotoxic drugs: strategies to increase the efficiency and consistency of drug delivery.
Investigational new drugs 2000;18(3):231-41.
2000: Evers R; de Haas M; Sparidans R; Beijnen J; Wielinga P R; Lankelma J; Borst P
Vinblastine and sulfinpyrazone export by the multidrug resistance protein MRP2 is associated with glutathione export.
British journal of cancer 2000;83(3):375-83.
2000: Maanen M J; Smeets C J; Beijnen J H
Chemistry, pharmacology and pharmacokinetics of N,N',N" -triethylenethiophosphoramide (ThioTEPA).
Cancer treatment reviews 2000;26(4):257-68.
2000: Kuiper R A; Malingré M M; Beijnen J H; Schellens J H
Cyclosporine-induced anaphylaxis.
The Annals of pharmacotherapy 2000;34(7-8):858-61.
2000: van Maanen M J; Smits K D; Beijnen J H
Simultaneous determination of thioTEPA, TEPA and a novel, recently identified thioTEPA metabolite, monochloroTEPA, in urine using capillary gas chromatography.
Journal of chromatography. B, Biomedical sciences and applications 2000;742(2):335-43.
2000: van Heeswijk R P; Veldkamp A I; Mulder J W; Meenhorst P L; Lange J M; Beijnen J H; Hoetelmans R M
Once-daily dosing of saquinavir and low-dose ritonavir in HIV-1-infected individuals: a pharmacokinetic pilot study.
AIDS (London, England) 2000;14(9):F103-10.
2000: Huitema A D; Mathôt R A; Tibben M M; Schellens J H; Rodenhuis S; Beijnen J H
Validation of techniques for the prediction of carboplatin exposure: application of Bayesian methods.
Clinical pharmacology and therapeutics 2000;67(6):621-30.
2000: Malingré M M; Terwogt J M; Beijnen J H; Rosing H; Koopman F J; van Tellingen O; Duchin K; Huinink W W; Swart M; Lieverst J; Schellens J H
Phase I and pharmacokinetic study of oral paclitaxel.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2000;18(12):2468-75.
2000: Kerbusch T; Huitema A D; Ouwerkerk J; Keizer H J; Mathôt R A; Schellens J H; Beijnen J H
Evaluation of the autoinduction of ifosfamide metabolism by a population pharmacokinetic approach using NONMEM.
British journal of clinical pharmacology 2000;49(6):555-61.
2000: Wijnholds J; Mol C A; van Deemter L; de Haas M; Scheffer G L; Baas F; Beijnen J H; Scheper R J; Hatse S; De Clercq E; Balzarini J; Borst P
Multidrug-resistance protein 5 is a multispecific organic anion transporter able to transport nucleotide analogs.
Proceedings of the National Academy of Sciences of the United States of America 2000;97(13):7476-81.
2000: Nuijen B; Bouma M; Henrar R E; Floriano P; Jimeno J M; Talsma H; Kettenes-van den Bosch J J; Heck A J; Bult A; Beijnen J H
Pharmaceutical development of a parenteral lyophilized formulation of the novel antitumor agent aplidine.
PDA journal of pharmaceutical science and technology / PDA 2000;54(3):193-208.
2000: Sparidans R W; Hoetelmans R M; Beijnen J H
Sensitive liquid chromatographic assay for amprenavir, a human immunodeficiency virus protease inhibitor, in human plasma, cerebrospinal fluid and semen.
Journal of chromatography. B, Biomedical sciences and applications 2000;742(1):185-92.
2000: van Maanen M J; Doesburg Smits K; Damen J M; Heck A J; Beijnen J H
Stability of thioTEPA and its metabolites, TEPA, monochloroTEPA and thioTEPA-mercapturate, in plasma and urine.
International journal of pharmaceutics 2000;200(2):187-94.
2000: van Heeswijk R P; Veldkamp A I; Mulder J W; Meenhorst P L; Wit F W; Lange J M; Danner S A; Foudraine N A; Kwakkelstein M O; Reiss P; Beijnen J H; Hoetelmans R M
The steady-state pharmacokinetics of nevirapine during once daily and twice daily dosing in HIV-1-infected individuals.
AIDS (London, England) 2000;14(8):F77-82.
2000: Vahrmeijer A L; van Dierendonck J H; Keizer H J; Beijnen J H; Tollenaar R A; Pijl M E; Marinelli A; Kuppen P J; van Bockel J H; Mulder G J; van de Velde C J
Increased local cytostatic drug exposure by isolated hepatic perfusion: a phase I clinical and pharmacologic evaluation of treatment with high dose melphalan in patients with colorectal cancer confined to the liver.
British journal of cancer 2000;82(9):1539-46.
2000: Kruijtzer CMF; Verweij J; Schellens J H; Beijnen J H; Pronk L; Bo M; Lustig V; van Tinteren H; Mackay M; Ten Bokkel Huinink W W
Docetaxel in 253 previously treated patients with progressive locally advanced or metastatic breast cancer: results of a compassionate use program in The Netherlands.
Anti-cancer drugs 2000;11(4):249-55.
2000: Rodenhuis S; Huitema A D; van Dam F S; de Vries E G; Beijnen J H
High-dose chemotherapy with peripheral blood progenitor cell transplantation in the adjuvant treatment of breast cancer.
Cancer journal (Sudbury, Mass.) 2000;6 Suppl 2():S125-30.
2000: van Asperen J; van Tellingen O; Beijnen J H
The role of mdr1a P-glycoprotein in the biliary and intestinal secretion of doxorubicin and vinblastine in mice.
Drug metabolism and disposition: the biological fate of chemicals 2000;28(3):264-7.
2000: Meerum Terwogt J M; Tibben M M; Welbank H; Schellens J H; Beijnen J H
Validated method for the determination of platinum from a liposomal source (SPI-77) in human plasma using graphite furnace Zeeman atomic absorption spectrometry.
Fresenius' journal of analytical chemistry 2000;366(3):298-302.
2000: Sparidans R W; den Hartig J; Cremers S; Beijnen J H; Vermeij P
Semi-automatic liquid chromatographic analysis of olpadronate in urine and serum using derivatization with (9-fluorenylmethyl)chloroformate.
Journal of chromatography. B, Biomedical sciences and applications 2000;738(2):331-41.
2000: van Maanen R J; Tijhof I M; Damen J M; Zwikker J W; Beijnen J H
The degradation of N,N',N"-triethylenephosphoramide in aqueous solutions: a qualitative and kinetic study.
International journal of pharmaceutics 2000;196(1):85-94.
2000: Nuijen B; Bouma M; Henrar R E; Brauns U; Bette P; Bult A; Beijnen J H
In vitro biocompatibility studies with the experimental anticancer agent BIBX1382BS.
International journal of pharmaceutics 2000;194(2):261-7.
2000: Hoitink M A; Beijnen J H; Bult A; Damen J M; van der Houwen O A; Kruijtzer J A; Tibben M M; Wiese G; Underberg W J
Degradation of azaglycinamido residues in model tripeptides derived from goserelin.
Journal of pharmaceutical sciences 2000;89(1):108-14.
2000: Schellens J H; Maliepaard M; Scheper R J; Scheffer G L; Jonker J W; Smit J W; Beijnen J H; Schinkel A H
Transport of topoisomerase I inhibitors by the breast cancer resistance protein. Potential clinical implications.
Annals of the New York Academy of Sciences 2000;922():188-94.
2000: Huitema A D; Kerbusch T; Tibben M M; Rodenhuis S; Beijnen J H
Reduction of cyclophosphamide bioactivation by thioTEPA: critical sequence-dependency in high-dose chemotherapy regimens.
Cancer chemotherapy and pharmacology 2000;46(2):119-27.
2000: Westermann A M; Dubbelman R; Baars J P; Moolenaar W H; Beijnen J H; Rodenhuis S
Feasibility and pharmacokinetics of intraperitoneal suramin in advanced malignancy.
Cancer chemotherapy and pharmacology 2000;46(1):57-62.
2000: Kruijtzer C M; Beijnen J H; Swart M; Schellens J H
Successful treatment with paclitaxel of a patient with metastatic extra-adrenal pheochromocytoma (paraganglioma). A case report and review of the literature.
Cancer chemotherapy and pharmacology 2000;45(5):428-31.
2000: Rosing H; Lustig V; van Warmerdam L J; Huizing M T; ten Bokkel Huinink W W; Schellens J H; Rodenhuis S; Bult A; Beijnen J H
Pharmacokinetics and metabolism of docetaxel administered as a 1-h intravenous infusion.
Cancer chemotherapy and pharmacology 2000;45(3):213-8.
1999: Veldkamp A I; Sparidans R W; Hoetelmans R M; Beijnen J H
Quantitative determination of abacavir (1592U89), a novel nucleoside reverse transcriptase inhibitor, in human plasma using isocratic reversed-phase high-performance liquid chromatography with ultraviolet detection.
Journal of chromatography. B, Biomedical sciences and applications 1999;736(1-2):123-8.
1999: Sparidans R W; Veldkamp A; Hoetelmans R M; Beijnen J H
Improved and simplified liquid chromatographic assay for adefovir, a novel antiviral drug, in human plasma using derivatization with chloroacetaldehyde.
Journal of chromatography. B, Biomedical sciences and applications 1999;736(1-2):115-21.
1999: Veldkamp A I; Hoetelmans R M; Beijnen J H; Mulder J W; Meenhorst P L
Ritonavir enables combined therapy with rifampin and saquinavir.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 1999;29(6):1586.
1999: Nuijen B; Bouma M; Henrar R E; Manada C; Bult A; Beijnen J H
Compatibility and stability of aplidine, a novel marine-derived depsipeptide antitumor agent, in infusion devices, and its hemolytic and precipitation potential upon i.v. administration.
Anti-cancer drugs 1999;10(10):879-87.
1999: Meerum Terwogt J M; Malingré M M; Beijnen J H; ten Bokkel Huinink W W; Rosing H; Koopman F J; van Tellingen O; Swart M; Schellens J H
Coadministration of oral cyclosporin A enables oral therapy with paclitaxel.
Clinical cancer research : an official journal of the American Association for Cancer Research 1999;5(11):3379-84.
1999: Pluim D; Maliepaard M; van Waardenburg R C; Beijnen J H; Schellens J H
32P-postlabeling assay for the quantification of the major platinum-DNA adducts.
Analytical biochemistry 1999;275(1):30-8.
1999: Nannan Panday V R; van Warmerdam L J; Huizing M T; Ten Bokkel Huinink W W; Schellens J H; Beijnen J H
A limited-sampling model for the pharmacokinetics of carboplatin administered in combination with paclitaxel.
Journal of cancer research and clinical oncology 1999;125(11):615-20.
1999: Veldkamp A I; van Heeswijk R P; Meenhorst P L; Mulder J W; Lange J M; Beijnen J H; Hoetelmans R M
Quantitative determination of efavirenz (DMP 266), a novel non-nucleoside reverse transcriptase inhibitor, in human plasma using isocratic reversed-phase high-performance liquid chromatography with ultraviolet detection.
Journal of chromatography. B, Biomedical sciences and applications 1999;734(1):55-61.
1999: van Tellingen O; Beijnen J H; Verweij J; Scherrenburg E J; Nooijen W J; Sparreboom A
Rapid esterase-sensitive breakdown of polysorbate 80 and its impact on the plasma pharmacokinetics of docetaxel and metabolites in mice.
Clinical cancer research : an official journal of the American Association for Cancer Research 1999;5(10):2918-24.
1999: Verschraagen M; Koks C H; Schellens J H; Beijnen J H
P-glycoprotein system as a determinant of drug interactions: the case of digoxin-verapamil.
Pharmacological research : the official journal of the Italian Pharmacological Society 1999;40(4):301-6.
1999: van Heeswijk R P; Veldkamp A I; Hoetelmans R M; Mulder J W; Schreij G; Hsu A; Lange J M; Beijnen J H; Meenhorst P L
The steady-state plasma pharmacokinetics of indinavir alone and in combination with a low dose of ritonavir in twice daily dosing regimens in HIV-1-infected individuals.
AIDS (London, England) 1999;13(14):F95-9.
1999: van Maanen M J; Beijnen J H
Liquid chromatographic-mass spectrometric determination of the novel, recently identified thioTEPA metabolite, thioTEPA-mercapturate, in urine.
Journal of chromatography. B, Biomedical sciences and applications 1999;732(1):73-9.
1999: van Helvoort A; de Brouwer A; Ottenhoff R; Brouwers J F; Wijnholds J; Beijnen J H; Rijneveld A; van der Poll T; van der Valk M A; Majoor D; Voorhout W; Wirtz K W; Elferink R P; Borst P
Mice without phosphatidylcholine transfer protein have no defects in the secretion of phosphatidylcholine into bile or into lung airspaces.
Proceedings of the National Academy of Sciences of the United States of America 1999;96(20):11501-6.
1999: van Tellingen O; Huizing M T; Panday V R; Schellens J H; Nooijen W J; Beijnen J H
Cremophor EL causes (pseudo-) non-linear pharmacokinetics of paclitaxel in patients.
British journal of cancer 1999;81(2):330-5.
1999: van Maanen M J; Tijhof I M; Damen J M; Versluis C; van den Bosch J J; Heck A J; Rodenhuis S; Beijnen J H
A search for new metabolites of N,N',N''-triethylenethiophosphoramide.
Cancer research 1999;59(18):4720-4.
1999: Kroep J R; Giaccone G; Voorn D A; Smit E F; Beijnen J H; Rosing H; van Moorsel C J; van Groeningen C J; Postmus P E; Pinedo H M; Peters G J
Gemcitabine and paclitaxel: pharmacokinetic and pharmacodynamic interactions in patients with non-small-cell lung cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1999;17(7):2190-7.
1999: Sparidans R W; Taal B G; Beijnen J H
Bioanalysis of m-iodobenzylguanidine in plasma by high-performance liquid chromatography after derivatization with benzoin.
Journal of chromatography. B, Biomedical sciences and applications 1999;730(2):193-9.
1999: Herben V M; Rosing H; ten Bokkel Huinink W W; van Zomeren D M; Batchelor D; Doyle E; Beusenberg F D; Beijnen J H; Schellens J H
Oral topotecan: bioavailablity and effect of food co-administration.
British journal of cancer 1999;80(9):1380-6.
1999: Panday V R; ten Bokkel Huinink W W; Vermorken J B; Rosing H; Koopman F J; Swart M; Schellens J H; Beijnen J H
Pharmacokinetics of paclitaxel administered as a 3-hour or 96-hour infusion.
Pharmacological research : the official journal of the Italian Pharmacological Society 1999;40(1):67-74.
1999: Herben V M; van Gijn R; Schellens J H; Schot M; Lieverst J; Hillebrand M J; Schoemaker N E; Porro M G; Beijnen J H; ten Bokkel Huinink W W
Phase I and pharmacokinetic study of a daily times 5 short intravenous infusion schedule of 9-aminocamptothecin in a colloidal dispersion formulation in patients with advanced solid tumors.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1999;17(6):1906-14.
1999: Herben V M; Schellens J H; Swart M; Gruia G; Vernillet L; Beijnen J H; ten Bokkel Huinink W W
Phase I and pharmacokinetic study of irinotecan administered as a low-dose, continuous intravenous infusion over 14 days in patients with malignant solid tumors.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1999;17(6):1897-905.
1999: Sparidans R W; den Hartigh J; Cremers S; Beijnen J H; Vermeij P
Semi-automatic liquid chromatographic analysis of pamidronate in urine after derivatization with 1-naphthylisothiocyanate.
Journal of chromatography. B, Biomedical sciences and applications 1999;730(1):95-9.
1999: Sparidans R W; Kettenes-van den Bosch J J; van Tellingen O; Nuyen B; Henrar R E; Jimeno J M; Faircloth G; Floriano P; Rinehart K L; Beijnen J H
Bioanalysis of aplidine, a new marine antitumoral depsipeptide, in plasma by high-performance liquid chromatography after derivatization with trans-4-hydrazino-2-stilbazole.
Journal of chromatography. B, Biomedical sciences and applications 1999;729(1-2):43-53.
1999: Léon J; Reubsaet E; Beijnen J H; van Bennekom W P; Bult A; Hoekstra A J; Hop E; van Os P J; Teeuwsen J; Underberg W J
Reduction of Cys36-Cys42 and Cys64-Cys74 disulfide bonds in recombinant human granulocyte colony stimulating factor.
Journal of pharmaceutical and biomedical analysis 1999;19(6):837-45.
1999: Boven E; Jansen W J; Hulscher T M; Beijnen J H; van Tellingen O
The influence of P170-glycoprotein modulators on the efficacy and the distribution of vincristine as well as on MDR1 expression in BRO/mdr1.1 human melanoma xenografts.
European journal of cancer (Oxford, England : 1990) 1999;35(5):840-9.
1999: Terwogt J M; Schellens J H; Huinink W W; Beijnen J H
Clinical pharmacology of anticancer agents in relation to formulations and administration routes.
Cancer treatment reviews 1999;25(2):83-101.
1999: Rosing H; van Zomeren D M; Doyle E; ten Bokkel W W; Schellens J H; Bult A; Beijnen J H
Quantification of topotecan and its metabolite N-desmethyltopotecan in human plasma, urine and faeces by high-performance liquid chromatographic methods.
Journal of chromatography. B, Biomedical sciences and applications 1999;727(1-2):191-203.
1999: Veldkamp A I; van Heeswijk R P; Hoetelmans R M; Meenhorst P L; Mulder J W; Lange J M; Beijnen J H
Rapid quantification of delavirdine, a novel non-nucleoside reverse transcriptase inhibitor, in human plasma using isocratic reversed-phase high-performance liquid chromatography with fluorescence detection.
Journal of chromatography. B, Biomedical sciences and applications 1999;727(1-2):151-7.
1999: Sparidans R W; Henrar R E; Jimeno J M; Faircloth G; Floriano P; Beijnen J H
Bioanalysis of thiocoraline, a new marine antitumoral depsipeptide, in plasma by high-performance liquid chromatography and fluorescence detection.
Journal of chromatography. B, Biomedical sciences and applications 1999;726(1-2):255-60.
1999: van Asperen J; van Tellingen O; Schinkel A H; Beijnen J H
Comparative pharmacokinetics of vinblastine after a 96-hour continuous infusion in wild-type mice and mice lacking mdr1a P-glycoprotein.
The Journal of pharmacology and experimental therapeutics 1999;289(1):329-33.
1999: Reubsaet J L; Beijnen J H; Belshof E H; Bouyakhrichan M; Bult A; Hop E; Kellekule Y; van Maanen R J; Teeuwsen J; Underberg W J
Qualitative and quantitative aspects of the degradation of several tripeptides derived from the antitumour peptide antagonist [Arg(6), D-Trp(7,9), MePhe(8)] substance P[6-11].
Journal of pharmaceutical and biomedical analysis 1999;19(3-4):277-84.
1999: Terwogt J M; Mandjes I A; Sindermann H; Beijnen J H; ten Bokkel Huinink W W
Phase II trial of topically applied miltefosine solution in patients with skin-metastasized breast cancer.
British journal of cancer 1999;79(7-8):1158-61.
1999: Herben V M; Panday V R; Richel D J; Schellens J H; van der Vange N; Rosing H; Beusenberg F D; Hearn S; Doyle E; Beijnen J H; ten Bokkel Huinink W W
Phase I and pharmacologic study of the combination of paclitaxel, cisplatin, and topotecan administered intravenously every 21 days as first-line therapy in patients with advanced ovarian cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1999;17(3):747-55.
1999: van Maanen M J; Brandt A C; Damen J M; Beijnen J H
Degradation study of thiotepa in aqueous solutions.
International journal of pharmaceutics 1999;179(1):55-64.
1999: Kuin A; Rutgers M; van der Valk M A; Beijnen J H; Smets L A
Bioavailability and toxicity after oral administration of m-iodobenzylguanidine (MIBG).
British journal of cancer 1999;79(5-6):802-6.
1999: Kuin A; Aalders M; Lamfers M; van Zuidam D J; Essers M; Beijnen J H; Smets L A
Potentiation of anti-cancer drug activity at low intratumoral pH induced by the mitochondrial inhibitor m-iodobenzylguanidine (MIBG) and its analogue benzylguanidine (BG).
British journal of cancer 1999;79(5-6):793-801.
1999: Huitema A D; Holtkamp M; Tibben M M; Rodenhuis S; Beijnen J H
Sampling technique from central venous catheters proves critical for pharmacokinetic studies.
Therapeutic drug monitoring 1999;21(1):102-4.
1999: Rosing H; ten Bokkel Huinink W W; van Gijn R; Rombouts R F; Bult A; Beijnen J H
Comparative open, randomized, cross-over bioequivalence study of two intravenous dexrazoxane formulations (Cardioxane and ICRF-187) in patients with advanced breast cancer, treated with 5-fluorouracil-doxorubicin-cyclophosphamide (FDC).
European journal of drug metabolism and pharmacokinetics 1999;24(1):69-77.
1999: van Asperen J; van Tellingen O; Tijssen F; Schinkel A H; Beijnen J H
Increased accumulation of doxorubicin and doxorubicinol in cardiac tissue of mice lacking mdr1a P-glycoprotein.
British journal of cancer 1999;79(1):108-13.
1999: van Gijn R; ten Bokkel Huinink W W; Rodenhuis S; Vermorken J B; van Tellingen O; Rosing H; van Warmerdam L J; Beijnen J H
Topoisomerase I/II inhibitor intoplicine administered as a 24 h infusion: phase I and pharmacologic study.
Anti-cancer drugs 1999;10(1):17-23.
1999: van Gijn R; van Tellingen O; Haverkate E; Kettenes-van den Bosch J J; Bult A; Beijnen J H
Pharmacokinetics and metabolism of the staurosporine analogue CGP 41 251 in mice.
Investigational new drugs 1999;17(1):29-41.
1999: Nannan Panday V R; de Wit R; Schornagel J H; Schot M; Rosing H; Lieverst J; ten Bokkel Huinink W W; Schellens J H; Beijnen J H
Pharmacokinetics of paclitaxel administered in combination with cisplatin, etoposide and bleomycin in patients with advanced solid tumours.
Cancer chemotherapy and pharmacology 1999;44(4):349-53.
1999: Nannan Panday V R; Hoetelmans R M; van Heeswijk R P; Meenhorst P L; Inghels M; Mulder J W; Beijnen J H
Paclitaxel in the treatment of human immunodeficiency virus 1-associated Kaposi's sarcoma--drug-drug interactions with protease inhibitors and a nonnucleoside reverse transcriptase inhibitor: a case report study.
Cancer chemotherapy and pharmacology 1999;43(6):516-9.
1999: Panday V R; van Warmerdam L J; Huizing M T; Rodenhuis S; Schellens J H; Beijnen J H
A single 24-hour plasma sample does not predict the carboplatin AUC from carboplatin-paclitaxel combinations or from a high-dose carboplatin-thiotepa-cyclophosphamide regimen.
Cancer chemotherapy and pharmacology 1999;43(5):435-8.
1998: Hoetelmans R M; van Heeswijk R P; Profijt M; Mulder J W; Meenhorst P L; Lange J M; Reiss P; Beijnen J H
Comparison of the plasma pharmacokinetics and renal clearance of didanosine during once and twice daily dosing in HIV-1 infected individuals.
AIDS (London, England) 1998;12(17):F211-6.
1998: Hoetelmans R M; Profijt M; Meenhorst P L; Mulder J W; van Heeswijk R P; Beijnen J H
Co-trimoxazole and stavudine interference in a high-performance liquid chromatographic analysis for didanosine in human plasma.
Therapeutic drug monitoring 1998;20(6):669-72.
1998: van Tellingen O; Kemper M; Tijssen F; van Asperen J; Nooijen W J; Beijnen J H
High-performance liquid chromatographic bio-analysis of PSC 833 in human and murine plasma.
Journal of chromatography. B, Biomedical sciences and applications 1998;719(1-2):251-7.
1998: van Heeswijk R P; Hoetelmans R M; Harms R; Meenhorst P L; Mulder J W; Lange J M; Beijnen J H
Simultaneous quantitative determination of the HIV protease inhibitors amprenavir, indinavir, nelfinavir, ritonavir and saquinavir in human plasma by ion-pair high-performance liquid chromatography with ultraviolet detection.
Journal of chromatography. B, Biomedical sciences and applications 1998;719(1-2):159-68.
1998: van Maanen R J; van Ooijen R D; Zwikker J W; Huitema A D; Rodenhuis S; Beijnen J H
Determination of N,N',N"-triethylenethiophosphoramide and its active metabolite N,N',N"-triethylenephosphoramide in plasma and urine using capillary gas chromatography.
Journal of chromatography. B, Biomedical sciences and applications 1998;719(1-2):103-12.
1998: Rosing H; Hillebrand M J; Jimeno J M; Gómez A; Floriano P; Faircloth G; Henrar R E; Vermorken J B; Cvitkovic E; Bult A; Beijnen J H
Quantitative determination of Ecteinascidin 743 in human plasma by miniaturized high-performance liquid chromatography coupled with electrospray ionization tandem mass spectrometry.
Journal of mass spectrometry : JMS 1998;33(11):1134-40.
1998: Crommentuyn K M; Schellens J H; van den Berg J D; Beijnen J H
In-vitro metabolism of anti-cancer drugs, methods and applications: paclitaxel, docetaxel, tamoxifen and ifosfamide.
Cancer treatment reviews 1998;24(5):345-66.
1998: van Asperen J; van Tellingen O; van der Valk M A; Rozenhart M; Beijnen J H
Enhanced oral absorption and decreased elimination of paclitaxel in mice cotreated with cyclosporin A.
Clinical cancer research : an official journal of the American Association for Cancer Research 1998;4(10):2293-7.
1998: Oostweegel L M; Beijnen J H; Mulder J W
Hepatitis during chloroguanide prophylaxis.
The Annals of pharmacotherapy 1998;32(10):1023-5.
1998: Reubsaet J L; Beijnen J H; Bult A; van Maanen R J; Marchal J A; Underberg W J
Analytical techniques used to study the degradation of proteins and peptides: physical instability.
Journal of pharmaceutical and biomedical analysis 1998;17(6-7):979-84.
1998: Reubsaet J L; Beijnen J H; Bult A; van Maanen R J; Marchal J A; Underberg W J
Analytical techniques used to study the degradation of proteins and peptides: chemical instability.
Journal of pharmaceutical and biomedical analysis 1998;17(6-7):955-78.
1998: Kerbusch T; Huitema A D; Kettenes-van den Bosch J J; Keizer H J; Ouwerkerk J; de Kraker J; Beijnen J H
High-performance liquid chromatographic determination of stabilized 4-hydroxyifosfamide in human plasma and erythrocytes.
Journal of chromatography. B, Biomedical sciences and applications 1998;716(1-2):275-84.
1998: Huitema A D; Tibben M M; Kerbusch T; Zwikker J W; Rodenhuis S; Beijnen J H
Simultaneous determination of N,N',N"-triethylenethiophosphoramide, cyclophosphamide and some of their metabolites in plasma using capillary gas chromatography.
Journal of chromatography. B, Biomedical sciences and applications 1998;716(1-2):177-86.
1998: Panday V R; ten Bokkel Huinink W W; Rosing H; Koopman F J; Hillebrand M J; Dubbelman R C; van Tellingen O; Schellens J H; Beijnen J H
Phase I and pharmacologic study of weekly doxorubicin and 1 h infusional paclitaxel in patients with advanced breast cancer.
Anti-cancer drugs 1998;9(8):665-73.
1998: van Gijn R; Herben V M; Hillebrand M J; ten Bokkel Huinink W W; Bult A; Beijnen J H
High-performance liquid chromatographic analysis of the investigational anticancer drug 9-aminocamptothecin, as the lactone form and as the total of the lactone and the hydroxycarboxylate forms, in micro-volumes of human plasma.
Journal of pharmaceutical and biomedical analysis 1998;17(8):1257-65.
1998: Panday V R; Huizing M T; van Warmerdam L J; Dubbelman R C; Mandjes I; Schellens J H; Huinink W W; Beijnen J H
Pharmacologic study of 3-hour 135 mg M-2 paclitaxel in platinum pretreated patients with advanced ovarian cancer.
Pharmacological research : the official journal of the Italian Pharmacological Society 1998;38(3):231-6.
1998: Hoitink M A; Beijnen J H; Boschma M U; Bult A; van der Houwen O A; Wiese G; Underberg W J
Degradation kinetics of three gonadorelin analogues: developing a method for calculating epimerization parameters.
Pharmaceutical research 1998;15(9):1449-55.
1998: Wijnholds J; Scheffer G L; van der Valk M; van der Valk P; Beijnen J H; Scheper R J; Borst P
Multidrug resistance protein 1 protects the oropharyngeal mucosal layer and the testicular tubules against drug-induced damage.
The Journal of experimental medicine 1998;188(5):797-808.
1998: Rosing H; van Zomeren D M; Doyle E; Bult A; Beijnen J H
O-glucuronidation, a newly identified metabolic pathway for topotecan and N-desmethyl topotecan.
Anti-cancer drugs 1998;9(7):587-92.
1998: Herben V M; Ten Bokkel Huinink W W; Schellens J H; Beijnen J H
Clinical pharmacokinetics of camptothecin topoisomerase I inhibitors.
Pharmacy world & science : PWS 1998;20(4):161-72.
1998: van Heeswijk R P; Hoetelmans R M; Meenhorst P L; Mulder J W; Beijnen J H
Rapid determination of nevirapine in human plasma by ion-pair reversed-phase high-performance liquid chromatography with ultraviolet detection.
Journal of chromatography. B, Biomedical sciences and applications 1998;713(2):395-9.
1998: Hoetelmans R M; Profijt M; Mennhorst P L; Mulder J W; Beijnen J H
Quantitative determination of (-)-2'-deoxy-3'-thiacytidine (lamivudine) in human plasma, saliva and cerebrospinal fluid by high-performance liquid chromatography with ultraviolet detection.
Journal of chromatography. B, Biomedical sciences and applications 1998;713(2):387-94.
1998: van Asperen J; van Tellingen O; Beijnen J H
Determination of doxorubicin and metabolites in murine specimens by high-performance liquid chromatography.
Journal of chromatography. B, Biomedical sciences and applications 1998;712(1-2):129-43.
1998: Huitema A D; Soesan M; Meenhorst P L; Koks C H; Beijnen J H
A dose-dependent delayed hypersensitivity reaction to acetaminophen after repeated acetaminophen intoxications.
Human & experimental toxicology 1998;17(7):406-8.
1998: Hoetelmans R M; Reijers M H; Weverling G J; ten Kate R W; Wit F W; Mulder J W; Weigel H M; Frissen P H; Roos M; Jurriaans S; Schuitemaker H; de Wolf F; Beijnen J H; Lange J M
The effect of plasma drug concentrations on HIV-1 clearance rate during quadruple drug therapy.
AIDS (London, England) 1998;12(11):F111-5.
1998: Van Asperen J; Van Tellingen O; Beijnen J H
The pharmacological role of P-glycoprotein in the intestinal epithelium.
Pharmacological research : the official journal of the Italian Pharmacological Society 1998;37(6):429-35.
1998: Rosing H; Hillebrand M J; Jimeno J M; Gómez A; Floriano P; Faircloth G; Cameron L; Henrar R E; Vermorken J B; Bult A; Beijnen J H
Analysis of Ecteinascidin 743, a new potent marine-derived anticancer drug, in human plasma by high-performance liquid chromatography in combination with solid-phase extraction.
Journal of chromatography. B, Biomedical sciences and applications 1998;710(1-2):183-9.
1998: Herben V M; ten Bokkel Huinink W W; Schot M E; Hudson I; Beijnen J H
Continuous infusion of low-dose topotecan: pharmacokinetics and pharmacodynamics during a phase II study in patients with small cell lung cancer.
Anti-cancer drugs 1998;9(5):411-8.
1998: Reubsaet J L; Beijnen J H; Bult A; Hop E; Scholten S D; Teeuwsen J; Underberg W J
Oxidation of recombinant methionyl human granulocyte colony stimulating factor.
Journal of pharmaceutical and biomedical analysis 1998;17(2):283-9.
1998: van Tellingen O; Nooijen W J; Schaaf L J; van der Valk M; van Asperen J; Henrar R E; Beijnen J H
Comparative pharmacology of the novel cyclopropylpyrroloindole-prodrug carzelesin in mice, rats, and humans.
Cancer research 1998;58(11):2410-6.
1998: Kaijser G P; De Kraker J; Bult A; Underberg W J; Beijnen J H
Pharmacokinetics of ifosfamide and some metabolites in children.
Anticancer research 1998;18(3B):1941-9.
1998: Huizing M T; Rosing H; Koopmans F P; Beijnen J H
Influence of Cremophor EL on the quantification of paclitaxel in plasma using high-performance liquid chromatography with solid-phase extraction as sample pretreatment.
Journal of chromatography. B, Biomedical sciences and applications 1998;709(1):161-5.
1998: Westermann A M; Havik E; Postma F R; Beijnen J H; Dalesio O; Moolenaar W H; Rodenhuis S
Malignant effusions contain lysophosphatidic acid (LPA)-like activity.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1998;9(4):437-42.
1998: Sparidans R W; den Hartigh J; Beijnen J H; Vermeij P
Semi-automatic liquid chromatographic analysis of pamidronate in serum and citrate plasma after derivatization with 1-naphthylisothiocyanate.
Journal of chromatography. B, Biomedical sciences and applications 1998;705(2):331-9.
1998: van de Vaart P J; van der Vange N; Zoetmulder F A; van Goethem A R; van Tellingen O; ten Bokkel Huinink W W; Beijnen J H; Bartelink H; Begg A C
Intraperitoneal cisplatin with regional hyperthermia in advanced ovarian cancer: pharmacokinetics and cisplatin-DNA adduct formation in patients and ovarian cancer cell lines.
European journal of cancer (Oxford, England : 1990) 1998;34(1):148-54.
1998: Kuiper R A; Schellens J H; Blijham G H; Beijnen J H; Voest E E
Clinical research on antiangiogenic therapy.
Pharmacological research : the official journal of the Italian Pharmacological Society 1998;37(1):1-16.
1998: Hoetelmans R M; van Essenberg M; Profijt M; Meenhorst P L; Mulder J W; Beijnen J H
High-performance liquid chromatographic determination of ritonavir in human plasma, cerebrospinal fluid and saliva.
Journal of chromatography. B, Biomedical sciences and applications 1998;705(1):119-26.
1998: Nannan Panday V R; van Warmerdam L J; Huizing M T; Ten Bokkel Huinink W W; Vermorken J B; Giaccone G; Veenhof C H; Schellens J H; Beijnen J H
Carboplatin dosage formulae can generate inaccurate predictions of Carboplatin exposure in carboplatin/paclitaxel combination regimens.
Clinical drug investigation 1998;15(4):327-35.
1998: Jonkman-de Vries J D; Rosing H; Talsma H; Henrar R E; Kettenes-van den Bosch J J; Bult A; Beijnen J H
Pharmaceutical development of a parenteral lyophilized formulation of the investigational antitumor neuropeptide antagonist [Arg6, D-Trp7,9, MePhe8]-Substance P [6-11].
Investigational new drugs 1998;16(2):99-111.
1998: van Tellingen O; Punt C J; Awada A; Wagener D J; Piccart M J; Groot Y; Schaaf L J; Henrar R E; Nooijen W J; Beijnen J H
A clinical pharmacokinetics study of carzelesin given by short-term intravenous infusion in a phase I study.
Cancer chemotherapy and pharmacology 1998;41(5):377-84.
1997: Mayer U; Wagenaar E; Dorobek B; Beijnen J H; Borst P; Schinkel A H
Full blockade of intestinal P-glycoprotein and extensive inhibition of blood-brain barrier P-glycoprotein by oral treatment of mice with PSC833.
The Journal of clinical investigation 1997;100(10):2430-6.
1997: Wijnholds J; Evers R; van Leusden M R; Mol C A; Zaman G J; Mayer U; Beijnen J H; van der Valk M; Krimpenfort P; Borst P
Increased sensitivity to anticancer drugs and decreased inflammatory response in mice lacking the multidrug resistance-associated protein.
Nature medicine 1997;3(11):1275-9.
1997: Davies B E; Minthorn E A; Dennis M J; Rosing H; Beijnen J H
The pharmacokinetics of topotecan and its carboxylate form following separate intravenous administration to the dog.
Pharmaceutical research 1997;14(10):1461-5.
1997: Crul M; Schellens J H; Beijnen J H; Maliepaard M
Cisplatin resistance and DNA repair.
Cancer treatment reviews 1997;23(5-6):341-66.
1997: van Maanen R J; van Ooijen R D; Beijnen J H
Determination of N,N',N"-triethylenthiophosphoramide in biological samples using capillary gas chromatography.
Journal of chromatography. B, Biomedical sciences and applications 1997;698(1-2):111-21.
1997: Westermann A M; Dubbelman R; Moolenaar W H; Beijnen J; Rodenhuis S
Successful intraperitoneal suramin treatment of peritoneal mesothelioma.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1997;8(8):801-2.
1997: Panday V R; Huizing M T; Willemse P H; De Graeff A; ten Bokkel Huinink W W; Vermorken J B; Beijnen J H
Hepatic metabolism of paclitaxel and its impact in patients with altered hepatic function.
Seminars in oncology 1997;24(4 Suppl 11):S11-34-S11-38.
1997: Sparidans R W; den Hartigh J; Beijnen J H; Vermeij P
Determination of pamidronate in urine by ion-pair liquid chromatography after derivatization with 1-naphthylisothiocyanate.
Journal of chromatography. B, Biomedical sciences and applications 1997;696(1):137-44.
1997: Rosing H; Lustig V; Koopman F P; ten Bokkel Huinink W W; Beijnen J H
Bio-analysis of docetaxel and hydroxylated metabolites in human plasma by high-performance liquid chromatography and automated solid-phase extraction.
Journal of chromatography. B, Biomedical sciences and applications 1997;696(1):89-98.
1997: Hoetelmans R M; Meenhorst P L; Mulder J W; Burger D M; Koks C H; Beijnen J H
Clinical pharmacology of HIV protease inhibitors: focus on saquinavir, indinavir, and ritonavir.
Pharmacy world & science : PWS 1997;19(4):159-75.
1997: van Asperen J; Mayer U; van Tellingen O; Beijnen J H
The functional role of P-glycoprotein in the blood-brain barrier.
Journal of pharmaceutical sciences 1997;86(8):881-4.
1997: Huizing M T; van Warmerdam L J; Rosing H; Schaefers M C; Lai A; Helmerhorst T J; Veenhof C H; Birkhofer M J; Rodenhuis S; Beijnen J H; ten Bokkel Huinink W W
Phase I and pharmacologic study of the combination paclitaxel and carboplatin as first-line chemotherapy in stage III and IV ovarian cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1997;15(5):1953-64.
1997: Wafelman A R; Hoefnagel C A; Maessen H J; Maes R A; Beijnen J H
Renal excretion of iodine-131 labelled meta-iodobenzylguanidine and metabolites after therapeutic doses in patients suffering from different neural crest-derived tumours.
European journal of nuclear medicine 1997;24(5):544-52.
1997: ten Bokkel Huinink W W; van Warmerdam L J; Helmerhorst T J; Schaefers M C; Beijnen J H; Rodenhuis S
Phase II study of the combination carboplatin and paclitaxel in patients with ovarian cancer.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1997;8(4):351-4.
1997: Westermann A M; Beijnen J H; Moolenaar W H; Rodenhuis S
Growth factors in human ovarian cancer.
Cancer treatment reviews 1997;23(2):113-31.
1997: Terwogt J M; Nuijen B; Huinink W W; Beijnen J H
Alternative formulations of paclitaxel.
Cancer treatment reviews 1997;23(2):87-95.
1997: Kaijser G P; Ter Riet P G; de Kraker J; Bult A; Beijnen J H; Underberg W J
Determination of 4-hydroxyifosfamide in biological matrices by high-performance liquid chromatography.
Journal of pharmaceutical and biomedical analysis 1997;15(6):773-81.
1997: Jonkman-de Vries J D; Van den Bemt B J; ten Bokkel-Huinink W W; Underberg W J; Kettenes-van den Bosch J J; Henrar R E; Bult A; Beijnen J H
Pharmaceutical development of a parenteral formulation of the investigational anticancer drug clanfenur.
PDA journal of pharmaceutical science and technology / PDA 1997;51(2):89-95.
1997: Kaijser G P; Beijnen J H; Bult A; Keizer H J; Underberg W J
Chromatographic analysis of the enantiomers of ifosfamide and some of its metabolites in plasma and urine.
Journal of chromatography. B, Biomedical sciences and applications 1997;690(1-2):131-8.
1997: Sparreboom A; van Asperen J; Mayer U; Schinkel A H; Smit J W; Meijer D K; Borst P; Nooijen W J; Beijnen J H; van Tellingen O
Limited oral bioavailability and active epithelial excretion of paclitaxel (Taxol) caused by P-glycoprotein in the intestine.
Proceedings of the National Academy of Sciences of the United States of America 1997;94(5):2031-5.
1997: van Warmerdam L J; Huizing M T; Giaccone G; Postmus P E; ten Bokkel Huinink W W; van Zandwijk N; Koolen M G; Helmerhorst T J; van der Vijgh W J; Veenhof C H; Beijnen J H
Clinical pharmacology of carboplatin administered in combination with paclitaxel.
Seminars in oncology 1997;24(1 Suppl 2):S2-97-S2-104.
1997: ten Bokkel Huinink W; Veenhof C; Huizing M; Rodenhuis S; Helmerhorst T; Dubbelman R; Dalesio O; Beijnen J; Winograd B
Carboplatin and paclitaxel in patients with advanced ovarian cancer: a dose-finding study.
Seminars in oncology 1997;24(1 Suppl 2):S2-31-S2-33.
1997: Huizing M T; Giaccone G; van Warmerdam L J; Rosing H; Bakker P J; Vermorken J B; Postmus P E; van Zandwijk N; Koolen M G; ten Bokkel Huinink W W; van der Vijgh W J; Bierhorst F J; Lai A; Dalesio O; Pinedo H M; Veenhof C H; Beijnen J H
Pharmacokinetics of paclitaxel and carboplatin in a dose-escalating and dose-sequencing study in patients with non-small-cell lung cancer. The European Cancer Centre.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1997;15(1):317-29.
1997: Herben V M; ten Bokkel Huinink W W; Dubbelman A C; Mandjes I A; Groot Y; van Gortel-van Zomeren D M; Beijnen J H
Phase I and pharmacological study of sequential intravenous topotecan and oral etoposide.
British journal of cancer 1997;76(11):1500-8.
1997: van Asperen J; van Tellingen O; Sparreboom A; Schinkel A H; Borst P; Nooijen W J; Beijnen J H
Enhanced oral bioavailability of paclitaxel in mice treated with the P-glycoprotein blocker SDZ PSC 833.
British journal of cancer 1997;76(9):1181-3.
1997: van Tellingen O; Boogerd W; Nooijen W J; Beijnen J H
The vascular compartment hampers accurate determination of teniposide penetration into brain tumor tissue.
Cancer chemotherapy and pharmacology 1997;40(4):330-4.
1997: Rosing H; Herben V M; van Gortel-van Zomeren D M; Hop E; Kettenes-van den Bosch J J; ten Bokkel Huinink W W; Beijnen J H
Isolation and structural confirmation of N-desmethyl topotecan, a metabolite of topotecan.
Cancer chemotherapy and pharmacology 1997;39(6):498-504.
1997: Veldhuis G J; Willemse P H; Beijnen J H; Boonstra H; Piersma H; van der Graaf W T; de Vries E G
Paclitaxel, ifosfamide and cisplatin with granulocyte colony-stimulating factor or recombinant human interleukin 3 and granulocyte colony-stimulating factor in ovarian cancer: a feasibility study.
British journal of cancer 1997;75(5):703-9.
1996: Kaijser G P; Beijnen J H; Rozendom E; Bult A; Underberg W J
Analysis of ifosforamide mustard, the active metabolite of ifosfamide, in plasma.
Journal of chromatography. B, Biomedical applications 1996;686(2):249-55.
1996: Rosing H; Doyle E; Beijnen J H
The impact of column temperature in the high performance liquid chromatographic analysis of topotecan in rat and dog plasma.
Journal of pharmaceutical and biomedical analysis 1996;15(2):279-86.
1996: Vries J D; Doppenberg W G; Henrar R E; Bult A; Beijnen J H
Systematic study on the chemical stability of the prodrug antitumor agent carzelesin (U-80,244)
Journal of pharmaceutical sciences 1996;85(11):1227-33.
1996: Mayer U; Wagenaar E; Beijnen J H; Smit J W; Meijer D K; van Asperen J; Borst P; Schinkel A H
Substantial excretion of digoxin via the intestinal mucosa and prevention of long-term digoxin accumulation in the brain by the mdr 1a P-glycoprotein.
British journal of pharmacology 1996;119(5):1038-44.
1996: Wolff I; Bench K; Beijnen J H; Bruntsch U; Cavalli F; de Jong J; Groot Y; van Tellingen O; Wanders J; Sessa C
Phase I clinical and pharmacokinetic study of carzelesin (U-80244) given daily for five consecutive days.
Clinical cancer research : an official journal of the American Association for Cancer Research 1996;2(10):1717-23.
1996: Witterland A H; Koks C H; Beijnen J H
Etoposide phosphate, the water soluble prodrug of etoposide.
Pharmacy world & science : PWS 1996;18(5):163-70.
1996: Hoitink M A; Beijnen J H; Bult A; van der Houwen O A; Nijholt J; Underberg W J
Degradation kinetics of gonadorelin in aqueous solution.
Journal of pharmaceutical sciences 1996;85(10):1053-9.
1996: Kaijser G P; Keizer H J; Beijnen J H; Bult A; Underberg W J
Pharmacokinetics of ifosfamide, 2- and 3-dechloroethylifosfamide in plasma and urine of cancer patients treated with a 10-day continuous infusion of ifosfamide.
Anticancer research 1996;16(5B):3247-57.
1996: van der Wall E; Schaake-Koning C C; van Zandwijk N; Baars J W; Schornagel J H; Richel D J; Rutgers E J; Borger J H; Beijnen J H; Rodenhuis S
The toxicity of radiotherapy following high-dose chemotherapy with peripheral blood stem cell support in high-risk breast cancer: a preliminary analysis.
European journal of cancer (Oxford, England : 1990) 1996;32A(9):1490-7.
1996: Herben V M; ten Bokkel Huinink W W; Beijnen J H
Clinical pharmacokinetics of topotecan.
Clinical pharmacokinetics 1996;31(2):85-102.
1996: Koks C H; Meenhorst P L; Hillebrand M J; Bult A; Beijnen J H
Pharmacokinetics of fluconazole in saliva and plasma after administration of an oral suspension and capsules.
Antimicrobial agents and chemotherapy 1996;40(8):1935-7.
1996: Wafelman A R; Hoefnagel C A; Maes R A; Beijnen J H
Radiochemical purity, at expiry, and radiochemical stability of iodine-131 labelled meta-iodobenzylguanidine concentrates for intravenous infusion.
Nuklearmedizin. Nuclear medicine 1996;35(4):122-5.
1996: de Wit R; Beijnen J H; van Tellingen O; Schellens J H; de Boer-Dennert M; Verweij J
Pharmacokinetic profile and clinical efficacy of a once-daily ondansetron suppository in cyclophosphamide-induced emesis: a double blind comparative study with ondansetron tablets.
British journal of cancer 1996;74(2):323-6.
1996: van Asperen J; Schinkel A H; Beijnen J H; Nooijen W J; Borst P; van Tellingen O
Altered pharmacokinetics of vinblastine in Mdr1a P-glycoprotein-deficient Mice.
Journal of the National Cancer Institute 1996;88(14):994-9.
1996: Sparreboom A; van Tellingen O; Huizing M T; Nooijen W J; Beijnen J H
Determination of polyoxyethyleneglycerol triricinoleate 35 (Cremophor EL) in plasma by pre-column derivatization and reversed-phase high-performance liquid chromatography.
Journal of chromatography. B, Biomedical applications 1996;681(2):355-62.
1996: Taal B G; Hoefnagel C A; Valdes Olmos R A; Boot H; Beijnen J H
Palliative effect of metaiodobenzylguanidine in metastatic carcinoid tumors.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1996;14(6):1829-38.
1996: Schellens J H; Creemers G J; Beijnen J H; Rosing H; de Boer-Dennert M; McDonald M; Davies B; Verweij J
Bioavailability and pharmacokinetics of oral topotecan: a new topoisomerase I inhibitor.
British journal of cancer 1996;73(10):1268-71.
1996: van der Wall E; Rutgers E J; Holtkamp M J; Baars J W; Schornagel J H; Peterse J L; Beijnen J H; Rodenhuis S
Efficacy of up-front 5-fluorouracil-epidoxorubicin-cyclophosphamide (FEC) chemotherapy with an increased dose of epidoxorubicin in high-risk breast cancer patients.
British journal of cancer 1996;73(9):1080-5.
1996: Sparreboom A; van Tellingen O; Nooijen W J; Beijnen J H
Nonlinear pharmacokinetics of paclitaxel in mice results from the pharmaceutical vehicle Cremophor EL.
Cancer research 1996;56(9):2112-5.
1996: Hoetelmans R M; Burger D M; Meenhorst P L; Beijnen J H
Pharmacokinetic individualisation of zidovudine therapy. Current state of pharmacokinetic-pharmacodynamic relationships.
Clinical pharmacokinetics 1996;30(4):314-27.
1996: Hoetelmans R M; Schornagel J H; ten Bokkel Huinink W W; Beijnen J H
Hypersensitivity reactions to etoposide.
The Annals of pharmacotherapy 1996;30(4):367-71.
1996: van Warmerdam L J; Rodenhuis S; van der Wall E; Maes R A; Beijnen J H
Pharmacokinetics and pharmacodynamics of carboplatin administered in a high-dose combination regimen with thiotepa, cyclophosphamide and peripheral stem cell support.
British journal of cancer 1996;73(8):979-84.
1996: Sparreboom A; van Tellingen O; Nooijen W J; Beijnen J H
Tissue distribution, metabolism and excretion of paclitaxel in mice.
Anti-cancer drugs 1996;7(1):78-86.
1996: Jonkman-de Vries J D; Kettenes-van den Bosch J J; Henrar R E; Bult A; Beijnen J H
Purity determinations in the bulk drug of the novel indoloquinone antitumor agent EO9.
Investigational new drugs 1996;14(2):181-91.
1996: van Tellingen O; Kuck M T; Vlasveld L T; Rodenhuis S; Nooijen W J; Beijnen J H
Unchanged pharmacokinetics of etoposide given by intra-arterial hepatic infusion as compared with i.v. infusion.
Cancer chemotherapy and pharmacology 1996;38(4):387-90.
1996: van Warmerdam L J; Creemers G J; Rodenhuis S; Rosing H; de Boer-Dennert M; Schellens J H; ten Bokkel Huinink W W; Davies B E; Maes R A; Verweij J; Beijnen J H
Pharmacokinetics and pharmacodynamics of topotecan given on a daily-times-five schedule in phase II clinical trials using a limited-sampling procedure.
Cancer chemotherapy and pharmacology 1996;38(3):254-60.
1996: van Warmerdam L J; Rodenhuis S; ten Bokkel Huinink W W; Maes R A; Beijnen J H
Evaluation of formulas using the serum creatinine level to calculate the optimal dosage of carboplatin.
Cancer chemotherapy and pharmacology 1996;37(3):266-70.
1995: van Gijn R; Havik E; Boven E; Vermorken J B; ten Bokkel Huinink W W; van Tellingen O; Beijnen J H
High-performance liquid chromatographic analysis of the new antitumour drug N-benzoylstaurosporine (CGP 41 251) and four potential metabolites in micro-volumes of plasma.
Journal of pharmaceutical and biomedical analysis 1995;14(1-2):165-74.
1995: Huizing M T; Sparreboom A; Rosing H; van Tellingen O; Pinedo H M; Beijnen J H
Quantification of paclitaxel metabolites in human plasma by high-performance liquid chromatography.
Journal of chromatography. B, Biomedical applications 1995;674(2):261-8.
1995: Reubsaet J L; Beijnen J H; Bult A; Hop E; Vermaas R; Kellekule Y; Kettenes-van den Bosch J J; Underberg W J
Structural identification of the degradation products of the antitumor peptide antagonist [Arg6,D-Trp7,9,MePhe8]substance P (6-11).
Analytical chemistry 1995;67(23):4431-6.
1995: Burger D M; Kraayeveld C L; Meenhorst P L; Mulder J W; Hoetelmans R M; Koks C H; Beijnen J H
Study on didanosine concentrations in cerebrospinal fluid. Implications for the treatment and prevention of AIDS dementia complex.
Pharmacy world & science : PWS 1995;17(6):218-21.
1995: Nortier Y L; van de Haven J A; Koks C H; Beijnen J H
Preparation and stability testing of a hydrogel for topical analgesia.
Pharmacy world & science : PWS 1995;17(6):214-7.
1995: Jonkman-De Vries J D; Rosing H; Henrar R E; Bult A; Beijnen J H
The influence of formulation excipients on the stability of the novel antitumor agent carzelesin (U-80,244).
PDA journal of pharmaceutical science and technology / PDA 1995;49(6):283-8.
1995: Burger D; Meenhorst P; Mulder J; Henrichs J; Frissen J; Kroon F; ten Napel C; Koks K; Bult A; Beijnen J
Substitution of didanosine sachets by chewable tablets: a pharmacokinetic study in patients with AIDS.
Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association 1995;10(2):163-8.
1995: Huizing M T; Vermorken J B; Rosing H; ten Bokkel Huinink W W; Mandjes I; Pinedo H M; Beijnen J H
Pharmacokinetics of paclitaxel and three major metabolites in patients with advanced breast carcinoma refractory to anthracycline therapy treated with a 3-hour paclitaxel infusion: a European Cancer Centre (ECC) trial.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1995;6(7):699-704.
1995: Wafelman A R; Nortier Y L; Rosing H; Maessen H J; Taal B G; Hoefnagel C A; Maes R A; Beijnen J H
Renal excretion of meta-iodobenzylguanidine after therapeutic doses in cancer patients and its relation to dose and creatinine clearance.
Nuclear medicine communications 1995;16(9):767-72.
1995: Zaman G J; Lankelma J; van Tellingen O; Beijnen J; Dekker H; Paulusma C; Oude Elferink R P; Baas F; Borst P
Role of glutathione in the export of compounds from cells by the multidrug-resistance-associated protein.
Proceedings of the National Academy of Sciences of the United States of America 1995;92(17):7690-4.
1995: Giaccone G; Huizing M; Postmus P E; ten Bokkel Huinink W W; Koolen M; van Zandwijk N; Vermorken J B; Beijnen J H; Dalesio O; Pinedo H M
Dose-finding and sequencing study of paclitaxel and carboplatin in non-small cell lung cancer.
Seminars in oncology 1995;22(4 Suppl 9):78-82.
1995: Vermorken J B; ten Bokkel Huinink W W; Mandjes I A; Postma T J; Huizing M T; Heimans J J; Beijnen J H; Bierhorst F; Winograd B; Pinedo H M
High-dose paclitaxel with granulocyte colony-stimulating factor in patients with advanced breast cancer refractory to anthracycline therapy: a European Cancer Center trial.
Seminars in oncology 1995;22(4 Suppl 8):16-22.
1995: van Warmerdam L J; ten Bokkel Huinink W W; Rodenhuis S; Koier I; Davies B E; Rosing H; Maes R A; Beijnen J H
Phase I clinical and pharmacokinetic study of topotecan administered by a 24-hour continuous infusion.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1995;13(7):1768-76.
1995: Beijnen J H; Flora K P; Halbert G W; Henrar R E; Slack J A
CRC/EORTC/NCI Joint Formulation Working Party: experiences in the formulation of investigational cytotoxic drugs.
British journal of cancer 1995;72(1):210-8.
1995: Rosing H; Doyle E; Davies B E; Beijnen J H
High-performance liquid chromatographic determination of the novel antitumour drug topotecan and topotecan as the total of the lactone plus carboxylate forms, in human plasma.
Journal of chromatography. B, Biomedical applications 1995;668(1):107-15.
1995: van Gijn R; van Tellingen O; de Clippeleir J J; Hillebrand M J; Boven E; Vermorken J B; ten Bokkel Huinink W W; Schwertz S; Graf P; Beijnen J H
Analytical procedure for the determination of the new antitumour drug N-benzoylstaurosporine and three potential metabolites in human plasma by reversed-phase high-performance liquid chromatography.
Journal of chromatography. B, Biomedical applications 1995;667(2):269-76.
1995: Reubsaet J L; Beijnen J H; Bult A; van der Houwen O A; Teeuwsen J; Koster E H; Underberg W J
Degradation kinetics of antagonist [Arg6, D-Trp7,9, MePhe8]-substance P [6-11] in aqueous solutions.
Analytical biochemistry 1995;227(2):334-41.
1995: Burger D M; Meenhorst P L; Beijnen J H
Concise overview of the clinical pharmacokinetics of dideoxynucleoside antiretroviral agents.
Pharmacy world & science : PWS 1995;17(2):25-30.
1995: van der Wall E; Beijnen J H; Rodenhuis S
High-dose chemotherapy regimens for solid tumors.
Cancer treatment reviews 1995;21(2):105-32.
1995: Sparreboom A; van Tellingen O; Nooijen W J; Beijnen J H
Determination of paclitaxel and metabolites in mouse plasma, tissues, urine and faeces by semi-automated reversed-phase high-performance liquid chromatography.
Journal of chromatography. B, Biomedical applications 1995;664(2):383-91.
1995: Huizing M T; Rosing H; Koopman F; Keung A C; Pinedo H M; Beijnen J H
High-performance liquid chromatographic procedures for the quantitative determination of paclitaxel (Taxol) in human urine.
Journal of chromatography. B, Biomedical applications 1995;664(2):373-82.
1995: Koks C H; Rosing H; Meenhorst P L; Bult A; Beijnen J H
High-performance liquid chromatographic determination of the antifungal drug fluconazole in plasma and saliva of human immunodeficiency virus-infected patients.
Journal of chromatography. B, Biomedical applications 1995;663(2):345-51.
1995: van Warmerdam L J; Verweij J; Schellens J H; Rosing H; Davies B E; de Boer-Dennert M; Maes R A; Beijnen J H
Pharmacokinetics and pharmacodynamics of topotecan administered daily for 5 days every 3 weeks.
Cancer chemotherapy and pharmacology 1995;35(3):237-45.
1995: van Warmerdam L J; Rodenhuis S; ten Bokkel Huinink W W; Maes R A; Beijnen J H
The use of the Calvert formula to determine the optimal carboplatin dosage.
Journal of cancer research and clinical oncology 1995;121(8):478-86.
1995: Sparreboom A; Huizing M T; Boesen J J; Nooijen W J; van Tellingen O; Beijnen J H
Isolation, purification, and biological activity of mono- and dihydroxylated paclitaxel metabolites from human feces.
Cancer chemotherapy and pharmacology 1995;36(4):299-304.
1994: Burger D M; Meenhorst P L; ten Napel C H; Mulder J W; Neef C; Koks C H; Bult A; Beijnen J H
Pharmacokinetic variability of zidovudine in HIV-infected individuals: subgroup analysis and drug interactions.
AIDS (London, England) 1994;8(12):1683-9.
1994: Burger D M; Meenhorst P L; Mulder J W; Kraaijeveld C L; Koks C H; Bult A; Beijnen J H
Therapeutic drug monitoring of phenytoin in patients with the acquired immunodeficiency syndrome.
Therapeutic drug monitoring 1994;16(6):616-20.
1994: Burger D M; Rosing H; ten Napel C H; Duyts T; Meenhorst P L; Mulder J W; Koks C H; Bult A; Beijnen J H
Application of a radioimmunoassay for determination of levels of zalcitabine (ddC) in human plasma, urine, and cerebrospinal fluid.
Antimicrobial agents and chemotherapy 1994;38(12):2763-7.
1994: Wafelman A R; Konings M C; Hoefnagel C A; Maes R A; Beijnen J H
Synthesis, radiolabelling and stability of radioiodinated m-iodobenzylguanidine, a review.
Applied radiation and isotopes : including data, instrumentation and methods for use in agriculture, industry and medicine 1994;45(10):997-107.
1994: Beijnen J H; Huizing M T; ten Bokkel Huinink W W; Veenhof C H; Vermorken J B; Giaccone G; Pinedo H M
Bioanalysis, pharmacokinetics, and pharmacodynamics of the novel anticancer drug paclitaxel (Taxol).
Seminars in oncology 1994;21(5 Suppl 8):53-62.
1994: Giaccone G; Huizing M; ten Bokkel Huinink W; Koolen M; Postmus P; van Kralingen K; van Zandwijk N; Vermorken J; Beijnen J; Dalesio O
Preliminary results of two dose-finding studies of paclitaxel (Taxol) and carboplatin in non-small cell lung and ovarian cancers: a European Cancer Centre effort.
Seminars in oncology 1994;21(5 Suppl 8):34-8.
1994: Pizao P E; Smitskamp-Wilms E; Van Ark-Otte J; Beijnen J H; Peters G J; Pinedo H M; Giaccone G
Antiproliferative activity of the topoisomerase I inhibitors topotecan and camptothecin, on sub- and postconfluent tumor cell cultures.
Biochemical pharmacology 1994;48(6):1145-54.
1994: Wafelman A R; Konings M C; Rosing H; Hoefnagel C A; Taal B G; Maes R A; Beijnen J H
High-performance liquid chromatographic determination of metaiodobenzylguanidine in whole blood and plasma of cancer patients.
Journal of pharmaceutical and biomedical analysis 1994;12(9):1173-9.
1994: Klaase J M; Kroon B B; Beijnen J H; van Slooten G W; van Dongen J A
Melphalan tissue concentrations in patients treated with regional isolated perfusion for melanoma of the lower limb.
British journal of cancer 1994;70(1):151-3.
1994: Reubsaet J L; Beijnen J H; Bult A; Teeuwsen J; Koster E H; Waterval J C; Underberg W J
Reversed-phase high-performance liquid chromatography and capillary electrophoresis in the stability study of the neuropeptide growth factor antagonist [Arg6,D-Trp7,9,MePhe8]-substance P (6-11): a comparative study.
Analytical biochemistry 1994;220(1):98-102.
1994: Wafelman A R; Hoefnagel C A; Maes R A; Beijnen J H
Radioiodinated metaiodobenzylguanidine: a review of its biodistribution and pharmacokinetics, drug interactions, cytotoxicity and dosimetry.
European journal of nuclear medicine 1994;21(6):545-59.
1994: Schinkel A H; Smit J J; van Tellingen O; Beijnen J H; Wagenaar E; van Deemter L; Mol C A; van der Valk M A; Robanus-Maandag E C; te Riele H P
Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs.
Cell 1994;77(4):491-502.
1994: Burger D M; Meenhorst P L; Koks C H; Beijnen J H
Pharmacokinetics of zidovudine and acetaminophen in a patient on chronic acetaminophen therapy.
The Annals of pharmacotherapy 1994;28(3):327-30.
1994: van Warmerdam L J; Verweij J; Rosing H; Schellens J H; Maes R A; Beijnen J H
Limited sampling models for topotecan pharmacokinetics.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1994;5(3):259-64.
1994: Kaijser G P; Beijnen J H; Bult A; Underberg W J
Ifosfamide metabolism and pharmacokinetics (review).
Anticancer research 1994;14(2A):517-31.
1994: ten Bokkel Huinink W W; van Warmerdam L J; Dubbelman A C; McVie J G; Beijnen J H
Intraperitoneal-administered carboplatin in patients with ovarian cancer; influence of a dwell-time on toxicity and response.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1994;5(2):133-9.
1994: Taal B G; Teller F G; ten Bokkel Huinink W W; Boot H; Beijnen J H; Dubbelman R
Etoposide, leucovorin, 5-fluorouracil (ELF) combination chemotherapy for advanced gastric cancer: experience with two treatment schedules incorporating intravenous or oral etoposide.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1994;5(1):90-2.
1994: van Tellingen O; Pels E M; Henrar R E; Schaaf L J; Padbury G E; Beijnen J H; Nooijen W J
Fully automated high-performance liquid chromatographic method for the determination of carzelesin (U-80,244) and metabolites (U-76,073 and U-76,074) in human plasma.
Journal of chromatography 1994;652(1):51-8.
1994: van Tellingen O; Sonneveldt A L; Beijnen J H; Nooijen W J; Kettenes-van den Bosch J J; Versluis C; Bult A
Plasma pharmacokinetics, tissue disposition, excretion and metabolism of vinleucinol in mice as determined by high-performance liquid chromatography.
Cancer chemotherapy and pharmacology 1994;33(5):425-34.
1994: van Warmerdam L J; ten Bokkel Huinink W W; Maes R A; Beijnen J H
Limited-sampling models for anticancer agents.
Journal of cancer research and clinical oncology 1994;120(7):427-33.
1994: Jonkman-de Vries J D; Talsma H; Henrar R E; Kettenes-van den Bosch J J; Bult A; Beijnen J H
Pharmaceutical development of a parenteral lyophilized formulation of the novel indoloquinone antitumor agent EO9.
Cancer chemotherapy and pharmacology 1994;34(5):416-22.
1994: van Warmerdam L J; Rodenhuis S; van Tellingen O; Maes R A; Beijnen J H
Validation of a limited sampling model for carboplatin in a high-dose chemotherapy combination.
Cancer chemotherapy and pharmacology 1994;35(2):179-81.
1994: Sips J H; van Tellingen O; Nooijen W J; Rodenhuis S; Ten Bokkel Huinink W J; Beijnen J H
The pharmacokinetics of reduced folates after intraperitoneal and intravenous administration of racemic [6S,R]-folinic acid.
Cancer chemotherapy and pharmacology 1994;35(2):144-8.
1994: Jonkman-de Vries J D; de Graaff-Teulen M J; Henrar R E; Kettenes-van den Bosch J J; Bult A; Beijnen J H
Pharmaceutical development of a parenteral formulation of the novel anti-tumor agent carzelesin (U-80,244).
Investigational new drugs 1994;12(4):303-14.
1994: Beijnen J H; Bais E M; ten Bokkel Huinink W W
Lithium pharmacokinetics during cisplatin-based chemotherapy: a case report.
Cancer chemotherapy and pharmacology 1994;33(6):523-6.
1993: Sweeb R K; Beijnen J H
Signal transduction pathways: new targets in oncology.
Pharmacy world & science : PWS 1993;15(6):233-42.
1993: Burger D M; Kraaijeveld C L; Meenhorst P L; Mulder J W; Koks C H; Bult A; Beijnen J H
Penetration of zidovudine into the cerebrospinal fluid of patients infected with HIV.
AIDS (London, England) 1993;7(12):1581-7.
1993: Burger D M; Rosing H; Koopman F J; Mennhorst P L; Mulder J W; Bult A; Beijnen J H
Determination of 3'-amino-3'-deoxythymidine, a cytotoxic metabolite of 3'-azido-3'-deoxythymidine, in human plasma by ion-pair high-performance liquid chromatography.
Journal of chromatography 1993;622(2):235-42.
1993: Wafelman A R; Nortier Y L; Rosing H; Underberg W J; Maes R A; Beijnen J H
High-performance liquid chromatographic determination of m-iodobenzylguanidine in urine of cancer patients.
Journal of chromatography 1993;622(1):71-7.
1993: van Gijn R; De Graaff-Teulen M J; van Tellingen O; Beijnen J H
Chemical stability of the new antitumour agent intoplicine in infusion fluids.
Journal of pharmaceutical and biomedical analysis 1993;11(11-12):1353-6.
1993: van Gijn R; Kuijs S; Rosing H; Dubbelman A C; van Tellingen O; ten Bokkel Huinink W W; Pinedo H M; Beijnen J H
Determination of intoplicine, a new antitumour drug, in human faeces by normal-phase high-performance liquid chromatography with fluorescence detection.
Journal of pharmaceutical and biomedical analysis 1993;11(11-12):1345-8.
1993: Huizing M T; Keung A C; Rosing H; van der Kuij V; ten Bokkel Huinink W W; Mandjes I M; Dubbelman A C; Pinedo H M; Beijnen J H
Pharmacokinetics of paclitaxel and metabolites in a randomized comparative study in platinum-pretreated ovarian cancer patients.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1993;11(11):2127-35.
1993: Knoester P D; Underberg W J; Beijnen J H
Clinical pharmacokinetics and pharmacodynamics of anticancer agents in pediatric patients (review).
Anticancer research 1993;13(5C):1795-808.
1993: Verweij J; Lund B; Beijnen J; Planting A; de Boer-Dennert M; Koier I; Rosing H; Hansen H
Phase I and pharmacokinetics study of topotecan, a new topoisomerase I inhibitor.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1993;4(8):673-8.
1993: Kaijser G P; Korst A; Beijnen J H; Bult A; Underberg W J
The analysis of ifosfamide and its metabolites (review).
Anticancer research 1993;13(5A):1311-24.
1993: Wafelman A R; Hoefnagel C A; Beijnen J H
Radiochemical stability during infusion of 131I-labelled metaiodobenzylguanidine for therapeutic use.
Nuclear medicine communications 1993;14(9):819-22.
1993: Beijnen J H; van Gijn R
Chemical stability of the cardioprotective agent ICRF-187 in infusion fluids.
Journal of parenteral science and technology : a publication of the Parenteral Drug Association 1993;47(4):166-71.
1993: Beijnen J H; Rosing H; ten Bokkel Huinink W W; Pinedo H M
High-performance liquid chromatographic analysis of the antitumour drug camptothecin and its lactone ring-opened form in rat plasma.
Journal of chromatography 1993;617(1):111-7.
1993: Wafelman A R; Suchi R; Hoefnagel C A; Beijnen J H
Radiochemical purity of iodine-131 labelled metaiodobenzylguanidine infusion fluids: a report from clinical practice.
European journal of nuclear medicine 1993;20(7):614-6.
1993: Burger D M; Meenhorst P L; Koks C H; Beijnen J H
Pharmacokinetic interaction between rifampin and zidovudine.
Antimicrobial agents and chemotherapy 1993;37(7):1426-31.
1993: Bekers O; Beijnen J H; Tank M J; Burger D M; Meenhorst P L; Lombarts A J; Underberg W J
2',3'-dideoxyinosine (ddI): its chemical stability and cyclodextrin complexation in aqueous media.
Journal of pharmaceutical and biomedical analysis 1993;11(6):489-93.
1993: Underberg W J; Beijnen J H
Kinetics and mechanism of the degradation of 1a-acetylmitomycin C in aqueous solution.
Pharmacy world & science : PWS 1993;15(3):123-7.
1993: Schellens J H; Loos W; Beijnen J H; Stoter G; Verweij J
Sensitive isocratic high-performance liquid chromatographic determination of a novel indoloquinone cytotoxic drug (EO9) in human plasma and urine.
Journal of chromatography 1993;615(2):309-15.
1993: van Tellingen O; Beijnen J H; Nooijen W J; Bult A
Plasma pharmacokinetics of vinblastine and the investigational Vinca alkaloid N-(deacetyl-O-4-vinblastoyl-23)-L-ethyl isoleucinate in mice as determined by high-performance liquid chromatography.
Cancer research 1993;53(9):2061-5.
1993: van Gijn R; Rosing H; ten Bokkel Huinink W W; van Tellingen O; Vermorken J B; Liefting A J; Bruno R; Pinedo H M; Beijnen J H
Determination of intoplicine, a new antitumour drug, in human whole blood and plasma by normal-phase high-performance liquid chromatography with fluorescence detection.
Journal of chromatography 1993;614(2):299-306.
1993: Kaijser G P; Beijnen J H; Jeunink E L; Bult A; Keizer H J; de Kraker J; Underberg W J
Determination of chloroacetaldehyde, a metabolite of oxazaphosphorine cytostatic drugs, in plasma.
Journal of chromatography 1993;614(2):253-9.
1993: van Tellingen O; Kuijpers A V; Beijnen J H; Nooijen W J; Bult A
Plasma pharmacokinetics, tissue disposition, excretion and metabolism of vinorelbine in mice as determined by high performance liquid chromatography.
Investigational new drugs 1993;11(2-3):141-50.
1993: Keijer W J; Burger D M; Neuteboom G H; Vrooland J L; Meenhorst P L; Koks C H; Beijnen J H
Ocular complications of the acquired immunodeficiency syndrome. Focus on the treatment of cytomegalovirus retinitis with ganciclovir and foscarnet.
Pharmacy world & science : PWS 1993;15(2):56-67.
1993: van Tellingen O; Beijnen J H; Nooijen W J; Bult A
Tissue disposition, excretion and metabolism of vinblastine in mice as determined by high-performance liquid chromatography.
Cancer chemotherapy and pharmacology 1993;32(4):286-92.
1993: Vlasveld L T; Beijnen J H; Sein J J; Rankin E M; Melief C J; Hekman A
Reconstitution of recombinant interleukin-2 (rIL-2): a comparative study of various rIL-2 muteins.
European journal of cancer (Oxford, England : 1990) 1993;29A(14):1977-9.
1992: Kaijser G P; Beijnen J H; Bult A; Wiese G; de Kraker J; Keizer H J; Underberg W J
Gas chromatographic determination of 2- and 3-dechloroethylifosfamide in plasma and urine.
Journal of chromatography 1992;583(2):175-82.
1992: Burger D M; Rosing H; van Gijn R; Meenhorst P L; van Tellingen O; Beijnen J H
Determination of stavudine, a new antiretroviral agent, in human plasma by reversed-phase high-performance liquid chromatography with ultraviolet detection.
Journal of chromatography 1992;584(2):239-47.
1992: Franssen R M; Meenhorst P L; Koks C H; Beijnen J H
Didanosine, a new antiretroviral drug. A review.
Pharmaceutisch weekblad. Scientific edition 1992;14(5):297-304.
1992: van Tellingen O; Sips J H; Beijnen J H; Bult A; Nooijen W J
Pharmacology, bio-analysis and pharmacokinetics of the vinca alkaloids and semi-synthetic derivatives (review).
Anticancer research 1992;12(5):1699-715.
1992: Beijnen J H
New cytotoxic drugs and targets in oncology.
Pharmaceutisch weekblad. Scientific edition 1992;14(4A):258-67.
1992: Beijnen J H; van Gijn R; Challa E E; Kaijser G P; Underberg W J
Chemical stability of two sterile, parenteral formulations of cyclophosphamide (Endoxan) after reconstitution and dilution in commonly used infusion fluids.
Journal of parenteral science and technology : a publication of the Parenteral Drug Association 1992;46(4):111-6.
1992: Hodes T J; Underberg W J; Los G; Beijnen J H
Platinum antitumour agents: a review of (bio)analysis.
Pharmaceutisch weekblad. Scientific edition 1992;14(3):61-77.
1992: Vlasveld L T; Rankin E M; Hekman A; Rodenhuis S; Beijnen J H; Hilton A M; Dubbelman A C; Vyth-Dreese F A; Melief C J
A phase I study of prolonged continuous infusion of low dose recombinant interleukin-2 in melanoma and renal cell cancer. Part I: Clinical aspects.
British journal of cancer 1992;65(5):744-50.
1992: Beijnen J H; Vlasveld L T; Wanders J; ten Bokkel Huinink W W; Rodenhuis S
Effect of cisplatin-containing chemotherapy on lithium serum concentrations.
The Annals of pharmacotherapy 1992;26(4):488-90.
1992: van Tellingen O; Sips J H; Beijnen J H; Schornagel J H; Nooyen W J
Bioanalysis of the investigational anti-tumour drug 5,10-dideaza-5,6,7,8-tetrahydrofolic acid by high-performance liquid chromatography with ultraviolet detection.
Journal of chromatography 1992;576(1):158-62.
1992: van Tellingen O; Beijnen J H; Baurain R; ten Bokkel Huinink W W; van der Woude H R; Nooyen W J
Biodetermination of N-(deacetyl-O-4-vinblastoyl-23)-L-tryptophan, a metabolite of vintriptol, by high-performance liquid chromatography with fluorescence detection.
Journal of chromatography 1992;574(2):293-8.
1992: van Tellingen O; Kuijpers A; Beijnen J H; Baselier M R; Burghouts J T; Nooyen W J
Bio-analysis of vinorelbine by high-performance liquid chromatography with fluorescence detection.
Journal of chromatography 1992;573(2):328-32.
1991: Kaijser G P; Beijnen J H; Bult A; Wiese G; de Kraker J; Underberg W J
Gas chromatographic determination of ifosfamide in microvolumes of urine and plasma.
Journal of chromatography 1991;571(1-2):121-31.
1991: van Tellingen O; Beijnen J H; Baurain R; ten Bokkel Huinink W W; van der Woude H R; Nooyen W J
High-performance liquid chromatographic determination of vinblastine, 4-O-deacetylvinblastine and the potential metabolite 4-O-deacetylvinblastine-3-oic acid in biological fluids.
Journal of chromatography 1991;553(1-2):47-53.
1991: Beijnen J H; Beijnen-Bandhoe A U; Dubbelman A C; van Gijn R; Underberg W J
Chemical and physical stability of etoposide and teniposide in commonly used infusion fluids.
Journal of parenteral science and technology : a publication of the Parenteral Drug Association 1991;45(2):108-12.
1991: Oosterkamp H M; Vlasveld L T; Wanders J; Beijnen J H; van Tellingen O; Dubbelman A C; Simonetti G P; Franklin H R; Vermorken J B; Ten Bokkel Huinink W W
Phase I study of vintriptol, a tryptophan ester of vinblastine.
European journal of cancer (Oxford, England : 1990) 1991;27(10):1222-6.
1991: Beijnen J H; Meenhorst P L; van Gijn R; Fromme M; Rosing H; Underberg W J
HPLC determination of doxorubicin, doxorubicinol and four aglycone metabolites in plasma of AIDS patients.
Journal of pharmaceutical and biomedical analysis 1991;9(10-12):995-1002.
1991: Beijnen J H; Meenhorst P L; van Gijn R; Hazelager W A; Koks C H; Underberg W J
Gas chromatographic analysis, with electron capture detection, of the antifungal drug fluconazole in microvolumes of human plasma.
Journal of pharmaceutical and biomedical analysis 1991;9(10-12):1173-5.
1991: Van Tellingen O; Beijnen J H; Nooyen W J
Analytical methods for the determination of vinca alkaloids in biological specimens: a survey of the literature.
Journal of pharmaceutical and biomedical analysis 1991;9(10-12):1077-82.
1991: Kaijser G P; Beijnen J H; Bult A; Hogeboom M H; Underberg W J
A systematic study on the chemical stability of ifosfamide.
Journal of pharmaceutical and biomedical analysis 1991;9(10-12):1061-7.
1991: Bekers O; Beijnen J H; Tank M J; Bult A; Underberg W J
Effect of cyclodextrins on the chemical stability of mitomycins in alkaline solution.
Journal of pharmaceutical and biomedical analysis 1991;9(10-12):1055-60.
1990: Kaijser G P; Underberg W J; Beijnen J H
The risks of handling cytotoxic drugs. II. Recommendations for working with cytotoxic drugs.
Pharmaceutisch weekblad. Scientific edition 1990;12(6):228-35.
1990: Kaijser G P; Underberg W J; Beijnen J H
The risks of handling cytotoxic drugs. I. Methods of testing exposure.
Pharmaceutisch weekblad. Scientific edition 1990;12(6):217-27.
1990: Beijnen J H; van Gijn R; Horenblas S; Underberg W J
Chemical stability of suramin in commonly used infusion fluids.
DICP : the annals of pharmacotherapy 1990;24(11):1056-8.
1990: Beijnen J H; van Gijn R; Underberg W J
Chemical stability of the antitumor drug mitomycin C in solutions for intravesical instillation.
Journal of parenteral science and technology : a publication of the Parenteral Drug Association 1990;44(6):332-5.
1990: van Tellingen O; van der Woude H R; Beijnen J H; Rao K S; ten Bokkel Huinink W W; Nooyen W J
High-performance liquid chromatographic bio-analysis and preliminary pharmacokinetics of the experimental antitumour drug vintriptol.
Journal of chromatography 1990;529(2):329-38.
1990: van Tellingen O; Beijnen J H; van der Woude H R; Bruning P F; Nooyen W J
High-performance liquid chromatographic method for the analysis of 10-ethyl-10-deaza-aminopterin and metabolites in plasma.
Journal of chromatography 1990;529(1):135-43.
1990: Beijnen J H; van Gijn R; Underberg W J
Gas chromatographic analysis, with nitrogen detection, of tocainide in plasma.
Journal of pharmaceutical and biomedical analysis 1990;8(8-12):1101-3.
1990: Beijnen J H; Smith B R; Keijer W J; van Gijn R; ten Bokkel Huinink W W; Vlasveld L T; Rodenhuis S; Underberg W J
High-performance liquid chromatographic analysis of the new antitumour drug SK&F 104864-A (NSC 609699) in plasma.
Journal of pharmaceutical and biomedical analysis 1990;8(8-12):789-94.
1990: Underberg W J; Goossen R M; Smith B R; Beijnen J H
Equilibrium kinetics of the new experimental anti-tumour compound SK&F 104864-A in aqueous solution.
Journal of pharmaceutical and biomedical analysis 1990;8(8-12):681-3.
1990: Bekers O; Beijnen J H; Otagiri M; Bult A; Underberg W J
Inclusion complexation of doxorubicin and daunorubicin with cyclodextrins.
Journal of pharmaceutical and biomedical analysis 1990;8(8-12):671-4.
1990: van Tellingen O; Beijnen J H; van der Woude H R; Baurain R; ten Bokkel Huinink W W; Nooyen W J
Bio-analysis of N-(deacetyl-O-4-vinblastoyl-23)-L-ethyl isoleucinate, methane sulphonate (VileE) by high-performance liquid chromatography with fluorescence detection.
Journal of pharmaceutical and biomedical analysis 1990;8(8-12):1029-31.
1989: van Tellingen O; van der Woude H R; Beijnen J H; van Beers C J; Nooyen W J
Stable and sensitive method for the simultaneous determination of N5-methyltetrahydrofolate, leucovorin, methotrexate and 7-hydroxymethotrexate in biological fluids.
Journal of chromatography 1989;488(2):379-88.
1989: Underberg W J; Hofman G A; Lubbers S C; Bekers O; Ten Bokkel Huinink W W; Beijnen J H
Bio-analysis and preliminary pharmacokinetics of the experimental antitumour drug LL-D49194 alpha 1.
Journal of pharmaceutical and biomedical analysis 1989;7(12):1791-7.
1988: Bekers O; Beijnen J H; Groot Bramel E H; Otagiri M; Underberg W J
Effect of cyclodextrins on anthracycline stability in acidic aqueous media.
Pharmaceutisch weekblad. Scientific edition 1988;10(5):207-12.
1988: van der Nat J M; Beijnen J H; Driebergen R J; Thart L A; van Dijk H; Underberg W J; Labadie R P
In vitro immunosuppressive activities of recently developed anthracycline cytostatics.
Anticancer research 1988;8(3):489-93.
1987: Underberg W J; Beijnen J H
Re-use of mitomycin C in the treatment of superficial tumours of the urinary bladder: an evaluation in view of its chemical stability.
Anticancer research 1987;7(4B):707-10.
1986: Beijnen J H; van der Houwen O A; Rosing H; Underberg W J
A systematic study on the chemical stability of mitomycin A and mitomycin B.
Chemical & pharmaceutical bulletin 1986;34(7):2900-13.
1986: Beijnen J H; Van der Nat J M; Labadie R P; Underberg W J
Decomposition of mitomycin and anthracycline cytostatics in cell culture media.
Anticancer research 1986;6(1):39-43.
1985: Beijnen J H; Wiese G; Underberg W J
Aspects of the chemical stability of doxorubicin and seven other anthracyclines in acidic solution.
Pharmaceutisch weekblad. Scientific edition 1985;7(3):109-16.

Sign-in to see more